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ABSTRACT
Approximately 30% of people with tuberculous meningitis (TBM) die despite modem 
treatment. Survival is dependent upon early treatment but diagnosis is difficult: the 
clinical features are non-specific, conventional bacteriology is widely regarded as 
insensitive, and newer diagnostic tests are incompletely evaluated. In addition, the 
pathogenesis of TBM remains so poorly understood that prospects for new 
interventions to improve outcome are few.
This thesis examines the diagnosis and pathophysiology of TBM in adults admitted to 
an infectious disease hospital in Ho Chi Minh City, Vietnam. The aim was to address 
three questions: what is the best method for distinguishing TBM from other central 
nervous system disorders, how does disease pathophysiology relate to treatment and 
clinical outcome, and what other variables influence prognosis?
Three methods for the diagnosis of TBM were studied: clinical, bacteriological and 
molecular. A diagnostic rule developed from five clinical features predictive of TBM 
was 86% sensitive and 79% specific when applied prospectively. A bacteriological 
diagnosis of TBM was confirmed in 107/132 (81%) adults: acid-fast bacilli were seen 
in 58% and cultured from 71%. Volume of CSF, duration of symptoms, CSF 
neutrophils, lactate and glucose all predicted bacteriological confirmation. The 
sensitivity and specificity of CSF Ziehl-Neelsen stain (52% and 100%) was greater 
than nucleic acid amplification (Gen-Probe Amplified Mycobacterium tuberculosis 
Direct test) (38% and 9 9%), although the combined performance of these tests on 
serial samples detected 83% of cases.
The pathogenesis of TBM was investigated by identifying clinical and molecular 
markers of poor outcome. Treatment before the onset of coma independently 
predicted survival, and death was associated with high CSF concentrations of lactate, 
low numbers of white cells, in particular neutrophils, and low CSF glucose. CSF 
lactate concentration is a good indicator of disease severity and CSF bacterial load, 
and neutrophils may have a hitherto unreported protective role.
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CHAPTER 1
INTRODUCTION
1.1 Tuberculosis
In the seventeenth century John Bunyan described tuberculosis as, ‘The Captain of all 
these Men of Death’. In the late twentieth centuiy the World Health Organisation 
(WHO) pronounced it a ‘global emergency’. Whether described by poetry or prose, 
tuberculosis has been the leading global infectious cause of morbidity and mortality 
for more than 500 years.
In the early twentieth centuiy tuberculosis declined amongst the richer nations. In 
1900 the incidence of tuberculosis in the United States was approximately 250 per 
100,000, with a death rate greater than 100 per 100,000 (Iseman MD, 2000). By 1973 
the incidence had fallen to 15/100,000, with a death rate of less than 2/100,000. These 
figures fuelled enormous optimism b est e ncapsulated i n 1 969 by W illiam S tewart. 
Surgeon General to the United States, when he suggested it was, ‘time to close the 
book on infectious disease.’
Unfortunately, the figures for the rest of the world told a different story. In 1995 the 
WHO published an overview of the global impact of tuberculosis (Raviglione MC et 
a l, 1995). They estimated that one in three people was infected with the tubercle 
bacillus, and that in 1 990 there were approximately 8 million new cases of active 
tuberculosis and 2.6 million deaths. The estimated tuberculosis incidence rates by 
country are presented in Figure 1.1.
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Introduction
1.1.1 History of tuberculosis
Humans have probably suffered from tuberculosis for more than 5000 years. 
Examination of Egyptian mummified human remains from around 3400 B.C have 
revealed dorsal spine deformities consistent with spinal tuberculosis (Cave AJE, 
1939), and there are allusions to a group of pulmonary and extra-pulmonary diseases 
that probably represent tuberculosis in ancient Chinese writings from around 3 000 
B.C (Iseman MD, 2000). But it was not until the time of Hippocrates (circa 460-375 
B.C), and the flowering of Greek medicine, that tuberculosis first received systematic 
study. The Greeks called it Phthisis, which means ‘I am wasting’, and remains an 
appropriate clinical description of tuberculosis to the present day. But despite 
increasing clinical recognition, the Greek understanding of the disease remained 
rudimentary. Unfortunately, Aristotle’s (354-322 B.C) prescient observation fell 
unheeded:
Why when one comes near consumptives does one contract their disease, 
while one does not contract dropsy, or apoplexy... ? With consumption, the 
reason is that the breath is bad and heavy.... One takes the disease 
because there is in the air something disease-producing.
It was to be another 1860 years until Girolamus Frascatorius (1483-1553) re­
examined Aristotle’s observations. His book De Contagioni (1546) concluded that 
there were three major routes of infection transmission: spread by direct contact; 
spread by an intermediary, or fomite; and spread over a distance involving tiny 
infectious particles which he called ‘seminaria’. The contagious theory of disease was
24
Introduction
bom, but remained highly controversial for a further 300 years and unaccepted by 
many physicians caring for patients with phthisis during this period.
The Age of Enlightenment brought new rigor to the study of phthisis. At the 
beginning of the seventeenth century, the English philosopher Francis Bacon 
formulated the ‘scientific method’: the generation of testable hypotheses from 
observable facts. For physicians this meant careful clinical observation of the living, 
and autopsy of the deceased. The post-mortem observations of Franciscus de la Boe, 
Professor of Anatomical Medicine at Leiden, were the first to describe the profusion 
of nodules within the organs of phthisical patients, and refer to them as ‘tubercles’. 
Then, in 1821, the French physician Laennec recognised that all the diverse clinical 
forms of ‘tubercle’ were a single disorder (Laennec RTH, 1821), although his thesis 
only gained complete acceptance with the discovery of the causative agent of 
‘tuberculosis’.
It took 217 days for Robert Koch to make that discovery (Brock TD, 1988). He began 
his first experiments on August 18^ ,^ 1881; reported his findings to the Berlin 
Physiological Society on March 24^ ,^ 1882; and published the paper three weeks later 
(Koch R, 1882). During this period Koch stained and cultured the bacillus for the first 
time, demonstrated its presence in tuberculous tissue, and inoculated guinea pigs with 
the culture to reproduce the disease. He concluded:
All these facts taken together lead to the conclusion that the bacilli which 
are present in the tuberculous substances not only accompany the 
tuberculosis process, but are the cause o f it. In the bacillus we have, 
therefore, the actual tubercle virus. (Koch R, 1882)
25
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1.1.2 Tuberculosis nomenclature and bacteriology
Koch’s tubercle bacilli belongs to the genus Mycobacterium (meaning ‘fungus- 
bacterium’), members of which share the property of ‘acid fastness’, the characteristic 
ability to resist decolourisation in the presence of a weak mineral acid after staining 
with an arylmethane dye (Collins CH et a l, 1997). In 1898 Theobold Smith divided 
the tubercle bacilli into human and bovine varieties (Smith T, 1898): Mycobacterium 
tuberculosis and Mycobacterium bovis. To these have been added Mycobacterium 
microti (Wells AQ, 1946), Mycobacterium africanum, the vaccine strain Bacille 
Calmette-Guerin (BCG) (Skerman VDB et a l, 1980), and more recently 
Mycobacterium canetti (van Soolingen D et a l, 1997). Together they are referred to 
as "Mycobacterium tuberculosis complex’, and only members of this group can cause 
human ‘tuberculosis’, although Mycobacterium microti, BCG, and Canetti rarely 
cause disease. Other members of the genus Mycobacterium can cause disease in 
humans, particularly in immune compromised individuals, but these diseases are not 
labelled as ‘tuberculosis’.
This thesis is concerned only with "Mycobacterium tuberculosis complex’ infection, 
although for ease and consistency the agent will simply be referred to as 
Mycobacterium tuberculosis {M.tb).
1.1.3 Tuberculosis infection and transmission
As with many infectious diseases, the number of people suffering from tuberculosis 
disease is a fraction of the total number infected. Estimates of the number infected 
have conventionally been calculated by intra-dermal reactivity to a purified protein
26
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derivative (PPD) of M.tb (ATS, 1990). Reactivity is taken to represent exposure with 
infection: one in three people are believed infected, and it is estimated that one in ten 
of these will develop active disease (Raviglione MC et ah, 1995). Active disease is 
broadly divided into three categories: sputum smear-positive pulmonaiy disease; 
sputum-smear negative pulmonary disease; and extra-pulmonary disease. Smear- 
positive disease is defined by demonstration of acid-fast bacilli (AFB) within a 
clinical specimen by light microscopy. From an epidemiological perspective, 
individuals with sputum smear-positive disease are the most important, as they 
represent infectious cases and are responsible for the majority of tuberculosis 
transmission (Grzybowski S et a l, 1975). The WHO, and International Union against 
Tuberculosis and Lung Disease (lUATLD), hold the detection and treatment of 
sputum smear-positive cases to be a fundamental tenet of tuberculosis control (WHO, 
1997)(ReiderHL, 2002).
Much of the current understanding of the airborne transmission of tuberculosis comes 
from a series of elegant experiments performed by Riley between 1956 and 1961 
(Riley RL et a l, 1961). Riley designed a ward for patients with tuberculosis in which 
the air from each room was ducted into cages containing guinea pigs (which are 
naturally highly susceptible to M.tb infection) (Riley RL et a l, 1962). The air leaving 
each room was split into equal columns, each being delivered to a different group of 
animals, with one column being irradiated with ultra-violet (UV) light. Monthly PPD 
skin testing of all animals identified those newly infected, and those found to be 
reactive were killed and dissected. There were no infections amongst the guinea pigs
27
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breathing UV irradiated air, but amongst the rest the average time to infection was 10 
days. Untreated patients and one adult with tuberculous laryngitis were responsible 
for the majority of infections. The study findings validate the theory of droplet­
generated airborne transmission of tuberculosis, and supported the premise that the 
likelihood of transmission increased with the concentration of airborne infectious 
particles and the volume of air inhaled.
Tuberculosis transmission by other routes can occur, but is rare. Infection with 
Mycobacterium bovis (a member of the Mycobacterium tuberculosis complex) 
through ingestion of contaminated cows milk used to be a significant global cause of 
tuberculosis but pasteurisation has largely removed this risk, alongside case detection 
with PPD skin tests and slaughter of infected animals. However, in regions with 
limited access to  these preventative measures, this route of transmission remains a 
major public health problem.
1.1.4 Risk factors for tuberculosis
There are two broad categories of risk for tuberculosis: environmental, and biological. 
Environmental risk factors determine the intensity and duration of exposure of an 
individual to other individuals with infectious tuberculosis. Prominent amongst this 
group are prisons, nursing homes, homeless shelters, and hospitals. High transmission 
rates and well-documented outbreaks have been reported in all of these institutions 
(Stead WW, 1978; Stead WW, 1981; Schieffelbein CW, Jr. et a l, 1988; Sepkowitz 
KA, 1994). However, sustained physical proximity is not the only reason these
28
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environments present special risk. Their populations frequently possess numerous 
biological reasons for increased susceptibility to tuberculosis. Alcohol dependence, 
intra-venous drug use, and human immunodeficiency virus (HIV) infection are 
common biological risk factors shared by the homeless and those in prisons (Iseman 
MD, 2000). Other important biological risk factors, often shared by those in nursing 
homes or hospitals, are diabetes mellitus (Kim SJ et a l, 1995), corticosteroid therapy 
(Sahn SA et a l, 1976), gastrectomy (Snider DE, Jr., 1985), end-stage renal disease 
(Andrew OT et a l, 1980), silicosis (Snider DE, Jr., 1978), and malnutrition (ATS, 
1994). Most recently, tobacco smoking has been shown to be a major risk factor for 
disease and death from pulmonary tuberculosis (Gajalakshmi V et a l, 2003). Many of 
these factors are believed to alter the immune response to infection with M.tb, and 
compromise the individual’s ability to resolve new infection or control reactivation of 
latent bacilli. The clearest example is HIV infection, which alters the risk of 
reactivation from 1 in 10 to 1 in 3 (Selwyn PA et a l, 1989), and increases the 
likelihood of progressive disease after new infection with M.tb (Di Perri G et a l ,  
1989). The HIV epidemic has had, and will continue to have, an enormous impact on 
the global prevalence of tuberculosis. WHO estimate that there are 40 million people 
currently infected with HIV of whom approximately 13 million are co-infected with 
tuberculosis (WHO, 2002). Estimated numbers of HIV-infected tuberculosis cases per
100,000 population in 2000 are shown in Figure 1.2. Conservative estimates, which 
take no account of rates of new infection, suggest that 4 million will reactivate and 
require treatment for active tuberculosis. Consequently, HIV infection dwarfs all other 
risk factors for tuberculosis.
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1.1.5 Clinical Tuberculosis
Tuberculosis can affect any organ of the body, but the first site of infection is nearly 
always the lung. In settings of high tuberculosis prevalence this ‘primary infection’ 
usually occurs in childhood and is asymptomatic in more than half (Starke JR et a l, 
1989). In the rest, the symptoms of cough and fever predominate (Pineda PR et a l,
1993). In most symptomatic cases the chest X-ray reveals hilar, mediastinal, or 
paratracheal lymphadenopathy (Figure 1.3), and there is evidence of lung 
parenchymal involvement in around 75% (Pineda PR et a l, 1993). The majority of 
primary infections are uncomplicated, but on rare occasions progressive primary 
tuberculosis develops: lung parenchymal involvement increases in the form of an
Figure 1.3 Primary tuberculosis with hilar lymphadeuopathy (arrow) (Hospital 
for Tropical Diseases [HTD])
%
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Figure 1.4 Typical Chest X-ray appearances of pulmonary tuberculosis: bilateral 
apical shadowing and cavities (arrows) (HTD)
/
intense and localised pneumonia, sometimes leading to the formation of cavities and 
often with haematogenous dissemination. The prognosis of this type of disease is 
poor.
The traditional distinction of primary from post-primary tuberculosis depends upon 
whether disease occurred before or after 5 years from the initial infection (Iseman 
MD, 2000). This arbitrary definition is only useful if all post-primary disease is 
considered to be consequent to endogenous reactivation of latent bacilli. There are 
increasing data to suggest this assumption is incorrect (Fine PE et a l, 1999). Recent 
studies using DNA fingerprinting techniques have shown that substantial numbers of 
adult post-primary pulmonary disease is due to re-infection with a different strain of
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M.tb (van Rie A et a l, 1999; Chaves F et a l, 1999). However, whilst re-infections 
may be more important than previously thought, the majority of disease in low 
prevalence settings is due to reactivation (Fine PE et a l, 1999).
Pulmonary tuberculosis is the commonest clinical phenotype, accounting for 
approximately 80% of all forms of tuberculosis (Iseman MD, 2000). Patients usually 
present with the symptoms of cough, fever, weight loss, and blood is often reported in 
the sputum (haemoptysis). Pulmonary tuberculosis is usually a slowly progressive 
condition: patients present with many days, if not weeks, of gradually worsening 
symptoms. Rapidly progressive disease does occur, particularly in some racial groups 
believed to be more susceptible to the disease (Stead WW, 1992). Physical 
examination is often unremarkable: the wasted, pthisical characteristics noted by the 
Greeks may not be present in early disease; chest examination is frequently normal (it 
is harder to elicit physical signs from the affected lung apices than the middle and 
lower lobes); and extra-pulmonary signs may be few. Fever is not universal, and in 
the elderly, in particular, may be absent (Korzeniewska-Kosela M et a l, 1994). 
Despite limited physical signs. X-ray of the chest will reveal the characteristics and 
extent of the disease (Figure 1.4). For reasons that remain obscure, pulmonary 
tuberculosis most frequently involves the lung apices (Balasubramanian V et a l,
1994). Complications of the disease include the formation of pulmonary cavities, 
sometimes with massive haemoptysis as a result of arterial invasion, pneumothorax 
with broncho-pleural fistulae, and contiguous spread to the mediastinum (the 
pericardium, for example), pleura and vertebral column (Figure 1.5).
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Figure 1.5. Tuberculous destruction of the thoracic vertebrae (arrow) (Potts 
disease) arising from secondary spread from the lung (HTD)
The advent of anti-tuberculosis chemotherapy (ATC) dramatically reduced the 
incidence of these complications, although they are being seen again in those with 
multi-drug resistant tuberculosis (Tahaoglu K et a l, 2001).
Haematogenous dissemination of the bacilli can occur at any time during infection 
with M.tb, and can result in infection of any organ (see Figures 1.6 and 1.7). 
Commonly affected are the brain, the kidneys, the bones and the cervical lymph nodes 
that drain the pulmonary vessels. In the United States in 2001, there were 15,989 
cases of tuberculosis reported to the Centre for Disease Control, Atlanta (CDC): 
12,768 (80%) were pulmonary, and 3,212 (20%) were extra-pulmonary (CDC, 2001).
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Figure 1.6 Dbsemmafed extra-pulmonary tuberculosis: bilateral fusiform psoas 
abscesses (thick arrows) with vertebral osteomyelitis (thin arrow) by MRI (HTD)
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Figure 1.7 IMscliargmg tuberculous lymph node (arrow), or scrofula, in an HIV 
infected adult with tuberculous meningitis (HTD)
35
Introduction
The extra-pulmonaiy cases reported were pleural (19%), lymph node (42%), bone or 
joint (10%), genito-urinary tract (6%), meningeal (6%), peritoneal (4%), and other 
sites (13%).
The proportion of extra-pulmonary cases has risen over the last 40 years in the United 
States and other wealthy countries for reasons that are poorly defined. HIV infection 
increases the risk of disseminated disease and is an important component of this 
change. Also important are the changes in the demographic profile of those with 
tuberculosis: in affluent countries, such as the United States, the burden of disease 
now falls amongst racial and ethnic minorities and recent immigrants.
The clinical manifestations of extra-pulmonary tuberculosis are as diverse as the 
organs it can affect, and it is not within the scope of this thesis to review them all. 
However, the non-specific clinical presentations, the difficulty in obtaining adequate 
diagnostic samples, and the paucity of bacilli causing disease, all serve to make the 
diagnosis difficult. Tuberculous meningitis, the focus of this thesis, provides an 
excellent example of all of these problems.
1.1.6 Diagnosis of tuberculosis
For most of the world the diagnostic methods for tuberculosis have not changed for 
120 years. Only recently have efforts been made to develop new diagnostic assays, 
some of which are available in the laboratories of wealthy countries. Fortunately, the 
diagnostic method developed by Franz Ziehl (1857-1926) and Friedrich Neelsen 
(1854-1894) in 1882 has sufficient diagnostic sensitivity and specificity to detect
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those with the most infectious forms of the disease, and therefore forms the basis of 
global tuberculosis control programmes. The Ziehl-Neelsen (ZN) stain depends upon 
the ‘acid-alcohol fast’ biological properties oïM.tb. Paul Ehrlich first elucidated these 
properties in 1882 (Ehrlich P, 1882), and they were developed into a test by Ziehl and 
Neelsen. Neelsen introduced the use of the dye basic fuchsin and found that tubercle 
bacilli were identifiable from nearly all other species of bacteria by their ability to 
resist decolouration with weakly acidified alcohol (Neelsen F, 1883). He found the 
red stained bacilli were easier to visualise with the background counter-stained with 
methylene blue (Figure 1.8). Small variations on this method exist, but the principles 
remain unchanged today.
The demonstration of AFB in the sputum of a patient suspected of tuberculosis is the 
primary diagnostic method for much of the world. However, there are some important 
limitations to this technique. First, the sensitivity of a direct sputum smear is between 
50-60% (Collins CH et a l, 1997). Examining at least 3 specimens, and concentrating 
the specimen by centrifugation after the addition of a mucolytic agent can increase the 
sensitivity. Second, it is impossible to tell the species of mycobacteria by microscopy. 
Other mycobacteria {Mycobacterium kansasii, for example) can cause pulmonary 
disease, or can contaminate respiratory specimens without causing disease. Only 
culture of the mycobacteria will allow a full identification and confirm the diagnosis 
of tuberculosis. More recently, fluorescence microscopy using the auromine- 
rhodamine stain has improved the speed and ease of microscopy. The staining 
principles are exactly the same, except the auromine-rhodamine stained bacilli 
fluoresce when excited with UV light. The bacilli are easier to see than by ZN
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Figure 1.8 Acid>fast bacilli in cerebrospinal fluid (arrow) (HTD)
Figure 1.9 Culture of Mycobacterium tuberculosis on Lowenstein-Jensen media
(HTD)
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stain, and slides can be quickly and effectively screened under low magnification. 
However, when few bacilli are present (in cerebrospinal fluid, for example), 
fluorescing debris can be mistaken for bacilli, and a confirmatory ZN stain should 
always be performed.
Confirmation of infection with M.tb can only be made by culture, but as Robert Koch 
found, M.tb does not grow well on conventional media. Koch eventually found the 
bacilli grew well on slopes of coagulated blood serum (Brock TD, 1988), and 
subsequently many different culture media have been devised. The solid media 
currently used are egg-based (Lowenstein-Jensen, Figure 1.9) and agar based 
(Middlebrook’s 7H10 or 7H11). Liquid media (Middlebrook’s 7H9, or Kirchners 
media) are less selective but especially useful when culturing specimens other than 
sputum, when the chances of contamination with other bacterial species are low. 
Simple growth characteristics will allow the preliminary identification of M.tb. The 
early bacteriologists recognised that cultivable mycobacteria could be divided into 
‘rapid growers’ (growth on egg-media within 5 days) and ‘slow growers’. M.tb, and 
most other pathogenic mycobacteria are ‘slow growers’ -  they often take between 4 
and 8 weeks to produce significant colonies on egg-based solid media. M.tb grows 
best at 37®C, is non-pigmented, and demonstrates characteristic ‘cords’ of bacilli 
when stained by ZN, but the formal identification rests on an array of confirmatory 
tests, or more recently by nucleic acid probes (Collins CH et a l, 1997). It is not 
within the scope of this thesis to review these methods, but they are time-consuming 
and difficult, and are usually only performed by experienced technicians in reference
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laboratories. For these reasons, in many settings the culture and identification of M.tb 
remains impossible, and diagnosis rests upon the result of the ZN stain.
The lack of diagnostic sensitivity and specificity of conventional diagnostic methods, 
and the time required to culture and identify the organism, has led to the development 
of more rapid, nucleic acid-based techniques. It is now possible to determine whether 
a specimen contains M.tb nucleic acid and is likely to be resistant to rifampicin within 
a few hours (Watterson SA et a l, 2000). However, despite the promise of these 
methods, their performance and role in clinical decision-making remains unclear 
(PfyfferGE, 1999).
The amplification and detection of regions of M  ^ 6-specific nucleic acid from clinical 
specimens is an attractive diagnostic prospect. To date, the Food and Drug 
Administration (FDA) of the United States have cleared two nucleic acid 
amplification assays for the direct detection of M.tb in respiratory samples: the 
Amplified Mycobacterium tuberculosis Direct Test (MTD) (Gen-Probe, Inc, San 
Diego, California) and the AMPLICOR Mycobacterium tuberculosis test (Roche 
Diagnostics, Inc, Indianapolis, Ind). The performance of these assays was good when 
testing AFB smear-positive specimens (sensitivity 95-96%, specificity 100%), but 
less satisfactory when AFB smear-negative sputum was tested (sensitivity 48-53%, 
specificity 96-99%) (Woods GL, 2001). As a consequence, the FDA limited the 
licence of these test to smear-positive specimens, and attempts were made to improve 
the performance of the assays in the smear-negative group. Gen-Probe modified the 
MTD to enhance sensitivity, and decrease the time-to-result. These efforts were 
rewarded in September 1999 when the FDA extended the licence of the improved
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MTD to include all respiratoiy samples, regardless of smear result. It remains the only 
test with a licence extending to all respiratory specimens. To date, the published data 
suggest the MTD performs well for the diagnosis of pulmonary tuberculosis, 
regardless o f  AFB smear result, provided there is a moderate to  high suspicion of 
tuberculosis (Gamboa F et a l, 1998; Bergmann JS et a l, 1999). These data suggest 
the sensitivity, specificity, and the positive and negative predictive values of the new 
MTD are approaching 100% for smear-positive respiratory specimens, and are 83%, 
99%, 71% and 99% respectively for smear-negative samples.
These assays are not licensed for use on extra-pulmonary samples, and there are 
limited data on their diagnostic performance with these types of specimens. Low 
concentrations of bacilli, small volumes of sample, and assay inhibitors, all contribute 
to low diagnostic sensitivity (Pfyffer GE, 1999). Attempts to increase diagnostic 
sensitivity have lead to unacceptable falls in specificity, and the role of the nucleic 
acid amplification techniques for the diagnosis of extra-pulmonary tuberculosis 
remains uncertain. These methods will be discussed in more detail below with respect 
to the diagnosis of TBM.
In summary, the currently available molecular diagnostic methods increase diagnostic 
speed, but they do not replace AFB smear and culture. On smear-positive specimens 
they have been shown to be highly reliable in confirming infection with M.tb. 
However, positive results on smear-negative specimens must be interpreted with 
caution, and treatment decisions should be based on the complete clinical picture.
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1.1.7 Treatment of tuberculosis
There was no effective treatment for tuberculosis until 1944. The Greeks and the 
Romans advocated fresh air and rest: factors they believed could redress the 
imbalance of the humors causing the disease. Two thousand years later, belief in the 
therapeutic effect of clean air remained, and led to the development of the 
tuberculosis sanatoria. Hermann Brehmer is credited with opening the first European 
‘Kurhaus’ for tubercular patients in 1859, inspiring Edward Trudeau to develop a 
similar institution in the United States at Saranac Lake in 1875. By 1942 there were 
nearly 100,000 sanatorium beds in the United States and similar numbers in European 
Alps, providing fashionable retreats for the tubercular middle and upper classes. They 
inspired some (notably Thomas Mann, who wrote The Magic Mountain in 1924 after 
his experiences in a sanatorium in Davos, Switzerland), but cured no one. However, 
institutionalising tuberculosis allowed physicians to experiment with alternative 
treatments on large numbers of individuals. Some of the methods developed were at 
best misguided and at worst dangerous and deforming. Pulmonary collapse therapy, 
either by pneumothorax, phrenic crush, or pneumoperitoneum, led the way, regardless 
of the lack of evidence for it working.
The chemotherapeutic era began with the inspiration from a soil microbiologist from 
the Ukraine and a Biochemist from Sweden. Selman Waksman was bom in the 
Ukraine and immigrated to the United States in 1910. By the 1930’s he was studying 
the mechanisms of action of fungal enzymes found in the soil and driven by the 
possibility of a soil microbe that could kill the tubercle bacillus. In 1943 Waksman’s 
laboratory discovered that Streptomyces griseus produced a substance that inhibited
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the growth of a wide range of bacteria, including M.tb. They named the substance 
streptomycin.
Jorgen Lehmann, a Dane working in Sweden, approached the same problem from a 
different perspective. In 1941 a single page report appeared in the journal Science that 
showed salicylate greatly increased the oxygen uptake of M.tb (Bemheim F, 1941). 
Lehmann reasoned that alteration of the salicylate molecule might inhibit M.tb 
metabolism, and believed the para-amino salt of salicylate was most likely to work. In 
1944, despite difficulties with production, Lehmann showed that para-amino salicylic 
acid (PAS) inhibited growth of M.tb in vitro, and was capable of reducing disease in 
both guinea pigs and humans.
The assessment of these two drugs for the treatment of tuberculosis was a defining 
moment in medicine. The need for a rapid, authoritative, unbiased assessment was 
recognised as paramount. The methodology chosen -  the random assignment of 
control and experimental treatment regimens -  would become the cornerstone of 
clinical research. The British Medical Research Council (MRC) performed the first of 
such trials, comparing streptomycin with bed-rest for acute progressive bilateral 
pulmonary tuberculosis (MRC, 1948a). This study showed that over 6 months 
streptomycin reduced mortality and improved bacteriological and radiological cure 
rates. However, resistance to  streptomycin developed in 35/41 patients and after 5 
years of follow-up the deaths in the streptomycin group (53%) were only slightly less 
than in controls (63%). Urgent strategies were required to overcome the problem of 
resistance and in 1948 the MRC started a trial comparing streptomycin alone, PAS
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alone, and the two in combination. It demonstrated unequivocally that combined 
therapy reduced the risk of acquisition of resistance (Fox W et a l, 1956).
Consistent and complete cures only became reality in 1952 with the addition of 
isoniazid to these two drugs. Although the curative power of this three-drug regimen 
was recognised quickly by some (Crofton J, 1958), it took some y ears t o b ecome 
universally accepted. There was a reasonable basis for scepticism: data from 
randomised trials were slow to appear and conclusive evidence of the efficacy of all 
three drugs in combination did not become available until 1964 (lUATLD, 1964).
At least 12 months of treatment were required for sustained cure with these regimens. 
The advent of ethambutol led to its exchange with PAS (which caused frequent side 
effects), and a better tolerated regimen (Doster B et a l, 1973), but reductions in 
treatment 1 ength only became possible with the addition of rifampcin. Rifampicin- 
containing regimens were tested in three different durations of chemotherapy: six, 
nine, and twelve months (Brouet G et al, 1977). The trial demonstrated that a 
sustained cure was possible with 9-months of treatment and the term ‘short-course 
chemotherapy’ was invented (Fox W, 1981).
A series of trials performed by the MRC in East and Central Africa defined the limits 
of ‘short course chemotherapy’, and demonstrated that complete cure could be 
achieved with 6-months (Fox W et a l, 1999). They discovered that pyrazinamide (a 
drug that was discarded initially due to fears of hepatic toxicity), in combination with 
rifampicin and isoniazid, showed powerful sterilising activity with rapid conversion to 
smear-negative sputum. After further trials in Hong Kong, Singapore, Madras and
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Algeria, it was shown that the best results were achieved using an ‘intensive’ phase of 
2-months rifampicin, isoniazid and pyrazinamide, followed by a ‘continuation’ phase 
of 4-months rifampicin and isoniazid. Thioacetazone or ethambutol could replace 
rifampicin in the continuation phase, but treatment should be extended by 2 months. 
The mechanisms of action of the first-line drugs, and ways in which M.tb can become 
resistant to their effects, are presented in Table 1.1.
By the late 1970’s the best drug combinations and the duration of treatment required 
had been worked out. Then, in 1986, the tuberculosis trials units of the MRC closed. 
In 40 years they had delineated all of the measures necessary for successful 
tuberculosis control, the optimal drug regimens and the importance of directly 
observed therapy (DOT). Two subsequent events suggest the closure of these units 
was premature. The first was predictable: the increasing prevalence of drug resistance 
and resulting treatment failures. The second, the arrival of HIV, was not predictable, 
although by 1986 there was already clear evidence that tuberculosis and HIV had a 
special relationship (Raymond CA, 1986)).
Patients with multi-drug resistant tuberculosis (defined as resistance to at least 
rifampicin and isoniazid) are considered incurable with conventional regimens, and 
are left untreated in many countries (Farmer P, 2001). Other drugs exist, but to date 
there have been no randomised controlled clinical trials to evaluate these regimens. 
HIV threatens all tuberculosis control programmes and presents special problems in 
clinical management (Small PM et a l, 2001). Adverse drug events are more common 
and standard regimens may be 1 ess efficacious. In  particular, regimens that do not 
contain rifampicin have shown a high frequency of failure and relapse
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Table 1.1. Mechanisms of action, and modes of resistance, for the first-line anti­
tuberculosis drugs (Iseman MD, 2000; Kucers A et a l, 1997)
Drug Mechanism of action Mechanism of 
resistance
Mutation locus
(prevalence among 
resistant strains)
Streptomycin Inhibition of protein 
synthesis by binding to 3 OS 
subunit oîM.tb ribosomes
i) Mutations of 3OS 
subunit binding site
ii) Possible changes 
in cell permeability 
to drug
rpsL (ribosomal 
protein subunit 12) 
(60%)
res (16S ribosomal 
RNA) (25%)
Ethambutol Inhibits biosynthesis of 
M.tb cell wall, in particular 
arabinogalactan (AG) + 
lipoarabinomannan (LAM)
Mutation in gene 
encoding arabinosyl 
transferase causing 
increased AG+LAM
embAB (50%)
Isoniazid Uncertain. Prodrug 
activated by M.tb catalase 
peroxidase {KatG) inhibits 
mycolic acid synthesis
Uncertain. Multiple 
possible mechanisms 
and loci.
KatG (50%) 
InhA (25%) 
ahpC (15%) 
kasA (unknown)
Rifampicin Inhibits RNA polymerase 
preventing mRNA 
production
RNA polymerase 
subunit B mutation 
prevent drug binding
rpoB (98%)
Pyrazinamide Unknown. M.tb 
pyrazinamidase converts to 
active pyazinoic acid
Unknown. pncA (unknown)
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(Perriens I¥i et a l, 1991). Antiretroviral therapy introduces new problems when used 
in combination with ATC: protease inhibitors and the non-nucleoside reverse 
transcription inhibitors interact with the rifamycins (CDC, 1998), and immune 
reconstitution can cause paradoxical clinical worsening of tuberculosis (Narita M et 
a l, 1998). The best clinical management of these problems is uncertain, particularly 
in poorer countries. The relative lack of importance of these issues to wealthy 
countries and the closure of institutions such as the MRC Tuberculosis Unit 
previously designed to address them, has reduced the political will to  solve them. 
Moreover, the skills required to perform clinical trials in patients with tuberculosis 
have been neglected and have to be re-leamt. For all of these reasons, the treatment of 
tuberculosis remains a formidable challenge.
1.2 Tuberculous Meningitis
Tuberculous meningitis (TBM) is caused by infection of the meninges and 
parenchyma of the brain or spinal cord with M.tb. TBM was invariably fatal before 
the advent of ATC. The post-mortem observations of Green, published in the Lancet 
in 1836 (Green PH, 1836), were the first to describe the distinct pathological features 
of the infection and set it apart from the other recognised causes of ‘acute 
hydrocephalus’. The challenge for the physician then lay in distinguishing the disease 
before death, and delivering the grave prognosis.
The ability to diagnose TBM became a priority in 1948 after streptomycin was found 
to reduce mortality by one third (MRC, 1948b). Over the next 5 years progress was 
rapid: the addition of para-aminosalicylic acid to streptomycin reduced mortality to
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30% and the addition of isoniazid to both of these compounds lowered the mortality 
to around 20% (Lorber J, 1960). However, the mortality from TBM has altered little 
since the introduction of isoniazid in 1952. The decline of tuberculosis in the 
developed world over this period lessened the search for new drugs and diagnostic 
methods. As a consequence, in 2003, the most widely available rapid diagnostic 
method for TBM remains the stain developed by Ziehl and Neelsen 120 years ago and 
the anti-tuberculosis drug regimen has not changed since the discovery of rifampicin 
and pyrazinamide more than 30 years ago.
1.2.1 Epidemiology of tuberculous meningitis
Prior to  the arrival of HIV the most important determinant for the development of 
TBM was age. In populations with high tuberculosis prevalence the peak age of 
incidence is from 0 - 4  years (Farer LS et a l, 1979), and there is close correlation 
between the incidence of TBM in this age group and the population annual average 
risk of M.tb infection. The childhood incidence of TBM probably represents 1% of 
the annual risk of infection in the overall population (de March-Ayuela P, 1994). 
Adults with infectious pulmonary tuberculosis are the greatest danger to children, as 
they are the source of most childhood TBM and successful adult treatment 
programmes have been shown to reduce the incidence of childhood TBM (Zhang LX 
et a l, 2000a).
In populations with lower tuberculosis prevalence, most cases of TBM are in adults. 
Recent series suggests that an increasing proportion of these adults are immigrants 
from areas of high prevalence for tuberculosis (Bidstrup C et a l, 2002). Risk factors
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also identified for the development of TBM are alcoholism, diabetes mellitus, 
malignancy and recent corticosteroid u se (Davis LE et a l, 1993; Mori MA et a l ,  
1992; Pablos-Mendez A et a l, 1997). However, co-infection with HIV now dwarfs 
these risk factors. HIV increases the lifetime risk of developing clinical tuberculosis 
post-infection to 1 in 3 (Selwyn PA et a l, 1989), and in particular, predisposes to the 
development of extra-pulmonary tuberculosis and TBM (Bishburg E et a l, 1986). The 
risk increases as the CD4 count declines (De Cock KM et a l, 1992) and the disease 
constitutes either reactivation of latent infection, or new infection.
Evidence of genetic variability in human susceptibility to tuberculosis has been 
difficult to obtain. There are data to suggest some races are more susceptible to 
tuberculosis infection than others (Stead WW et a l, 1990) and more recent reports 
have focused upon specific allelic polymorphisms associated with the disease. Case- 
control association studies have recently revealed several polymorphisms in the 
NRAMPl gene and the vitamin D receptor gene that are associated with human 
susceptibility to tuberculosis (Bellamy R et a l, 1998; Wilkinson RJ et a l, 2000). 
Immunological and genetic studies support the notion that innate immunity may be 
important in the control of M.tb (van Crevel R et a l, 2002), and an inadequate early 
innate immune response represents one hypothesis to explain the haematogenous 
dispersal of M.tb from the lung to other tissues like the brain. However, the extent to 
which an individual's genetic constitution affects resistance or susceptibility to 
infection remains uncertain (Bloom BR et a l, 1998) and there are no data to suggest 
genetic susceptibility to cerebral tuberculosis.
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Whether BCG vaccination affords protection against pulmonary tuberculosis is still 
debated. A meta-analysis of the published trials on the efficacy of BCG vaccination 
suggested a protective effect against TBM of 64% (Colditz GA et a l, 1994). This 
figure is higher than that suggested for pulmonary tuberculosis (50%), but may only 
reflect more accurate case ascertainment of TBM given the universal requirement for 
hospitalisation. There are data from populations in which BCG vaccination has been 
withdrawn that suggests stopping vaccination has had no impact of the incidence of 
TBM (Zhang LX et a l, 2000b). However, it is likely that BCG vaccination protects 
against haematogenous dissemination of M.tb in childhood, in particular against 
miliary and cerebral tuberculosis.
1.2.2 Causative agent of tuberculous meningitis
The characteristics o f M.tb enabling it to cause disease are complex and incompletely 
understood. Evidence that clinical isolates of M.tb have different biological 
characteristics has long been available. As discussed earlier, Riley demonstrated that 
guinea pigs exposed to air vented from the hospital rooms o f  tuberculosis patients 
showed remarkable variations in transmission (Riley RL et a l, 1961). The variations 
may be explained by differences in environment, infectious burden and host 
immunity. Experimental evidence suggests that the virulence of individual strains is 
also significant and selected gene mutations have been shown to affect virulence 
(Collins DM et a l, 1995; Valway SE et a l, 1998).
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More recently, particular strains of tuberculosis have been associated with high rates 
of person-to-person transmission (Valway SE et a l, 1998) and possibly with cerebral 
tuberculosis (Arvanitakis Z et a l, 1998). There are, however, few data on the 
molecular characteristics of M.tb strains associated with different clinical phenotypes 
or outcomes. The determination of the complete genomic sequence for M.tb should 
accelerate research and understanding (Cole ST et a l, 1998) and future opportunities 
for research in this area are discussed in Chapter 8.
1.2.3 Pathogenesis of tuberculous meningitis
The pathogenesis of TBM can be viewed on two levels: macroscopically there are the 
mechanisms by which the bacilli disseminate to the CNS; microscopically there are 
the cellular and immune mechanisms that can result in the disease and its control.
The macroscopic development of TBM is a two-step process (Rich AR et al., 1933). 
Bacilli enter the host lung by droplet inhalation, and invade the pulmonary alveolar 
macrophage. Local infection escalates within the lung and disseminates to the 
regional lymph nodes producing the 'primaiy complex' characterised by the chest X- 
ray appearances of hilar lymph node enlargement and evidence of peripheral 
pulmonary infection (Figure 1.3). During this stage there may be a short but 
significant bacteraemia that can seed tubercle bacilli to other organs in the body. In 
those who develop TBM, bacilli seed to the meninges or brain parenchyma, forming 
small subpial or subependymal foci. These are called Rich foci, after the author of the 
original pathological studies describing this sequence of events (Rich AR et al., 
1933). In approximately 10% of cases, particularly in children, the primary complex
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does not heal but progresses to ‘primary progressive tuberculosis’. Tuberculous 
pneumonia develops with heavier and more prolonged bacillaemia, and dissemination 
to the brain is more likely.
The second step in the development of TBM is rupture of a Rich focus into the 
subarachnoid space. This heralds the onset of meningitis, which if left untreated, will 
result in severe and irreversible neurological pathology. In 75% of children the onset 
of TBM is less than 12 months after the primary infection (Lincoln EM et a l, 1960). 
This period is believed to be much longer in adults. Three processes produce the 
subsequent neurological pathology: adhesion formation, an obliterative vasculitis and 
an encephalitis or myelitis (Dastur DK et a l, 1995). Adhesions result from a dense 
basal meningeal exudate that develops following inoculation of bacilli into the 
subarachnoid space. The exudate contains lymphocytes, plasma cells and 
macrophages, with increasing quantities of fibrin. Blockage, through adhesion 
formation, of the basal subarachnoid cisterns can result in obstruction of the 
cerebrospinal fluid (CSF) and hydrocephalus (Figure 1.10). Adhesions around the 
interpendicular fossa and related structures can compromise cranial nerves, 
particularly III, IV and VI, and the internal carotid artery. An obliterative vasculitis of 
both large and small vessels develops that can result in infarction and stroke 
syndromes (Figure 1.11). These commonly occur in the territories of the internal 
carotid artery, proximal middle cerebral artery and the perforating vessels to the basal 
ganglia (HsiehFY et a l ,  1 992). Infarction through vasculitis is the mechanism by 
which many of the diverse clinical neurological abnormalities in TBM occur, and 
accounts for an appreciable part of the irreversible neurological sequelae.
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Figure 1.10 Gross hydrocephalus secondary to TBM (MRI) (HTD)
n
%
%
Figure 1.11 Infarction (thin arrow) secondary to extensive inflammatory exudates 
(thick arrow) compromising the left middle cerebral artery (MRI) (HTD)
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The intensity of the basal inflammatory process extends into the parenchyma resulting 
in encephalitis. Oedema, occurring as a consequence, can be marked throughout both 
hemispheres, and will contribute to rising intra-cranial pressure and the global clinical 
neurological deficit.
The pathogenesis of TBM at the cellular and molecular level is poorly understood. 
Knowledge regarding the pathogenesis of pulmonary infection is limited, but may 
serve to illustrate some of the processes evident in the central nervous system (CNS). 
Theories of tuberculosis immuno-pathogenesis try to explain the roles and interactions 
between macrophage, T-helper cell and M.tb. Cell-mediated immunity is central to 
both the control of infection and the production of tissue damage (Dannenberg AM, 
Jr., 1991). Lurie's experiments on tuberculosis in rabbits described the fundamental 
stages of the disease (Lurie MB, 1964), and theories of immuno-pathogenesis aim to 
explain these stages.
The initial stage of infection is the ingestion o f  the inhaled tubercle bacilli by  the 
alveolar macrophage. The bacilli multiply, and destroy the macrophage, depending on 
the ability of the macrophage to resist infection. The innate and possibly genetically 
determined resistance to infection at this stage has been discussed earlier. During the 
second stage bacilli grow logarithmically within newly recruited macrophages 
(Dannenberg AM, Jr., 1991). After approximately 2 weeks CD4 T-cells specific for 
mycobacterial peptides appear. Activated macrophages produce interleukin 1-beta, 
and tumour necrosis factor- alpha (TNF-a) that promote granuloma formation and 
enhance bacterial killing (Flynn JL et a l, 2001).
The primary complex results in the development of cell-mediated immunity; therefore
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the rupture of the Rich focus, with release of bacilli into the subarachnoid space, 
probably results in a local T-cell dependant response. This response is characterised 
macroscopically as caseating granulomatous inflammation (Dastur DK et a l, 1995). 
Dannenberg hypothesizes that necrosis is the result of a delayed-type hypersensitivity 
reaction to exposed tuberculoproteins (Dannenberg AM, Jr., 1991). Others propose 
that the granuloma architecture dictates the extent of the central necrosis: a reduced 
capacity for focusing T-lymphocytes within a point of infection may result in failure 
to deliver adequate cytokine concentrations to the centres of large granulomas, 
resulting in degeneration and necrosis (Orme IM, 1998; Turner OC et a l, 2003).
The intra-cerebral immune response to M.tb is at least in part dependent on the 
production and regulation of cytokines. M.tb induces TNF-a secretion from 
macrophages, dendritic cells and T-cells and is required for successful control of 
infection (Flynn JL et a l, 2001). In particular, TNF-a is considered to be critical for 
granuloma formation (Flynn JL et a l, 1995), but is also cited as a major factor in 
host-mediated destruction of infected tissue (Rook GA et a l, 1987). Small 
concentrations of TNF-a given to animals previously exposed to M tb result in 
substantial tissue necrosis (Filley EA et a l, 1991). Studies in bacterial meningitis 
show CSF levels of TNF-a correlated with disease severity (Sharief MK et a l, 1992). 
Rabbit models of TBM show CSF concentrations of TNF-a correlated with clinical 
progression (Tsenova L et a l, 1999), and intervention with antibiotics and 
thalidomide, an anti-TNF-a agent, resulted in an improvement in survival and 
neurological outcome (Tsenova L et a l, 1998).
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However, CSF TNF-a concentrations in TBM from human subjects are lower than in 
human bacterial meningitis (Akalin H et a l, 1994) or in the rabbit TBM model and 
have not been correlated with disease severity or outcome. Studies in humans have 
been small and have lacked the statistical power to confirm associations between any 
CSF cytokine and disease severity and outcome. Clearly, the roles of TNF-a in 
tuberculosis protection and disease are complex and incompletely understood. 
Although a protective response to M.tb is dependent on cell-mediated immunity, little 
is known about the cells present in the CSF in those with TBM and their role in 
pathogenesis. Clinical series attest to the difference in CSF cellular responses between 
bacterial and tuberculous meningitides: CSF cell counts in  bacterial meningitis are 
frequently greater than 5000 x 10^  white cells/ml, but in TBM they are rarely greater 
than 1000 x 10^  white cells/ml. Few studies have attempted to phenotype the cells 
beyond the basic divisions of neutrophil and lymphocyte. The limited available data 
suggests many of the lymphocytes are CD4+ T-helper cells (El-Naggar A et a l, 
1981), although more recent evidence suggests gamma delta (yô) T-cells (CD4 and 
CD8 negative) may be important (Dieli F et a l, 1999). Further characterisation of the 
cells, cytokines, and chemokines found in the CSF from patients with TBM and how 
they change with treatment is required to increase understanding of disease 
pathogenesis.
It is also clear that other classes of compounds may be important to pathogenesis, in 
particular the matrix metalloproteinases. These molecules, secreted by monocytes and 
macrophages, are zinc-containing proteases that degrade extra-cellular matrix (Goetzl 
EJ et a l, 1996). They may cause cerebral injury by disrupting the blood brain barrier
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(BBB), facilitating 1 eukocyte migration, and by cleaving myelin proteins. Elevated 
CSF matrix metalloproteinase-9 (MMP-9) concentrations have been associated with 
focal neurological deficit and fatal outcome in Vietnamese adults with TBM (Price 
NMer a/., 2001).
1.2.4 Clinical features of tuberculous meuiugitis
Physicians find the diagnosis of TBM difficult because the clinical features are 
variable and non-specific. These features have been extensively described in a 
multitude of case reports and clinical series and are similar to many sub-acute 
meningo-encephalitides (Davis LE et a l, 1993; Farinha NJ et a l, 2000; Girgis NI et 
a l, 1998; Kent SJ et a l, 1993; Verdon R et a l, 1996). Diagnostic uncertainty 
commonly arises in a comatose patient presenting with a few days of headache, fever 
and neck-stiffhess; undefined treatment in the community, and a CSF containing 
mostly lymphocytes, with a low glucose.
The patient’s description of the onset and variety of symptoms is often unhelpful. One 
series reported that on admission to hospital only 28% complained of headache, 25% 
were vomiting, 13% reported fever, and 2% described the classical meningitic 
symptoms of photophobia and neck stiffness (Kent SJ et a l, 1993). As a consequence, 
TBM was considered a diagnosis in 36% of cases, with only 6% receiving immediate 
treatment. A history of recent contact with tuberculosis may be more helpful, 
particularly in children: several studies report 50-90% of children recalled recent 
contact with an adult with tuberculosis (Donald PR et a l, 1998) (Farinha NJ et a l, 
2000).
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The neurological complications of TBM are legion (Leonard JM et a l, 1990). Their 
nature and diversity can be predicted from the site of disease and the pathogenesis. 
Adhesions can result in cranial nerve palsies (particularly II, III, FV, VI, VII), or 
constriction of the vessels resulting in stroke. Obstruction of CSF flow leads to raised 
intra cranial pressure, l^drocephalus and reduced conscious level (Figure 1.12 and 
1.13). In6rcts occur in approximately 30% of cases (Tartaglione T et al, 1998), 
commonly in the intOTial capsule and basal ganglia, causing a range of problems from 
hemiparesis to movanent disorders.
Seizures are more common in children than adults, and be caused by 
hydroc^halus, tuberculoma, oedema and hyponatraemia due to inappropriate anti­
diuretic hormone secretion. The diagnosis of spinal meningitis should be considered 
in those presenting with root pain, with dther spastic or flaccid paralysis and loss of 
sphincter control.
Figure 1.12 Right Lateral rectus palsy (Vlth cranial nerve) in young woman with 
TBM (HTD)
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Figure 1.11 Hydrocephalus and multiple tuberculomas in adult with TBM (CT
with contrast) (HTD)
Diagnosis is dependent on lumbar puncture and CSF examination. Abnormalities in 
the CSF depend upon a tuberculin reaction within the subarachnoid space. The usual 
findings are of between 100 -  1000 cells/mm3 in the CSF: the majority are normally 
lymphocytes, although neutrophils may predominate early in the disease (Jeren T et 
al,  1982). Those with depressed cell-mediated immunity may have atypical findings, 
and acellular CSF is reported in elderly and HIV positive patients (Karstaedt AS et 
al, 1998; Laguna F et a l,  1992). An elevated CSF protein occurs in the majority and 
CSF glucose will be reduced in 70% or more (Verdon R et a l, 1996).
Over the last 10 years there have been a number of studies documenting the 
relationship between HIV and TBM (Berenguer J et a l,  1992; Dube MP et a l,  1992;
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Yechoor VK et a l,  1996). These reports suggest HIV infected patients are at 
increased risk of TBM, but the clinical features and outcomes of the disease are 
similar. However, concomitant extra-meningeal disease may be more common: in one 
report 77% with HIV had clinical evidence of extra-meningeal tuberculosis, compared 
with 9% without HIV (Karstaedt AS et a l,  1998). Cerebral tuberculoma may also be 
more common in those infected with HIV (Dube MP et a l,  1992). These 
characteristics may help suggest the diagnosis of TBM in those with HIV.
1.2.5 Prognosis of tuberculous meningitis
A number of studies have assessed the clinical and laboratory parameters that might 
predict outcome. The first studies used univariate analysis to suggest extremes of age, 
advanced stage of disease, concomitant extra-meningeal tuberculosis, and evidence of 
raised intra-cranial pressure were associated with a poor outcome (Gulati PD et al, 
1970). Later studies have adjusted for the effect o f  co-variables using multivariate 
analyses and have consistently shown that treatment before the onset of coma 
improves outcome. A retrospective study of 434 Turkish adults revealed convulsions, 
coma and delayed or interrupted treatment to be independent predictors of mortality 
(Hosoglu S et al, 2002). Extra-meningeal tuberculosis, cranial nerve palsy, focal 
weakness, multiple neurological abnormalities and drowsiness independently 
predicted later neurological disability.
The message for physicians is simple -  they must not delay treatment in  those in 
whom the diagnosis is suspected, although the limitations of current diagnostic 
methods will result in many patients starting treatment without a confirmed diagnosis.
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1.2.6 Diagnosis of tuberculous meningitis
The diagnosis of TBM is difficult regardless of the resources available to the 
physician. As untreated TBM is almost always fatal it is essential that any diagnostic 
test is sensitive. The test must also be rapid, because a poor outcome is strongly 
associated with delayed treatment (Hosoglu S et al., 2002). At present, no diagnostic 
method satisfies both these requirements. The methods available are limited, despite 
the wealth of possibilities suggested in the literature.
Clinical diagnostic methods
Few studies have attempted to define exactly which clinical features are predictive of 
the diagnosis of TBM. In one, five presenting clinical features were found to be 
independently predictive of the diagnosis in 232 children: prodromal stage > 7 days, 
optic atrophy, focal neurological deficit, abnormal movements and CSF leucocytes < 
50% polymorphs (Kumar R et al, 1999). The authors developed a simple diagnostic 
rule: when at least one feature was present diagnostic sensitivity was 98%, specificity 
44%; if three or more features were present sensitivity was reduced to 55% but 
specificity rose to 98%. However, there may be problems applying this rule: if one 
feature is taken to be diagnostic more than half will be given ATC unnecessarily, but 
if three features are required nearly half with TBM will not be treated. The 
consequences of the former will be unnecessary toxicity, and death in the later. 
Furthermore, the performance of this rule, and others like it, will depend upon the 
prevalence of tuberculosis in the population in which they are used.
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Direct CSF examination and culture for acid-alcohol fast bacilli 
The search for AFB in clinical specimens has remained the cornerstone of diagnosis 
ever since Robert Koch first saw the bacillus in 1882. In 1953 Stewart described the 
method by which her laboratory demonstrated acid-alcohol fast bacilli in 91 of 100 
consecutive cases of TBM, all of which were subsequently confirmed by culture 
(Stewart SM, 1953). Similar results were reported more recently by Kennedy, who 
found that bacilli were present in  the CSF of 45/52 (87%) patients with a clinical 
diagnosis of TBM (Kennedy DH et al, 1979). However, many laboratories find these 
results difficult to reproduce. The sensitivity of the direct smear may depend upon the 
volume of CSF: 10-20ml were examined by Stewart, and as many as four specimens 
by Kennedy. Clinicians may be reluctant to take the volumes of CSF required to 
demonstrate the bacilli. Also, the laboratory must undertake a meticulous search for 
AFB. Stewart suggested a slide should be examined for between 30 and 120 minutes, 
a feat that few modem laboratories would have the staff or patience to complete. An 
understanding of the factors that govern the performance of conventional bacteriology 
is required.
Although culture of CSF fox M.tb is the diagnostic ‘gold standard’ for TBM, it takes 
too long for early diagnosis and treatment. The factors that govern sensitivity are 
probably the same as for direct smear and diagnostic confirmation by culture can be 
extremely helpful in patients who have been started on ATC on clinical grounds 
alone. In most circumstances the sensitivity and specificity of culture will exceed that
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of direct smear. However, once treatment has been started the sensitivity of culture 
falls quickly. AFB (presumed to be dead) can be found in the CSF for some days after 
the start of treatment even though they will not grow in culture (Kennedy DH et al, 
1979).
CSF adenosine deaminase activity
The activity of adenosine deaminase, an enzyme produced by CD4+ lymphocytes and 
monocytes, is raised in the CSF of patients with TBM. A number of s tudies h ave 
evaluated this as a diagnostic assay (Table 1.2). The enzyme activity cut-off value 
used by each study varied from 4 - 1 0  lU/ml. Diagnostic sensitivity ranges between 
44 and 100%, and specificity between 71 and 99%. There are three important 
problems with this assay.
First, there is no accepted diagnostic cut-off for the levels of CSF enzyme activity. 
Second, the assay has not been evaluated in those with HIV infection, which depletes 
adenosine deaminase producing T-lymphocytes and may reduce diagnostic 
sensitivity. Third, patients with lymphomas, malaria, brucellosis and pyogenic 
meningitides also have high levels of CSF adenosine deaminase activity. In particular, 
the clinical and laboratory features of partially treated pyogenic meningitis commonly 
cause diagnostic confusion with tuberculous meningitis - an assay that cannot reliably 
discriminate between these two conditions is not useful.
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Table 1.2 Studies of CSF adenosine deaminase activity for the diagnosis of TBM
Study Case mix Cut-off
(lU/ml)
Sensitivity Specificity
(Mann MD et al., 1982) Suspected TBM only TBM >5 85% 84%
(Coovadia YM et al. Unselected TBM >10 73% 71%
1986)
(Ribera E et al, 1987) Unselected TBM >9 100% 99%
(Rohani MY et al, 1995) Unselected TBM >9 100% 88%
(Mishra OP et al, 1995) TBM and partially 
treated bacterial 
meningitis
TBM >5 63% 89%
(Lopez-Cortes LF et al. Unselected TBM >10 50% 96%
1995)
(Mishra OP et al, 1996) Unselected TBM > 5 89% 92%
(Baro M et al, 1996) Unselected TBM > 6.5 83% 85%
(Gambhir IS et al, 1999) Unselected TBM > 8 44% 75%
The detection of Mycobacterium tuberculosis nucleic acid in the CSF 
The amplification and detection of M.tb nucleic acid from CSF is an attractive 
diagnostic prospect. Diagnostic specificity is dependent on selecting a region of the 
genome unique to M.tb while sensitivity is enhanced by amplification of the selected 
region from a clinical specimen. This method would appear to be particularly suitable
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Table 1.3 Amplification and detection of nucleic acid for the diagnosis of 
tuberculous meningitis
STUDY TARGET GOLD
STANDARD
SENSITIVITY SPECIFICITY
(Kaneko K et al, MBP64 Clinical (5/6) 83% (20/20) 100%
1990)
(Shankar P et al. MPB64 Clinical (22/34) 65% (45/51) 88%
1991)
(Machado LR et 65KDa Clinical (7/10) 70% (10/10) 100%
al, 1994)
(Lee BW et al,
antigen 
MPB 64 Clinical (5/6) 83% (12/13) 92%
1994)
(Folgueira L et IS6110 Clinical (8/8) 100% (14/14) 100%
al, 1994)
(Liu PY et al. MPB 64 Clinical (19/21)90% (79/79) 100%
1994)
(Lee BW et al. 1)186110 l)(6/6) 100% (8/21) 38%
1994) 2)MPB 64 Clinical 2)(5/6) 83% (19/21)90%
(Kox LF et a l ,
3)65 KDa 
IS6110 Clinical
3)(5/6) 83%
(11/23) 48%
(14/21) 67% 
(19/19) 100%
1995)
(Miomer H et al. IS6110 Clinical (18/33) 54% (32/34) 94%
1995)
(Scarpellini P et IS6110 Culture and (17/17) 100% (24/24) 100%
al, 1995) 
(Lin JJ et al. MBP64
autopsy
Clinical (14/20) 70% (26/27) 96%
1995)
(Seth P et al. MBP 64 Clinical (34/40) 85% (46/49) 94%
1996)
(Nguyen LN et IS6110 Clinical (27/97) 28% (36/39) 92%
al, 1996)
(Pfyffer GE et al. rRNA" Clinical (54/54) 100% (52/54) 97%
1996)
(Bonington A et 16SrRNA" Clinical (10/40) 25% (29/29) 100%
al, 1998)
(Lang AM et al. rRNA" Clinical (8/24) 33% (60/60) 100%
1998)
(Wei CY et al. IS6110 + Clinical (3/5) 60% (4/6) 67%
1999)
(Caws M et al.
MPB 64 
IS6110 Clinical (9/23) 39% (107/108) 99%
2000)
(Bonington A et 16SrRNA^ Clinical (7/35) 20% (31/31) 100%
al, 2000) 
(Narayanan S et 1)IS6110 Clinical l)(54/67) 81% (23/29) 79%
al, 2001) 2)TRC4 2)(61/67) 91% (22/29) 76%
® commercial Roche AMPLICOR kit
bcommercial Roche COBAS AMPLICOR kit 
commercial ‘Amplified M.tuberculosis Direct test’ (MTD)
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for the diagnosis of TBM when there are few tubercle bacilli in the CSF and a low 
chance o f  contamination with other bacteria. However, despite the development of 
commercially available assays, the promise is not yet matched by consistent 
diagnostic performance. Table 1.3 shows the DNA or RNA target sequence, 
diagnostic gold standard, and sensitivity and specificity of 20 studies evaluating the 
use of the nucleic acid amplification (NAA) tests for the diagnosis of TBM. The 
variety of targets and ‘gold standard’ diagnostic criteria is a major impediment to 
comparing these studies. Few studies have carefully compared the sensitivity of NAA, 
smear and culture using large volumes of CSF. Those that have suggest the sensitivity 
of CSF smear is similar to NAA (Bonington A et al, 2000). However, once treatment 
has begun NAA may be more helpful as the sensitivity of both smear and culture fall 
sharply - mycobacterial DNA remains detectable within the CSF for up to one month 
after the start of treatment (Donald PR et al, 1993).
The variable specificity of NAA tests may arise for a number of reasons. False- 
positives may occur through cross-reaction with other mycobacteria, from 
contamination with other clinical samples, or from contaminating DNA in the 
laboratory (Noordhoek GT et al, 1996). For this reason, a positive result should be 
placed within the clinical context before starting treatment, and laboratories must be 
committed to rigorous internal and external quality control of the use of the assay in 
different clinical specimens. This is time-consuming and expensive and is probably 
only possible within defined diagnostic reference centres.
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The tuberculin skin test
The value of the tuberculin skin test for the diagnosis of TBM varies according to age, 
vaccination with BCG, nutritional status, HIV infection and the prevalence of 
tuberculosis. Diagnostic sensitivity is most commonly compromised by the 
phenomenon of ‘anergy’ - the failure of those with known infection with M.tb to 
respond to intra-dermal injection of tuberculin. These false negative results occur 
most commonly in elderly, malnourished patients with disseminated tuberculosis and 
in those with HIV infection i.e. those most at risk of developing TBM. Reports 
suggest only 20% have a positive tuberculin test (Girgis NI et a l,  1998). However, 
skin testing may be more useful in children: a South African series reported 86% had 
greater than 15mm of induration with 5 Units of tuberculin (Donald PR et a l, 1998). 
Positive results must also be seen within the context of the tuberculosis prevalence in 
the area. Individuals from high prevalence areas are more likely to have positive tests 
with an unrelated illness. The limitations must be appreciated before interpreting the 
results of a skin test. The test is never diagnostic of TBM, but it can be helpful when 
assessing the likelihood of disease.
The chest X-ray and brain imaging
About one half of patients with TBM have a chest X-ray suggesting active or previous 
pulmonary tuberculosis (Girgis NI e ta l ,  1998). But, in  areas of high tuberculosis 
prevalence radiological evidence of previous pulmonary infection is common, and the 
finding must be interpreted with caution. A proportion of patients with TBM (-10%) 
have a miliary chest X-ray appearance (Figure 1.14).
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A  number of studies have investigated the role of brain c omputerised tomography 
(CT) - hydrocephalus and contrast enhancing exudates in the basal cisterns are the 
most common findings (Figure 1.15) (Bhargava S et al, 1982; Bullock MR et al, 
1982; Hsieh FY et al,  1992; Kumar R et al, 1996; Ozates M et al, 2000; Teoh R et 
al, 1989). However, as autopsy studies have also shown, hydrocephalus is more 
common in children than adults - brain CT demonstrates severe hydrocephalus in 87% 
of children, but only 12% of adults (Bhargava S et al, 1982). Kumar compared the 
CT appearances of 94 children with TBM and 52 with pyogenic meningitis.
Figure 1.14 Chest X-ray showing miliary tuberculosis (HTD)
■
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Figure 1.15 CT brain (with contrast) showing basal meningeal enhancement
(thick arrow) and hydrocephalus ((thin arrows) (HTD)
Basal meningeal enhancement, tuberculoma, or both, were 89% sensitive and 100% 
specific for the diagnosis of TBM (Kumar R et al, 1996). Teoh suggested, “a normal 
scan in a drowsy patient excludes the diagnosis of tuberculous meningitis” (Teoh R et 
al,  1989). However, in a recent series the scan was normal in 35 of 289 (12%) 
patients with TBM and not all were fully conscious (Ozates M et al,  2000). The 
abnormalities in this series were hydrocephalus (80% of children, 43% of adults), 
parenchymal enhancement (26% of children, 8% of adults), contrast enhancement of 
basal cisterns (15% of children, 23% of adults), cerebral infarct and focal or diffuse 
brain oedema (14% of children, 13% of adults) and tuberculoma (4% of children, 7% 
of adults) (Ozates M et al, 2000).
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Cranial magnetic resonance imaging (MRI) may provide more diagnostic information 
than CT when assessing space-occupying lesions, infarcts and the extent of the 
inflammatory exudates (Offenbacher H et al, 1991; Schoeman J et al, 1988; 
Tartaglione T et al, 1998). However, data regarding the diagnostic sensitivity and 
specificity of MRI for TBM are limited -  those studies that do exist are small and 
only include a highly selected patient population. However, it is reasonable to 
conclude that MRI is more sensitive than CT for detecting the diverse cranial 
pathology of TBM, although neither will reveal appearances specific for the diagnosis 
of TBM. Cryptococcal meningitis, cytomegalovirus encephalitis, sarcoidosis, 
meningeal métastasés, and lymphoma may all produce similar radiographic findings 
(Figures 1.16 and 1.17).
Figure 1.16 MRI of adult with TBM showing dilated ventricles and peri­
ventricular enhancement (arrows) (HTD)
I
w
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Figure 1.17 MRI of HIV negative adult with cryptococcal meningitis showing 
dilated ventricles and peri ventricular enhancement mimicking TBM
Alternative diagnostic approaches
The challenge facing new diagnostic strategies in TBM is that they must improve on 
the sensitivity of conventional ZN staining and culture, but maintain the specificity. In 
the developed world cost is less critical, but in the developing world cost 
considerations mandate tests that are cheap, use standard reagents with long shelf 
lives that do not require refrigeration and are simple to perform.
Tuberculosteric acid (TSA) is a structural component of mycobacteria that was first 
detected in the CSF of a patient with TBM in 1983 (Mardh PA et al., 1983). 
Frequency pulsed electron-capture gas-liquid chromatography has been used to detect 
femtomole quantities of TSA in CSF, with reported sensitivity 91% and specificity 
95% (Brooks JB et al., 1990). However, the cost of the equipment, and the
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complexity of the technique mean it is unlikely to be adopted as standard diagnostic 
procedure.
Serological techniques that detect the intra-thecal synthesis of anti-mycobacterial 
antibodies have been studied over many years. Many have shown promise, but none 
have demonstrated consistent performance in a routine diagnostic laboratory. A good 
test will require an antigen with high species specificity and good immunogenicity. 
Enzyme-linked immunosorbent assays (ELISA) using crude antigens such as PPD 
have resulted in low sensitivity and specificity (Kalish SB et al., 1983; Watt G et al., 
1988). The adaptation of ELISA techniques, and the identification of specific M.tb 
antigens have improved results. Using a solid phase antibody competition assay with 
mouse monoclonal antibodies (MABs) to the 38 kDA antigen (also known as antigen 
5, or antigen 78), a large study was performed in pulmonary and extra-pulmonary TB 
(Wilkins EG et al., 1990). In extra-pulmonary tuberculosis diagnostic sensitivity was 
73% and specificity 98%, regardless of organ site. More recently, the presence of IgG 
antibodies against six protein antigens (ESAT-6, 14kDa, 19kDa, MPT63, MPT64, 
38kDa) were assessed by ELISA in the CSF of 442 patients with TBM and 102 
controls (Chandramuki A et al., 2002). None of the controls had detectable IgG to any 
of the antigens. IgG to at least one antigen were detectable in 228/264 (87%) of HIV 
negative patients with clinical TBM, 50/69 (72%) with culture-proven TBM and 
47/72 (65%) with autopsy-proven TBM. The CSF of more than 50% of TBM patients 
was reactive to all 6 antigens. There was some evidence of preferential antigen 
recognition according to clinical grouping: the culture confirmed cases reacted most 
strongly against the 14kDa, and antibodies against MPT64 were lowest in the CSF
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from autopsy proven cases. Different stages of TBM may correlate with preferential 
recognition of different antigens, and disease progression may alter the antibody 
profiles. This study suggests future antibody detection diagnostic assays for TBM 
may have to assess reactivity to a range of antigens.
The differentiation of acute infection from previous exposure may be problematic in 
antibody detection tests, and test sensitivity may be compromised in immune 
compromised individuals. Methods to directly detect specific M.tb antigens in the 
CSF have been developed to tackle these inadequacies. Initial studies used a variety of 
ELISA techniques (Brooks JB et al, 1990; Kadival GV et al, 1986; Radhakrishnan 
W  et a l,  1990; Sada E et al, 1983; Watt G et a l,  1988); the majority using 
polyclonal antibodies directed against crude antigen. Despite an expected lack of 
sensitivity and specificity, one retrospective study revealed a sensitivity of 68% and 
specificity of 100% using these components (Radhakrishnan et al.,1990). Other 
studies have claimed the identification of novel specific TB antigens and based 
specific serological tests on them. F or example, 1 00% sensitivity (when compared 
with culture) and 100% specificity was reported by using a preparation of 3 5kDA 
M.tb antigen contained on nitrocellulose strips (Mathai A et a l,  1994). The test was 
simple to perform and the strips had a shelf life of 2 years. Unfortunately this and 
many similar assays have showed early promise in highly controlled studies, but have 
not performed so well in clinical practice.
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1.2.7 Treatment of tuberculous meningitis 
Anti-tuberculosis chemotherapy
The treatment of TBM follows the model of short course chemotherapy for 
pulmonary tuberculosis - an intensive phase of treatment, followed by a continuation 
phase. But unlike pulmonary tuberculosis, the optimal drug regimen and duration of 
each phase are uncertain.
Streptomycin was first used to treat tuberculosis in 1944, and in 1946 the UK MRC 
began studies using streptomycin for TBM. In 1948 they published data that 
demonstrated a marked improvement in outcome for those with TBM treated with 
streptomycin (MRC, 1948b). Mortality fell to 46% in those presenting with stage 1 
(conscious, no neurological deficit), 66% in stage 2 (disturbed consciousness, with or 
without focal neurology) and 86% in stage 3 (comatose, with or without focal signs). 
The introduction of isoniazid and para-amino-salicylic acid (PAS) led to further 
improvements in prognosis. A report documenting the changes in available 
chemotherapy between 1947-1958 reveals mortality fell from 64% using streptomycin 
alone to 27% with streptomycin and PAS, then to 17% with the addition of isoniazid 
(Lorber J, 1960).
The addition of rifampicin to the treatment of TBM was immediately accepted 
although the prognostic benefits of rifampicin have been questioned (Ramachandran P 
et al, 1986; Ramachandran P et al, 1989), and uncertainty surrounds its penetration 
into the CSF. Rifampicin is 80% protein bound in plasma, enabling a maximum of 
20% to penetrate the CSF in those with an intact BBB. Studies have shown slow 
penetration of rifampicin into the CSF of patients with TBM, with levels just above
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the minimum inhibitory concentrations (MIC) for M.tb (Ellard GA et a l,  1993) 
(Table 1.4). Meningeal inflammation enhances CSF penetration of anti-tuberculosis 
drugs, although there is limited evidence to suggest rifampicin penetration occurs 
independently of inflammation (Nau R et al, 1992).
There is no conclusive evidence to demonstrate improvement in outcome with the use 
of pyrazinamide. It is well absorbed orally, and has excellent penetration into the CSF 
(Forgan-Smith R et a I ,  1973). These factors, and the s terilising effect on tubercle 
bacilli, have resulted in pyrazinamide being considered mandatory at the beginning of 
TBM treatment (BTS, 1998; Humphries M, 1992). It has been suggested that given 
the uncertain benefit and penetration of rifampicin, pyrazinamide should be given for 
the duration of the treatment (Donald PR et al, 1998).
The British Thoracic Society (BTS) (BTS, 1998), the Infectious Diseases Society of 
America, and the American Thoracic Society (ATS) (ATS, 1994) recommend that all 
patients start on isoniazid, rifampicin, and pyrazinamide. Isoniazid is believed to be 
critical because it penetrates the CSF freely and has potent early bactericidal activity. 
Choosing the fourth drug of the intensive phase is more difficult. The BTS 
recommend either streptomycin or ethambutol, although neither penetrates the CSF 
well in the absence of inflammation, and both can produce significant adverse 
reactions. Streptomycin should not be given to those who are pregnant or have renal 
impairment. Intra-thecal streptomycin is no longer used, although this route of 
administration is being revisited for the treatment of multi-drug resistant cases.
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Introduction
Some centres, notably in South Africa, advocate ethionamide, which penetrates healthy 
and inflamed meninges (Donald PR et a l ,  1989). However, despite theoretical 
attractions, there are no data demonstrating any clear advantage o f one drug over another. 
The p revalence a n d p  attems o f  d rug r esistance m ay i nfluence t h e e  hoice o f  d rug. F or 
example, streptomycin resistance is common (>25%) in Vietnam, particularly in the HIV 
population, and ethambutol is favoured as a consequence.
Isoniazid and rifampicin should be given throughout the continuation phase o f treatment. 
Although there are no data to suggest pyrazinamide improves outcome, some authorities 
suggest it should accompany these drugs given the high CSF concentrations achieved 
throughout the course of the disease (Humphries M, 1992).
TBM caused by organisms resistant to both isoniazid and rifampicin (multi-drug 
resistance) presents a formidable therapeutic challenge. For suspected or proven multi­
drug resistant pulmonary tuberculosis the World Health Organisation recommend an 
aminoglycoside (kanamycin, amikacin, or capreomycin), ethionamide, pyrazinamide, and 
ofloxacin for the initial phase o f treatment (Crofton J et a l ,  1997). There are no 
equivalent recommendations for multi-drug resistant TBM, and few data are available on 
the CSF penetration and effectiveness of possible agents. Ethionamide, prothionamide, 
and cycloserine have been reported to penetrate the blood-brain barrier and may be 
effective. The combination of intra-thecal amikacin and levofloxacin has also been 
suggested (Beming SE et a l ,  2001). Until more data become available, the treatment of
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patients with multi-drug resistant TBM should be guided by individual resistance profiles 
and the predicted CSF penetration of candidate drugs, although in many areas o f the 
world suitable alternative drugs are not available.
The B TS recommendations for the dosages o f the standard anti-tuberculosis drugs are 
shown in Table 1.5. Some authors have suggested using doses o f isoniazid greater than 5 
mg/kg for the treatment of TBM (Humphries M, 1992). The potent early bactericidal 
effect o f isoniazid, and the uncertain CSF penetration of other drugs in the standard 
regimen, makes this an attractive suggestion. However, at standard doses isoniazid 
achieves CSF levels 10-15 times the minimum inhibitory concentration of M.tb 
(Kaojarem S et ah, 1991) (Table 1.4), and there are no data to suggest higher doses 
improve outcome or shorten treatment in adults with TBM.
TBM should be treated for at least six months. However, it is unclear whether more 
prolonged treatment is required. The BTS recommend 12 months in uncomplicated cases, 
extending to 18 months should pyrazinamide be omitted (BTS, 1998). Treatment for 12 
months is probably an over-estimate of the time required for bacterial cure, and there is 
evidence to suggest shorter courses are effective. A recent systematic review concluded 
that six months of anti-tuberculosis drugs for TBM is probably sufficient, provided the 
likelihood of drug resistance is low (van Loenhout-Rooyackers et al, 2001). Disease 
severity, drug toxicity, and patient compliance should all be considered when deciding 
the duration o f treatment.
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Table 1.5 Recommended daily dosages of standard anti-tuberculosis drugs (BTS, 
1998)
Drug Children Adults
Isoniazid 5 mg/kg 300 mg
Rifampicin 10 mg/kg 450 mg if  weight < 50 kg
600 mg if  weight > 50 kg
Pyrazinamide 35 mg/kg 1.5 g if  weight < 50 kg
2.0 g if  weight > 50 kg
Ethambutol 15 mg/kg 15 mg/kg
Streptomycin 15 mg/kg 15 mg/kg (max 1 g)
Adjunctive corticosteroids
The use o f corticosteroids in the treatment o f tuberculous meningitis is still controversial. 
The rationale lies in reducing the harmful effects of inflammation as the antibiotics kill 
the organisms, although corticosteroids do not appear to reduce the pro-inflammatory 
cytokines found in the CSF of those with TBM (Donald PR et a l ,  1995). However, 
clinical trials suggest that corticosteroids may have a beneficial effect in some groups o f 
patients and a consensus has emerged that adjuvant corticosteroids should be used in 
those presenting with MRC stage II or III TBM (BTS, 1998; Dooley DP et a l ,  1997; 
Humphries M, 1992).
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The limited evidence for this view is as follows. The first controlled trial to suggest 
benefit in using corticosteroids for TBM was published in 1955 (Ashby M et a l ,  1955). 
Six out o f 12 patients with TBM received steroids in addition to streptomycin and 
isoniazid. CSF white count fell faster in the steroid group, recovery from the acute phase 
was quicker, and none of the patients given steroids had any long-term sequelae. Four of 
the six who did not receive corticosteroids suffered chronic neurological sequelae. Trials 
with larger numbers were not performed until the mid 1970's when a prospective, 
randomised, double blind trial was performed in 72 patients (Escobar JA et a l ,  1975). A 
reduction in mortality in the steroid group was shown, but the effect on neurological 
morbidity could not be assessed. The largest prospective, randomised, controlled trial to 
date enrolled 160 patients with TBM (Girgis NI et a l ,  1991). Mortality and neurological 
sequelae were reduced in those treated with corticosteroids. The group that benefited the 
most were those with disease of intermediate severity. Those presenting either in a coma 
or with mild disease (MRC grades III and I) received minimal benefit.
Raised intra-cranial pressure (ICP) has long been considered important in the prognosis 
o f TBM (Gulati PD et a l ,  1970). Reduction o f ICP by steroids was felt to be one o f the 
means by which corticosteroids exerted their beneficial effect. A recent trial assessed the 
efficacy of steroids with regard to CT evidence o f elevated ICP, parenchymal brain 
involvement, direct ICP measurements, and clinical outcome (Schoeman JF et a l ,  1997). 
The trial showed no difference in ICP, ventricular size, or extent o f infarction between 
those treated with or without steroids.
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The benefit to mortality was again observed, as well as improved intellectual outcome in 
the steroid group. The data from six randomised controlled trials o f corticosteroids for 
TBM, involving a total o f 595 patients, has been subjected to a Cochrane review (Prasad 
K et a l ,  2000). Those receiving corticosteroids had a lower death rate (relative risk 0.79, 
95% Confidence Interval [Cl] 0.65-0.97) and a reduced risk o f death or severe 
neurological sequaelae (relative risk 0.58, 95% Cl 0.38-0.88). Subgroup analysis 
suggested a beneficial effect on mortality in children, but inconclusive results in adults 
partly due to the small numbers o f adult patients. The reviewers concluded that 
adjunctive corticosteroids may be of benefit in patients with TBM, but the evidence is 
limited. Existing studies are small with poor allocation concealment and publication bias 
may account for the results favouring corticosteroids.
There are no conclusive data regarding the choice o f corticosteroid, dose or duration of 
treatment. A reduction in mortality has been suggested using either prednisolone or 
dexamethasone for at least the first three weeks o f anti-tuberculosis chemotherapy, 
followed by a similar period, as the dose is decreased to zero (Girgis W. et a l ,  1991; 
Schoeman JF e t  a l ,  1997). T hese trials g ave c hildren 4 mg/kg/day o f p  rednisolone, o r 
12mg/day o f dexamethasone, and adults’ 16mg/day o f dexamethasone.
It has been suggested that steroids may reduce the penetration o f anti-tuberculous drugs 
into the CSF by reducing inflammation. There is little evidence for this occurring.
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One study found no difference between the plasma/CSF level ratios o f isoniazid, 
pyrazinamide, rifampicin, or streptomycin, in those on or off corticosteroids (Kaojarem S 
et a l ,  1991).
Neurosurgery
Neurosurgical intervention may be indicated for hydrocephalus, tuberculoma, and 
abscess formation complicating TBM. Unfortunately, there are no published randomised 
trials of surgery for any of these complications. Hydrocephalus occurs more commonly in 
children than adults, but is the commonest reason for neurosurgical referral in both 
groups. A recent series reported that ventriculo-peritoneal shunting was performed in 
30% (65/217) o f children with hydrocephalus complicating TBM (Lamprecht D et a l ,  
2001). After six months of treatment 12% had died and 45% had severe sequelae. It is 
difficult to predict which patients with hydrocephalus will benefit from shunts. Clinical 
response to external ventricular drainage has been assessed for this purpose, but failed to 
predict benefit, so perhaps early ventriculo-peritoneal shunting should be considered in 
all patients with hydrocephalus (Mathew JM et a l ,  1998; Palur R  et a l ,  1991). But this 
aggressive approach does not acknowledge the significant complications o f shunt 
surgery, the variable resources and experience o f surgical units, and the  lack  o f  trials 
demonstrating any benefit.
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1.2.8 Response to treatm ent
Ninety percent o f deaths from TBM occur in the first month o f treatment (Girgis NI et 
a l ,  1998). The response to treatment is usually slow and may fluctuate. Indeed, a rapid 
and sustained response over a few days suggests the diagnosis is wrong. The CSF mirrors 
the slow clinical response - cell counts are raised for 1-2 months, glucose remains low for 
a similar duration and total CSF protein can rise before falling slowly over many months 
(Schoeman JF et a l ,  2001).
Transient episodes o f high fever, worsening headache and increased neck rigidity c an 
occur during the first two months o f treatment, particularly in those with more severe 
disease. Distinguishing self-limiting events from the onset o f more serious complications 
is difficult. Brain imaging should be arranged urgently if  new clinical signs develop 
during treatment. Hydrocephalus, cerebral infarction, the expansion o f intra-cranial 
tuberculoma (Figure 1.18), cerebral abscess formation (Figure 1.19) and poor adherence 
to therapy, are the foremost reasons for severe acute deterioration (Ranjan P et a l ,  2003) 
(Table 1.6).
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Table 1.6 Common reasons for clinical deterioration in patients with tuberculous 
meningitis.
Early deterioration (1-3 months) Late deterioration (3-12 
months)
1. Prescription error 1. Prescription error
2. Poor patient compliance 2. Poor patient compliance
3. Drug reaction requiring either reduction in 3. Paradoxical treatment
dose, or withdrawal o f all or some of the drugs
4. Neurological drug reactions
5. Paradoxical treatment reactions
reactions
Paradoxical treatment reactions are a well-recognised phenomenon in all forms of 
tuberculosis. Although the pathogenesis remains unclear, such reactions are characterised 
by an intense inflammatory response. Data on the frequency and timing o f these events in 
TBM are restricted to occasional case reports. The expansion of intra-cranial tuberculoma 
after the start o f anti-tuberculosis drugs is the most widely reported example, and can 
occur at any time during treatment (Afghani B et a l ,  1994). Most authors suggest 
treatment with prolonged high-dose corticosteroids, although there are no controlled trials 
to support this recommendation.
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Figure 1.18 In tra-cranial tuberculom as developing after the s ta rt of ATC (MRI post 
contrast) (arrows) (HTD)
s
Figure 1.17 Tuberculous cerebral abscess (M RI ) (arrow) (HTD)
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Adverse reactions to ATC are a common problem, and can have a devastating effect on
the outcome (Hosoglu S et a l ,  2002). Table 1.7 presents the common, the rare, and the
neurological adverse reactions to the main antituberculosis drugs.
Table 1.7 Adverse reactions to antituberculosis drugs (BTS, 1998) (Holdiness MR, 
1987)
Drug Common Rare Neurological
Isoniazid • Hepatitis • haemolytic anaemia • peripheral
• aplastic anaemia neuropathy
• sideroblastic anaemia • convulsions
• agranulocytosis • optic neuritis
• lupoid reactions • mania/psychosis
• arthralgia
• gynaecomastia
Rifampicin • hepatitis • haemolytic anaemia • headaches
• thrombocytopenia • acute renal failure • confusion
• fever • drowsiness
Pyrazinamide • hepatitis • gout
• anorexia • photosensitivity
• flushing
• arthralgia
• hyperuricaemia
Ethambutol • arthralgia • hepatitis • retrobulbar
• rash neuritis
• peripheral
neuropathy
• confusion
Streptomycin • vertigo • neuromuscular
• deafness block
• acute renal failure
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Hepatic toxicity is the commonest adverse event, and the BTS recommend stopping 
isoniazid, rifampicin, and pyrazinamide immediately if  the transaminases rise to five 
times normal, or the bilirubin level rises (BTS, 1998). In most forms o f tuberculosis a 
short period without treatment does not affect outcome. Unfortunately, treatment 
interruptions of this type in TBM are an independent predictor o f death as they often lead 
to relapse with neurological deterioration (Hosoglu S et a l ,  2002). Streptomycin and 
ethambutol should both b e  given in  these circumstances, and isoniazid and rifampicin 
restarted as soon as possible. Treatment should be extended if the patient cannot adhere 
to the conventional nine-month regimen.
1.2.9 Summary
TBM is a difficult disease to diagnose and treat. The clinical features are non-specific, 
conventional bacteriology is widely regarded as too insensitive, and newer diagnostic 
methods are incompletely evaluated. Treatment relies on 4 drugs, all are more than 30 
years old, and only prevents death in around 70%. M.tb resistant to these agents threatens 
to return TBM to the pre-chemotherapeutic era o f 100% case fatality. Adjunctive 
treatment with corticosteroids might work, although it is not known how or why, and a 
sufficiently large controlled trial has yet to be completed. In short, clinical researchers 
have neglected TBM and a multitude of important questions concerning the diagnosis, 
pathophysiology and treatment of TBM require answers. Can currently available 
diagnostic methods be improved? What is the role o f molecular diagnostic tests?
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What are the mechanisms that lead to coma and death? Do corticosteroids improve 
outcome? These are some of the major questions that need answering, and this thesis will 
address all but the last. The answer to this question, in the form of a randomised 
comparison o f adjunctive dexamethasone and placebo in 545 Vietnamese adults with 
TBM, will be reported elsewhere.
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MATERIALS AND METHODS
2.1 Introduction
This chapter describes the general setting o f the work undertaken, the region, the hospital 
and the study wards, and outlines the focus, aims, and structure o f the thesis. Laboratory 
methods are also described, although further relevant details are provided in subsequent 
chapters.
2.1.1 Geography
Vietnam is the second largest country in South East Asia after Indonesia, and lies 
between 8° and 24° north of the Equator. It is the largest and most populous o f the three 
Indochinese countries, and borders Cambodia and Laos in the west, and the People’s 
Republic of China in the north. It stretches over 1,600 km along the eastern cost of the 
Indochinese Peninsula and covers an area o f 329,560 square kilometers (Figure 2.1).
It is divided into 3 regions:
• Northern Vietnam consisting o f provinces bordering China and those that lie in 
the Red River Delta.
• Central Vietnam with provinces lying between the central coast and the Truong 
Son mountain range.
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• Southern Vietnam which includes Ho Chi Minh City, the few provinces east o f  
the city, and the rice-rich provinces o f  the Mekong River Delta.
Administratively, Vietnam consists o f 53 provinces, divided into 555 districts and fiirther 
subdivided into 9,960 communes. The capital city, Hanoi, lies within the Red river delta 
in the north o f the country. The research described in this thesis was all undertaken in Ho 
Chi Minh City, which is situated by the Mekong river delta in the south.
Figure 2.1 Map o f Vietnam
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Vietnam is home to 79 million people (UK 59 million), the majority o f whom live in 
rural areas. Ho Chi Minh City (formerly Saigon) is the largest city with a population o f 7 
million. Approximately 40% of the populations are under 15 years old, with 2 million 
children bom each year.
The climate varies throughout the country. It is tropical in the south, with warm and 
humid weather all year round (22-35°C). The dry season extends from November to 
April, and it rains between May and October. In the north, temperatures fall from 
November to April to an average 16^C, but the summer months are very hot and humid.
2.1.2 Health Care
Vietnam’s health care system is positioned 160^  ^ in the World Health Organisation’s 
ranking o f health care systems. Infant mortality is 34 per 1000 live births and under 5’s 
mortality rate is 45/1000 (UK rates 5 and 7 respectively) (WHO, 2002). The average life 
expectancy for men is 66.9 years, and 71.8 years for women.
In 2002, Vietnam had a gross national product (GNP) per capita o f $390 (UK: GNP 
$24,420) (WHO, 2002). The health expenditure per capita was $129 /year. Vietnam has a 
well-developed health inffastmcture formed hy nearly 10,000 commune health centers, 
each serving around 8000 people. There are approximately 850 government hospitals 
employing 27000 doctors. Recently, the private s eetor has developed rapidly in  urban 
areas, particularly in Ho Chi Minh City, where ATC and other antibiotics are freely 
available over the counter.
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2.1.3 Tuberculosis in Vietnam
In 2001, the estimated incidence o f all cases o f tuberculosis in Vietnam was 179/100 000 
population, which ranked 13^  ^ highest in the world. These figures, along with data 
regarding case detection rates, and directly observed therapy (DOT), are shown in Table 
2.1.
Table 2.1 Incidence, HIV associated disease, multi-drug resistance, and case 
detection and treatment of tuberculosis in Vietnam, 2000 (WHO, 2003).
Population 79 174 738
Estimated incidence
(all cases/100  000  population) 179
Estimated incidence
(new sputum smear +/100  000  population) 80
Estimated % of adult (15-49 years) eases HIV + 1.4
Estimated % new cases multidrug resistant 2.3
Case detection rate (new sputum smear +, %) 84%
DOT treatment success rate (%) 92%
2.1.4 Tuberculosis control in Vietnam
Vietnam has an excellent tuberculosis control program according to government and 
WHO statistics (WHO, 2003). In 2001, for the 5* consecutive year, Vietnam met both of 
the global targets for tuberculosis control: 84% of cases were detected, and 92%
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treatment suecess rate was reported. DOT was reported to be available to 100% of the 
population (WHO, 2003).
However, despite the performance of the control program, the incidence o f tuberculosis 
has not changed over the last 4 years, and there has been no demonstrable impact on the 
prevalence or death rate from tuberculosis. The reasons for this are likely to be complex, 
but probably include a developing private sector with inadequate training in tuberculosis 
treatment and control, poor access to control services for certain high risk groups (drug 
users, prisoners, illegal residents), an unregulated drug market with use o f non-standard 
anti-tuberculosis drugs, and increasing prevalence of HIV infection.
2.1.5 Hospital for Tropical Diseases
The Hospital for Tropical Diseases (HTD) in Ho Chi Minh City acts as a primary, 
secondary and tertiary referral centre for patients with infectious diseases, and serves the 
whole o f southern Vietnam (population around 35 million). The hospital has 
approximately 500 beds, including separate paediatric, adult, and tetanus intensive care 
units. HTD has laboratories for haematology, biochemistry, microbiology, serology and 
parasitology. In September 2002 these faeilities were moved to a new building, and now 
share space with the Oxford University research laboratories.
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2.1.6 Oxford University Clinical Research Unit
The Oxford University Clinical Research Unit opened in 1991, funded by the Wellcome 
Trust o f Great Britain. The Unit, located within the HTD, serves as a eollaborative centre 
between HTD and Oxford University and started as an 8-bed ward for the treatment of 
patients w ith severe malaria. Over 1 0 years the U nit has expanded and now performs 
research on five core areas: malaria, dengue, typhoid, central nervous system infection 
and tetanus.
The Research for this thesis was performed on the Clinical Research Unit (CRU), a 15 
bed ward for the treatment o f adults (>15 years) with central nervous system infection, 
severe malaria, severe sepsis and acute renal failure. The CRU has faeilities for 
mechanical ventilation and haemofiltration. Adults with TBM were treated for the first 
few weeks on this ward, and then transferred to a general recovery ward. Further eare and 
follow-up was coordinated through the staff of this ward. Staff from this ward visited 
adults failing to attend follow-up visits.
A number of eollaborative links exist with other specialist hospitals in the city, in 
particular Pham Ngoc Thach Hospital for tuberculosis. This hospital coordinates the 
National Tuberculosis Control program for southern Vietnam, and serves as the 
secondary and tertiary referral hospital for the region with 500 beds for adults and 
children suffering from severe tuherculosis.
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2.2 Focus, aims and structure of the thesis
This thesis focuses upon the diagnosis and pathophysiology of TBM and aims to address 
three questions:
1. What is the best method for distinguishing TBM from other central nervous 
system disorders?
2. How does disease pathophysiology relate to treatment and clinical outcome?
3. What other variables influence prognosis?
Each chapter examines a single hypothesis relating to this question (Table 2.2).
Table 2.2. Hypothesis examined by each thesis chapter
CHAPTER HYPOTHESIS
3 Simple clinical features are predictive o f a diagnosis o f TBM
4 The sensitivity of conventional bacteriology are dependent upon volume 
of CSF examined, and duration o f microscopy
5 NAA (MTD) is more sensitive than conventional bacteriology for the 
diagnosis of TBM
6 The cellular and molecular intra-cerebral immune response predicts death 
or survival from TBM
7 Death or survival from TBM is dependent upon HIV infection, drug 
resistance, and bacterial genotype
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Chapter 8 unites the findings, examines whether the thesis has fulfilled its two aims, and 
discusses directions for future research.
2.3 Clinical Methods
2.3.1 Scientific and ethical approval
HTD scientific and ethical committee approved all study protocols, and informed consent 
was obtained from each patient or accompanying relative.
2.3.2 Patients and treatment
The adults described in this thesis were all admitted to the CRU between 1998 and 2003. 
The timing o f the individual studies, and how they relate to the strueture o f this thesis are 
presented in Figure 2.2. All adults (>15 years old) with a diagnosis o f TBM were eligible 
to enter the studies described.
The diagnostic criteria for TBM was the same for all studies:
1. Definite TBM: AFB seen and/or M.tb cultured from the CSF
2. Probable TBM: clinical signs o f meningitis and/or evidence o f active 
tuherculosis infection on chest X-ray and/or AFB isolated from any extra-neural 
site and/or elinical evidence of extra-pulmonary/extra-neural tuberculosis.
3. Possible TBM: clinical signs o f meningitis and 4 or more o f the following: 
history o f tuberculosis; gradual onset (>5 days); reduced GCS; focal neurology; 
yellow CSF; CSF lymphocyte predominance; low CSF glucose.
4. Not TBM: either positive CSF gram stain or culture or recovery without ATC
96
s5T
Wih
Cl
CTQ
CL
K»g
Oar
G T Q
îO'
CL
CL
K>
CL K»
ss.V3
K»
W
f
K»
M
f
O
S"
s
90
2, 
f
IO.
i '
î
&
§
«
i
o»n
I
f
Materials and Methods
Severity of TBM at the start o f treatment was graded according to a modified MRC 
criteria (MRC, 1948b): Grade I had a Glasgow coma score (GCS) o f 15/15 with no focal 
neurological signs, grade II either had a GCS 11-14 or GCS 15 with focal neurological 
signs. Grade III had a GCS of < 10.
All patients with TBM received daily intra-muscular streptomycin 20mg/kg (maximum 
Ig), and oral i soniazid 5 mg/kg, rifampicin 1 Omg/kg, and pyrazinamide 3 Omg/kg for 3 
months, followed by 3 drugs (isoniazid, rifampicin, pyrazinamide) fo r 6 months. Oral 
ethambutol was substituted for streptomycin in those with HIV infection to reduce the 
needle-stick injury risk to staff and because of the high prevalence o f streptomycin 
resistant M.tb in this population.
None of the patients described received corticosteroids, although a large randomised 
controlled trial is being performed to address this issue. Clinical data were recorded 
prospectively in individual study notes, and entered onto a Microsoft excel worksheet. 
All the data were double-checked before analysis.
2.3.3 Routine investigations
It is routine clinical practice in HTD for all patients with TBM to have a lumbar puncture 
at diagnosis (day 0), day 3, day 7, day 30, day 60, and day 270 o f treatment. Like others 
(Feigin RD et a l,  1973; Smith HV, 1963; Teoh R et a l ,  1986), repeated lumbar 
punctures are considered helpful in management, particularly when assessing poor
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response to ATC or when the diagnosis remains questionable. Computerised tomography 
(CT) o f the brain before lumbar puncture was arranged in all patients with a clinical 
suspicion o f raised intra-cranial pressure (coma and/or focal neurological signs).
CSF cell counts and biochemistry were performed by standard methods upon each 
sample. CSF lactate was only measured during the first 30 days o f treatment. Routine 
microbiological investigation included microscopy of the centrifuged CSF deposit after 
Ziehl-Neelsen, Gram’s and Indian ink stains, with culture for fungi, pyogenic bacteria, 
and mycobacteria. CSF supernatant and deposit from each sample submitted for 
microbiological analysis was stored at -70^C. Serum and plasma taken at the time of
lumbar puncture was frozen at -70^C.
2.4 Laboratory methods
2.4.1 Bacteriological diagnosis of tuberculous meningitis 
Preparation of specimens
Taking large volumes of CSF probably improves bacteriological yield (Kennedy DH et 
a l,  1979; Stewart SM, 1953), therefore the CRU physicians collected 5-1 Omis into a 
30ml clear sterile universal container from all patients with suspected TBM. In each case 
the volume of CSF was recorded and centrifuged at 3000 x g for 15 minutes as soon as 
possible after collection.
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After centrifugation most o f the supernatant was removed using a sterile pipette, and 
stored in eppendorfs at -70^C. These frozen samples were used later for the experiments 
on pathophysiology (C hapter 6).
The deposit was vigorously re-suspended in the remaining 300-400pl of supernatant. 
Two drops (approximately lOOpl each drop) were dried onto a heated clean slide 
(diameter <lcm ), two drops were frozen at -IQpC for later testing by Mycobacterium 
Tuberculosis Direct (MTD) test (Gen probe, USA) (C hapter 5), and remaining deposit 
was divided equally between for aerobic culture on Lowenstein-Jensen media and liquid 
Mycobacterium Growth Indicator Tubes (MGIT, Becton Dickinson, USA).
Ziehl-Neelsen stain of CSF
The reagents for the ZN method were prepared according to Collins et al (Collins CH et 
a l,  1997).
i) Preparation o f  the ZN  stain:
5g basic fuchsin 
25g phenol crystals 
5Omis ethanol, 95%
500mls distilled water
The fuchsin and phenol were dissolved in the ethanol, and then the water 
added.
The solution was filtered before use.
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ii) Preparation o f  the acidified alcohol decolourising solution
970mls ethanol, 95%
3Omis concentrated hydrochloric acid 
Mixed well. 
in) Preparation o f  the Counter-stain
2.5g methylene blue 
500mls distilled water.
Mixed well.
Once the drops of deposit had dried, the slide was passed through a Bunsen flame twice 
in quick succession and placed on a staining rack over a sink. Filtered ZN stain was 
poured over the slide until the deposit was well covered. The slide was then heated from 
below with a spirit lamp flame until steam rose from the stain. The stain was not allowed 
to boil, or dry on the slide.
After 5 minutes the slide was washed well with running water, and covered with acid- 
alcohol for 3-5 minutes, or until all the stain had left the deposit. After careful washing 
with running water the slide was placed on a heating block for 1-2 minutes. Without this 
step the deposit was frequently washed off the slide when the methylene blue was added. 
Once the deposit was dry, it was covered with methylene blue for 30-60 seconds, and 
washed very carefully with running water.
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Once dry, the slide was first examined under low power for areas o f high cellular density. 
Experience showed that AFB were most frequently found in these areas; therefore they 
were examined first under high power using an oil-emersion lens. I f  these areas proved 
negative, the rest o f the slide was systematically examined for at least 20 minutes. A slide 
was termed positive if  2 or more bacilli were seen, and the time to see the bacilli was 
recorded. The time spent looking at negative slides was also recorded.
Culture, identification, and drug susceptibility testing ofM.tb
CSF cultures were examined weekly for signs o f growth for 12 weeks. Once the presence 
of AFB was confirmed by a ZN stain, cultures were sent the Pham Ngoc Thach Hospital 
laboratory for identification and susceptibility testing. This laboratory serves as the 
tuberculosis reference laboratory for southern Vietnam, and their performance is audited 
by the WHO quality control scheme for mycobacterial identification and drug 
susceptibility testing. Briefly, M.tb was identified on  the b asis o f  acid-fastness, and 4 
biochemical tests:
i) A positive Niacin test
ii) Positive Nitratase activity
iii) Inhibition of growth by 500mg/l p-nitrobenzoic acid (PNB)
iv) Growth in the presence of thiopen-2-carboxylic acid hydrazine (TCH)
Drug susceptibility was performed using the proportion method (Collins CH et a l ,  1997). 
In principle, the number of colonies growing on drug-free medium is compared with the
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number on drug-containing medium and the proportion o f resistant organisms is 
calculated. Pham Ngoc Thach laboratory compared growth on drug free media, with 
growth on media with the following concentration of drugs:
Pyrazinamide 200 pg/ml 
Isoniazid 0.2 pg/ml 
Streptomycin 4 pg/ml 
Rifampicin 40 pg/ml 
Ethambutol 2 pg/ml
The criterion for resistance was the number o f colonies on the drug-containing medium 
was 1% or more of the number developing on the drug-free medium.
2.4.2 Amplified Mycobacterium Tuberculosis Direct Test
All reagents and equipment were purchased from Gen-Probe (California, USA) at 
commercial rates. The manufacturer’s instructions were followed for all steps except for 
the pre-treatment o f CSF, where a modified protocol was used.
Preparation o f specimens and lysis
The MTD was developed for use on respiratory samples and is not licensed for use with 
CSF. Previous authors have suggested alterations to the manufacturers protocol may 
improve performance with CSF (Pfyffer GE et a l ,  1996). In particular, these authors 
found increased sensitivity by increasing the volume of sample, pretreatment with a
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denaturing agent, and increasing the amplification time from 2 to 3 hours. Further details 
of this method are provided in Chapter 5.
Amplification and hybridisation
1. 25 pi of lysate was added to the bottom of an amplification tube containing 50 pi 
of reconstituted amplification reagent and 200 pi oil reagent.
2. Incubated for 15 minutes at 95®C.
3. Tube transferred to 42^C and allowed to cool for 5 minutes
4. 25 pi of reconstituted enzyme reagent added, mixed, and incubated for 3 hours
5. 100 pi of reconstituted hybridisation reagent added to tube, vortexed, and 
incubated at 60^C for 15 minutes.
6 . 300 pi of selection reagent added to tube, vortexed, and incubated at 60^C for 15 
minutes. Then cooled to room temperature.
7. Insert tube into luminometer to obtain RLU readout
Controls
H37Rv M.tb was used as the positive controls and Mycobacterium avium as the negative 
control.
2.4.3 Cytokine and matrix metalloproteinase assays
Commercial capture ELISA kits were used to measure CSF and blood concentrations o f 
IFN-y, TNF-a, IL-8, and IL-10 (OPTEIA ELISA, Becton Dickinson, San Jose,
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California, USA), and the CSF concentrations o f MMP-9, TIMP-1, and the soluble TNF- 
a  receptors 1 and 2 (R and D systems, Abingdon, UK). The manufacturers methods were 
followed in each case. The lower limits of detection were 10 pg/ml o f IFN-y, TNF-a, 
TNF-a R l, TNF-a R2, and IL-8; 15 pg/ml o f IL-10; 200 pg/ml o f TIMP-1, and 350 
pg/ml o f MMP-9.
2.4.4 Albumin and IgG indices
A commercial analyser measured albumin and IgG concentrations in blood and CSF 
(Hitachi 917, Hitachi, Japan) by immunoturbimetry using polyclonal anti-human 
albumin, or IgG antibodies (Roche diagnostics, Switzerland). The albumin index (AI) 
was calculated by [albumin]csf/[albumin]piasma. Normal ranges for albumin in plasma are 
36-50 g/1, and 0.16-0.36 g/1 in CSF (Fishman R, 1992): the normal range for AI is
0.0032- 0 .01 . The formula used to calculate the IgG index (IgGI) was ([IgGJcsf x 
[albumin]piasma)/([albumin]csf X [IgG]piasma) (Fishman R, 1992). The normal range for the 
IgG index is 0.34-0.58 (Fishman R, 1992).
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CHAPTER 3
THE CLINICAL DIAGNOSIS OF
TUBERCULOUS MENINGITIS
3.1 Introduction
The diagnosis of TBM is dependent upon isolating M.tb from the CSF, but culture is too 
slow to aid clinical decision-making. Direct ZN staining o f the CSF for AFB remains the 
cornerstone of rapid diagnosis in most laboratories, but the sensitivity is variable. Newer 
diagnostic techniques, such as those employing the polymerase chain reaction (PCR), are 
incompletely evaluated (Pai M et a l, 2003) (Pfyffer GE, 1999) and not currently possible 
in most settings in the developing world where the majority of TBM is seen (Foulds J et 
a l,  1998; Wilson SM, 1998). As a consequence the decision to treat a patient for TBM is 
frequently empirical, regardless of the diagnostic facilities available to the clinician, and 
the clinician must depend upon the discriminative clinical and laboratory features of the 
disease for successful diagnosis and treatment.
The presenting clinical features of TBM in adults are similar to many meningo- 
encephalitides and results in frequent diagnostic confusion. Delay in starting appropriate 
antibiotics for TBM or pyogenic meningitis worsens prognosis, yet physicians are often 
reluctant to start months o f anti-tuberculosis treatment without firm evidence.
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Diagnostic uncertainty arises commonly in patients presenting with a few days of 
headache, fever and neck-stiffness; undefined treatment in the community; a low CSF 
glucose (<50% of blood), and neutrophils and lymphocytes in the CSF.
As described in C hapter 1, multivariate logistic regression has been used to model the 
clinical predictors of TBM in 232 children (Kumar R  et a l ,  1999). Five presenting 
clinical features were found to be independently predictive o f the diagnosis o f TBM: 
prodromal stage > 7 days, optic atrophy on fundal examination, focal deficit, abnormal 
movements, and CSF leucocytes < 50% polymorphs. The authors d eveloped a s impie 
diagnostic rule: sensitivity was 98%, and specificity 44%, when one or more predictor 
variables were present; and specificity was 98% and sensitivity 55%, if  three or more 
were present. Although this, and similar rules have their limitations (see C hapter 1), 
there are strong arguments for developing a simple diagnostic algorithm for TBM in 
areas of high tuberculosis prevalence. First, TBM tends to be commonest in areas with 
the least clinical and laboratory resources. Second, a diagnostic rule developed and used 
in high tuberculosis prevalence areas may perform consistently. And third, early 
diagnosis and treatment improves outcome (Kennedy DH et a l ,  1979). This chapter 
examines the hypothesis that simple clinical features are predictive o f a diagnosis of 
TBM.
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3.2 Methods
The adults described in this study were admitted to the CRU as described in Chapter 2. 
An HIV test was not performed on all patients in this study. In general, only those 
considered to be at risk o f infection were tested. A second lumbar puncture was 
performed as part of routine hospital management in most patients after 48 hours to 
assess response to treatment. Those with culture proven or suspected bacterial meningitis 
(BM) received 10 days o f intra-venous ceftriaxone (Rocephin®, Roche) (2 grams twice a 
day). Those with TBM were treated with ATC as described in Chapter 2.
Table 3.1 Diagnostic criteria for TBM and BM.
Tuberculous Meningitis Bacterial meningitis
M.tb isolated from the CSF 
Or
Clinical meningitis with negative Gram and 
India ink stains, and sterile bacterial and fungal 
cultures, and one or more of the following:
1 .Cranial CT consistent with TBM 
(hydrocephalus, oedema, basal meningeal 
enhancement)
2. Chest radiograph consistent with active 
pulmonary TB
3. Good response to ATC.
Pathogenic bacteria isolated from the CSF 
Or
Clinical meningitis with all of the following:
1. Lymphocytes and neutrophils in the CSF
2. Low CSF glucose (<50% blood)
3. Sterile blood and CSF cultures.
4. Full recovery (without ATC) 3 months after 
admission
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3.2.1 Diagnostic criteria
Diagnostic criteria for TBM and BM were applied to all patients admitted to the CRU 
with meningitis. The criteria are presented in Table 3.1. There is no acceptable ‘gold 
standard’ diagnostic test for TBM. Culture and ZN staining o f the CSF are specific, but 
too insensitive to be used as the sole criteria for diagnosis. Clinical criteria were therefore 
developed for this study that are comparable to those used by other authors (Ahuja GK et 
a l, 1994). The criteria for the diagnosis of BM aimed to include partially treated BM 
(with sterile CSF cultures) in the study. This group is important as diagnostic confusion 
with TBM occurs commonly in these patients. TBM was excluded by their full recovery, 
without ATC, 3 months after admission: untreated TBM would almost always be fatal 
within this time.
3.2.2 Statistical methods
The clinical and laboratory features o f those fulfilling the diagnostic criteria for TBM and 
BM were compared. Twenty-six admission clinical and laboratory parameters, including 
characteristics of the admission CSF sample, were studied. Additionally, data from a 
second CSF sample were collected from all patients receiving 48 hours o f intra-venous 
ceftriaxone. Diagnostic uncertainty on admission often leads clinicians in our hospital to 
use a ‘trial’ of ceftriaxone, and reconsider the diagnosis after a 2"^ CSF examination. The 
purpose of collecting these additional data was to compare the CSF parameters in both 
groups, and to develop a second diagnostic rule for patients managed by this approach.
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The relative change in each CSF parameter was calculated by (a(CSF 2) -  «(CSF !))/«( 
CSF 1), where a is the specified parameter. All those given immediate ATC were 
excluded from this analysis. Kruskal-Wallis test was used to compare continuous 
parameters; the chi square test (or Fisher’s exact test for small proportions) was used for 
categorical variables.
Three diagnostic aids were developed using two statistical approaches: classification trees 
(CART), and logistic regression. The classification trees were developed by consideration 
of all the variables separately. The range of each variable was divided into two groups to 
obtain the best separation between the BM and TBM patients. The division 
corresponding to the best separation was selected. The resulting subsets o f cases were 
then partitioned independently in turn. The process was performed recursively, until a 
stopping condition was satisfied. Node deviance, which measures node heterogeneity, 
was set to 0.1 to stop the tree growing process. Subsets smaller than 10 were not 
partitioned further.
Logistic regression was used to model the probability of having TBM. A stepwise 
forward variable selection procedure was employed to find independent predictors of 
TBM with p-to-enter < 0.05, and p-to-remove > 0.055. Once the final model was 
constructed, the continuous variables in the model were dichotomized using cutoffs from 
the univariate classification trees, and the model was refitted. Rounded p-coefficients 
from the model with dichotomized variables were used to define a diagnostic index (DI) 
for each o f the clinical variables. A receiver operator characteristic (ROC) curve analysis
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was selected to find an optimal cutoff for the combined diagnostic indices. ROC analysis 
was performed upon the original dataset, and the completed rule (DI with cutoff) was 
applied to the test data.
The three diagnostic aids were evaluated using resubstitution and prospective test data 
methods. The sensitivity and specificity w ere calculated and compared w ith  the  study 
diagnostic criteria. The resubstitution method used the original data s et. The t est data 
method employed data recorded from a further 75 patients enrolled in the same manner 
and subject to the same diagnostic criteria. All analyses were performed using ST AT A 
and Spins.
3.3 Results
3.3.1 Adults satisfying diagnostic criteria
Three hundred and fifty-seven adults were admitted to the CRU with meningitis between 
1998-2000. 251 satisfied the diagnostic criteria for inclusion in this study: 143 with 
TBM, and 108 with BM. An HIV test was performed in 66/251 adults: 8 were positive (7 
had TBM, 1 had BM).
163/357 adults received ATC for suspected TBM: M.tb was isolated from the CSF o f 37 
patients, and 106 were defined as having clinical TBM. Supportive radiological evidence 
for TBM was present in 85/106 adults with clinical TBM. 20 patients treated for TBM 
were excluded because they did not meet the study criteria for the diagnosis o f TBM, and 
all died shortly after the start o f ATC. No significant (p<0.05) differences were found
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between the admission clinical and laboratory parameters o f those with culture-confirmed 
and clinical TBM.
194/357 adults admitted over the same period were not treated for TBM: 108 satisfied the 
study criteria for a diagnosis of BM. A bacterial pathogen was isolated from the CSF of 
68 adults (Table 3.2). A further 40 adults satisfied the diagnostic criteria for BM 
(presumed partially treated). 86 adults were excluded from the study for the following 
reasons: 61 had a normal CSF glucose (>50% blood), 15 died within 3 months, and 11 
were lost to follow-up. Admission variables are shown in Table 3.3.
Table 3.2 M icrobiology of culture proven bacterial meningitis.
Organism  from  CSF Number Percentage
Streptococcus pneumoniae 24/68 35.3%
Streptococcus suis 31/68 45.6%
Neisseria meningitidis 4/68 5.9%
Haemophilus influenzae 4/68 5.9%
Klebsiella sp 4/68 5.9%
Escherichia coli 1/68 1.5%
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Table 3.3 Univariate analysis comparing admission parameters between patients 
with TBM and BM
Parameter Tuberculous meningitis
Median 90% range (n)
Bacterial meningitis
Median 90% range (n)
P-value
A ge (years) 34 16-64 (143) 41 17-70 (108) 0.008
Male sex 91 (64%) 84 (78%) 0.016
Duration o f  illness (days)
12 4-34 (142) 3 1-11 (107) <0.001
Duration o f  fever (days) 10 2-30 (139) 3 1-11 (106) <0.001
Duration o f  headache 10 1-30 (136) 3 1-11 (106) <0.001
(days)
N eck stiffness 120 (91%) (143) 81 (84%) (106) 0.091
Presence o f  coma before 49 (36%) (143) 53 (50%) (106) 0.027
admission (Yes)
Glasgow coma score (/15) 13 7-15 (143) 14 6-15 (107) 0.091
Pulse (/min) 90 60-120 (143) 92 72-120 (108) 0.003
Systolic BP (mmHg) 120 90-150 (143) 120 90-150 (108) 0.76
Diastolic BP (mmHg) 70 50-90 (143) 70 50-90 (108) 0.24
Hemiplegia 11(8% ) 4(4% ) 0.28
Cranial nerve palsies 32 (22%) (143) 9(8% ) (107) 0.003
Haematocrit (%) 40 30-48 (139) 42 30-48 (104) 0.12
White blood cell count 9800 5000-16200 (137) 15250 7470-31500 (107) <0.001
(lOUml)
% neutrophils 80 6 0 - 8 9 (130) 86 7 0 - 9 5 (107) <0.001
Blood sodium (mmol/1) 135 122-143 (98) 138 125-148 (102) 0.001
CSF opening pressure (cm 23 9-44 (133) 24 7.5-40 (60) 0.92
H2O)
Clear CSF appearance 81(57%) (141) 2 (2%) (107) <0.001
CSF total WCC 300 70-1090 (143) 2583 382-20000 (108) <0.001
(lOUml)
CSF % neutrophils 37 1-84 (142) 90 60-99 (108) <0.001
CSF % lymphocytes 64 16-99 (142) 10 1-40 (108) <0.001
CSF/Blood glucose 0.28 0.11-0.52 (139) 0.20 0.03-0.46 (101) <0.001
CSF chloride (mmol/1) 108 85-120 (136) 109 97-121 (67) 0.012
CSF protein 191 80-490 (141) 270 89-730 (107) <0.001
(g/dl)
CSF lactate (mmol/1) 5.4 1.5-9.8 (102) 9.4 2.1-19.7 (92) <0.001
Excluding the 92 patients who received immediate ATC, the results from a 2"  ^ lumbar 
puncture performed after 48 hours of ceftriaxone were available in 157/251 patients - 51 
patients with TBM, and 106 patients with BM (Table 3.4).
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Table 3.4 Second CSF analysis taken after 48-72 hours of parenteral ceftriaxone.
TBM BM
Median Median p-value
48hr CSF 90% range (number) 90% range (number)
CSF opening pressure (cm 27 8-44 (43) 14 4-27 (58) 0.003
H2O)
Clear CSF appearance 21 (49%) 23 (23%) <0.001
CSF total WCC 470 173-2575 (51) 760 80-12000 (106) 0.048
(10" /ml)
CSF % neutrophils 47 4-87 (51) 74 8-97 (106) <0.001
CSF % lymphocyte 53 13-96 (51) 26 3-90 (106) <0.001
CSF/Blood glucose 0.27 0.13-0.5 (47) 0.43 0.11-0.69 106) <0.001
CSF chloride (mmol/1) 102 81-116 (48) 115 105-126 (64) <0.001
CSF protein 190 98-680 (49) 110 37-580 (104) <0.001
(g/dl)
CSF lactate 6.4 2.9-11 (36) 4.8 1.8-10.4 (77) 0.011
(mmol/1)
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2/251 patients with culture confirmed BM died before a 2"  ^sample could be taken. After 
48 hours o f ceftriaxone a low CSF glucose (<50% blood) was found in 68/106(64%) of 
adults with BM, and 44/51(94%) o f those with TBM (Table 3.5)
Table 3.5 Change in the CSF parameters after 48-72 hours of parenteral ceftriaxone 
as calculated by (CSF2 -  CSF 1/ CSF 1). Expressed as % change.
TBM
Median % change 
90% range 
number
BM
Median % change 
90% range 
number
p-value
CSF opening pressure +8% -41% <0.001
-75 to +267% -83 to +56%
36 51
CSF WCC +13% -75% <0.001
-68 to + 964% -97 to + 918%
51 106
CSF % Neutrophils -1% -15% 0.001
-45 to + 500% -88 to + 23%
50 106
CSF +5% +144% <0.001
% lymphocytes -54 to +145% -88 to +155%
50 106
CSF glucose/blood ratio -6% + 100% <0.001
-66 to + 92% -61 to + 833%
45 99
CSF lactate +0% -48% <0.001
-55 to + 314% -81 to + 114%
27 70
CSF Protein +2% -54% <0.001
-37 to + 275% -90 t o + 51%
49 103
CSF chloride -4% +4% <0.001
-14% to +8% -8 to +21%
48 63
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3.3.2 Diagnostic classification trees
Figures 3.1 and 3.2 show the diagnostic trees generated from the CART analysis. Figure
3.1 is for use on admission; Figure 3.2 is for use after 48 hours o f broad-spectrum 
antibiotics.
Figure 3.1 Admission diagnostic classification tree
CSF WCC <760x107ml
YES
History of illness < 6 days
NO
History of illness < 7 days
NO
Blood WCC < 10200\l07m l
NOYES
BM TBMTBM
YES NO
Age < 42 years
YES NO
TBMBM BM
Figure 3.2 Diagnostic classiBcation tree for use after a trial of 48 hours broad 
spectrum antibiotics
History of illness <8 days 
YES NO
Blood neutrophils < 80%
YES NO
CSF neutrophils < 81%
YES
BM BMTBM
Rise in CSF/blood glucose <100%
YES NO
TBM BM
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3.3.3 Diagnostic rule from Logistic regression
Multivariate analyses were performed to construct a diagnostic rule. A number of 
variables were excluded from the analyses. Admission Glasgow Coma Score, diastolic 
and systolic BP, presence o f hemiplegia, and blood haematocrit, were excluded due to the 
non-significant (p>0.05) results by univariate analysis. Blood sodium, CSF opening 
pressure, CSF chloride, and CSF lactate were excluded because o f  a large number o f  
missing values. Only the total duration of combined symptoms before admission was 
included for analysis: the length o f fever, and headache, were excluded.
Stepwise logistic regression analysis found 5 variables independently associated with a 
diagnosis of TBM on admission. The final logistic model with these variables is 
described in Table 3.6.
Table 3.6 Multivariate logistic regression analysis of admission data
P-Coefficient OR (95% Cl) p-value
Age -0.069 0.933 (0.885-0.984) 0.010
History of illness 0.243 1.275 (1.132-1.437) <0.001
Blood WCC -0.0003 0.9997 (0.9995-0.9999) 0.001
CSF WCC -0.002 0.998 (0.996-0.999) <0.001
CSF % neutrophils -0.075 0.928 (0.884-0.973) 0.002
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The formula for diagnostic index (DI) was derived from the final model by 
dichotomizing the variables and rounding the coefficients in the model. The index was 
adjusted to a positive scale for ease o f use.
The DI for each of the 5 variables is given in Table 3.7
Table 3.7 Weighted Diagnostic index scores for the dichotomized clinical variables 
used for the admission diagnostic rule
Variable DI
Age (years)
> 36 +2
< 36 0
Blood WCC (lOVml)
>15000 +4
<15000 0
History o f illness (days)
> 6 -5
< 6 0
CSF total WCC (lOVml)
>900 +3
<900 0
CSF % neutrophils
>75 +4
<75 0
Suggested Diagnostic Rule: Total DI score < +4 = TBM
Total DI score > +4 = BM
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The Total DI was calculated for each patient according to the formula:
Total DI = DI (age) + DI (blood WCC) + DI (history o f illness) + DI (CSF WCC) + DI 
(CSF % neutrophils). The optimal cut-off for Total DI (to classify a patient as a TBM 
case) was found using a ROC curve (Figure 3.3). There are three points close to the top 
left-hand comer o f the curve: these correspond to cut-offs o f +4, +3, or +2. The 
respective diagnostic sensitivities and specificities for each point are 97%, 91%; 96%, 
91%; and 91%, 97%.
Figure 3.3 Receiver-operator characteristic curve for prognostic index derived from 
the logistic regression model.
Area under RO C  curve = 0.9901
1.00
0.75
0.50
0.25
0.00
1.000.25 0.50 0 .750.00
1 - Specificity
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No improvement in the diagnostic rule was obtained by employing data from both 
admission and the second CSF. Missing values, which reduced the sample size to 121 
observations, may have accounted for this failure.
Table 3.8 Misclassification rates of the three diagnostic aids
Resubstitution method Test data method
Sensitivity Specificity Sensitivity Specificity
At admission:
Classification 99% (134/136) 93% (99/107) 88% (37/42) 70% (23/33)
tree
Diagnostic rule 91% (123/135) 97% (104/107) 86% (36/42) 79% (26/33)
After r ‘‘ CSF:
Classification 93% (39/42) 95% (92/97) 57% (8/14)
tree
76% (25/33)
3.3.4 Performance
The performances of each of the diagnostic aids (from CART or logistic regression) are 
summarized in Table 3.8. Resubstitution of the original data set into the admission 
diagnostic tree misclassified 10 patients (2 TBM and 8 BM) giving 99% sensitivity and 
93% specificity.
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The second tree misclassified 8 patients (3 TBM and 5 BM) giving 93% sensitivity and 
95% specificity.
The test data were recorded from  a further 75 patients satisfying the  study diagnostic 
criteria: 20 adults had culture-confirmed TBM; 22 adults had clinical TBM; 21 adults had 
culture-confirmed BM; and 12 adults had clinical BM. Clinical data from this group was 
applied to  each diagnostic aid: the admission tree (figure 3.1) was 88% sensitive and 
70% specific; the admission diagnostic rule (table 3.7) was 86% sensitive and 79% 
specific; and the second diagnostic tree (figure 3.2) was 57% sensitive and 76% specific.
3.4 Discussion
The diagnosis of TBM in adults is difficult regardless o f the resources available to the 
physician. This study employed diagnostic criteria that derive from CSF culture results, 
and observed response to specific treatment. Such criteria suggest that even in the best 
settings a proportion of those with TBM or BM will never be proven microbiologically. 
As untreated TBM is always fatal it is essential that a clinical diagnostic aid or laboratory 
assay for TBM is sensitive. The potential toxicity and duration o f ATC, and the limited 
resources o f many tuberculosis control programs, also mandates diagnostic specificity. At 
present no rapid laboratory method for the diagnosis o f TBM satisfies these requirements. 
A clinical diagnostic rule or classification tree for TBM may improve upon the sensitivity 
o f current laboratory methods, and it may be
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used in settings with limited microbiological diagnostic support, i.e. where TBM is most 
common. This study compared patients with TBM with confirmed or probable BM for 
two reasons: first, both groups of patients require immediate decisions regarding 
chemotherapy, and second, those with BM, particularly partially treated BM, are difficult 
to distinguish from those with TBM. Low CSF glucose is usually present in both 
conditions, and forms an important discriminating feature from other meningo- 
encephalitides. The CSF:blood glucose ratio is usually >50% in patients with viral 
meningo-encephalitis. A low CSF glucose (<50% blood) was present on admission in all 
but one patient entering this study.
The most common agent isolated from patients with BM was Streptococcus suis, which 
has been well described in south east Asia (Kay R et al., 1995). The infection is most 
commonly seen in men working in frequent contact with pigs, which explains the 78% 
male preponderance in the BM group. The organisms isolated were all sensitive to 
ceftriaxone, as were all the isolates of Streptococcus pneumoniae. The clinical features of 
Streptococcus suis meningitis are comparable to other bacterial meningitides, and their 
inclusion in this study is unlikely to affect the application o f the diagnostic aids produced. 
The prevalence of HIV infection in the study population was low, although only 66/251 
patients were tested. At the time of the study the prevalence of HIV infection was high in 
two groups: commercial sex workers, and intra-venous drug addicts (Nguyen TH et a l ,  
1999). The prevalence of HIV infection amongst women attending maternity clinics in 
Vietnam, 1994-1998 was less than 0.15%.
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Although HIV testing was limited to at-risk groups, the study is unlikely to have included 
substantial numbers of patients with unrecognised HIV infection. Although HIV appears 
to increase risk of developing TBM (Berenguer J et al., 1992), it may not alter the clinical 
and laboratory features o f the disease (Yechoor VK et ah, 1996). However, HIV infection 
alters the differential diagnosis in meningitic adults: opportunistic infection with unusual 
pathogens must be considered, in particular Cryptococcus neoformans, which may 
present sub-acutely, similar to TBM. The results o f this study should therefore be applied 
with caution in areas with a high prevalence o f HIV infection.
The univariate analysis of admission variables suggests a set of potentially discriminative 
clinical features. Patients with TBM present with a longer history; they are more likely to 
have cranial nerve palsies; they will not usually have a blood leucocytosis; and their CSF 
will frequently be clear, with moderate numbers o f lymphocytes and neutrophils, in 
combination with an elevated protein and a low CSF:blood glucose ratio. However, 
diagnostic uncertainty frequently persists despite the first CSF analysis. In such cases, 
physicians in our hospital may assess response to treatment after 48 hours with a broad- 
spectrum antibiotic. Tables 3.4 and 3.5 demonstrate significant differences are apparent 
between the two groups. A s expected, the CSF parameters change little in  those w ith 
TBM. The changes observed in BM presumably reflect successful antimicrobial effect: 
CSF pressure, white cell count, protein and lactate fall whilst CSF:blood glucose ratio 
rises.
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The dangers o f delayed ATC focus attention on a diagnostic aid using admission clinical 
features. Multivariate logistic regression analysis defines five characteristics 
independently predictive of a diagnosis o f TBM from BM: age, history o f illness, blood 
white cell count, CSF white cell count, and the CSF neutrophil percentage (table 3.6). A 
diagnostic rule can be suggested from the ROC analysis: those patients presenting with a 
total DI score of +4 or less have TBM, those with a score greater than +4 have BM. A 
cut-off of +4 was chosen as it provided the greatest sensitivity (97%) with acceptable 
specificity (91%). Applying the test data the rule is  86% sensitive, and 7 9% specific, 
figures that are comparable to the best available laboratory assays (Thwaites G et a l, 
2000a).
Two diagnostic classification trees were developed: the first for admission, and a second 
to be used after a trial o f broad-spectrum antibiotics (figures 3.1 and 3.2). When the test 
data are applied to the admission tree diagnostic sensitivity is similar to that of the rule 
(88%), but specificity is reduced (70%). The second tree performs less well, although the 
data available to test this tree were small: 14 patients with TBM, 33 with BM. 
Nevertheless, a diagnostic tree incorporating the second CSF is attractive given the 
striking differences documented between those with TBM and treated BM, but requires 
further development and prospective assessment.
There are some important limitations to this study. First, the prevalence o f both 
tuberculosis and HIV infection will affect the performance o f the rule. Therefore, this
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rule should not be used in areas o f substantially different tuberculosis and HIV 
prevalence to southern Vietnam without prospective evaluation in those settings.
As this will remain a fundamental problem for all similar diagnostic methods, future 
research should also be directed at investigating their impact upon outcome. Early 
treatment o f TBM is known to save lives (Kennedy DH et a l ,  1979), the impact o f a 
diagnostic rule upon outcome should be prospectively evaluated.
This study suggests that simple clinical and laboratory data can be used to help diagnose 
TBM in adults, and develops an admission diagnostic rule with 86% sensitivity and 79% 
specificity. The rule should be applied to adults in high tuberculosis prevalence settings 
with meningitis and a CSFiblood glucose < 50%. As the diagnosis and management o f 
meningitis rests on clinical and CSF assessment, efforts are necessary to support clinical 
and appropriate laboratory diagnostic services in low-income countries.
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CHAPTER 4
THE BACTERIOLOGICAL
DIAGNOSIS OF TUBERCULOUS
MENINGITIS
4.1 Introduction
The demonstration o f AFB in the CSF by the ZN stain remains the most widely available 
rapid diagnostic test for TBM. However, there is large and unexplained variability in the 
sensitivity of this method. Recent authors report bacilli are seen in the CSF o f less than 
10% of cases (Garg RK, 1999), but the older literature suggests much better results can 
be achieved. In 1953 Stewart found AFB in the CSF o f 91/100 consecutive cases of 
TBM, all were subsequently confirmed by culture (Stewart SM, 1953). Similar results 
were reported in 1979 by Kennedy, who found AFB in the CSF o f 45/52 (87%) patients 
treated for TBM (Kennedy DH et a l,  1979). The reasons why many laboratories fail to 
replicate these results are uncertain. Stewart suggested diagnostic performance was 
dependent upon the volume of CSF submitted for examination, the speed and duration of 
centrifugation, and meticulous microscopy (Stewart SM, 1953). Kennedy ascribed their 
results to the repeated and thorough examination of CSF for AFB, even after ATC had
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started (Kennedy DH et a l,  1979). However, there are few data to support these 
assertions.
The aim o f this study was to prospectively assess the procedural and clinical variables 
affecting the sensitivity o f CSF ZN stain and culture ioxM.tb, and test the hypothesis that 
the sensitivity of conventional bacteriology is dependent upon the volume o f CSF 
examined and the duration of microscopy.
4.2 Methods
4.2.1 Clinical methods
A special laboratory diagnostic service for TBM was set up at the CRU in 2000, and the 
attending physicians were encouraged to submit 5-1 Omis o f CSF from any adult admitted 
with possible TBM. The volume o f each CSF sample submitted to the service was 
recorded, and processed according to  the methods described in Chapter 2. I f  two or 
more AFB were identified the slide was termed positive, and the time to see 2 bacilli 
recorded. The time taken to examine negative slides was also recorded. Only one slide 
was made per CSF specimen. The remaining deposit was cultured in liquid 
Mycobacterial Growth Indicator Tubes (MGIT, Becton Dickenson, USA), and on 
Lowenstein-Jenson (LJ) media for a minimum of 8 weeks.
The clinical and laboratory features, and the final diagnosis of each patient admitted to 
the CRU were recorded prospectively in individual study notes as described in Chapter 
2. All patients with TBM were tested for antibodies to HIV.
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4.2.2 Statistical methods
Normally distributed continuous variables were compared by the Student t-test; all other 
continuous variables were compared by the Mann-Whitney U test. Categorical variables 
were compared by the chi-squared test. Multivariate analysis by forward logistic 
regression was performed to model the likelihood o f seeing bacilli or isolating M.tb from 
the CSF. The following variables were selected a priori to enter the model: age, sex, HIV 
status, duration of symptoms and disease grade; volume of CSF, CSF opening pressure, 
CSF total white cell count with neutrophil and lymphocyte percentages, CSF total 
protein, lactate, chloride, and CSFiblood ratio. The analysis was performed using 
‘Statistical Product and Service Solutions’ (SPSS) software version 10.0 (Microsoft, 
USA).
4.3 Results
4.3.1 Patients satisfying diagnostic criteria
Seven hundred and twenty CSF specimens from 320 adults were submitted to the 
laboratory between May 2000 and April 2003: 384 were ‘diagnostic’ specimens, taken 
before the start o f ATC from 320 adults; 346 samples were taken from 132 adults after 
starting treatment for TBM.
198 adults (241 specimens) were not treated or diagnosed as having TBM: 70 (35%) had 
bacterial meningitis, 68 (34%) had viral meningo-encephalitis, 15 (8%) had parasitic 
meningitis, 13 (7%) had cryptococcal meningitis, and other diagnoses were recorded in
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32 ( 16%). AFB w ere neither seen nor cultured from any o f the specimens from these 
patients. 132 adults had clinical TBM: 107 (81%) had bacteriological confirmation of the 
diagnosis, 15 (11%) had probable TBM, and 10 (8%) had possible TBM. 14/132 were 
infected with HIV.
4.3.2 Performance of ZN stain and cnitnre
The sensitivity, specificity, positive and negative predictive values o f CSF stain and 
culture before the start o f ATC are presented in Table 4.1. AFB were seen in the CSF of 
73/132 (55%) patients (73/143 specimens) before the start o f ATC.
Table 4.1 Sensitivity, specificity, and positive and negative predictive vaines of CSF 
stain and cnitnre before the start of ATC
GOLD STANDARD
Sensitivity 
Specificity 
Positive predictive 
valne 
Negative 
predictive valne
M.tb CSF culture 
CSF ZN stain 
65/90 (72%) 
286/294 (97%) 
65/73 (89%)
286/311 (92%)
Clinical diagnosis 
CSF ZN stain M.tb CSF cnitnre
73/143 (51%) 90/143 (63%)
241/241 (100%) 241/241 (100%)
73/73 (100%) 93/93 (100%)
241/311 (77%) 241/291 (82%)
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After 2 days o f treatment bacilli were seen in 9/50 (18%) patients (50 specimens), and in 
5/73 (7%) patients (73 specimens) taken after 7 days o f treatment. No bacilli were seen in 
the CSF after this time. AFB were seen in the CSF of 4 patients after the start of 
treatment in which the pre-treatment slides were negative. Therefore, bacteriological 
confirmation of the diagnosis of TBM was made by CSF stain in 77/132 (58%) during 
the first week of ATC.
M.tb was isolated from the CSF of 90/132 (68%) patients (90/141 specimens) before the 
start o f treatment. ATC quickly reduced the likelihood of isolating an organism from the 
CSF: after 2 days M.tb was cultured from 18/50 (36%) adults (50 specimens), and 11/73 
(15%) (73 specimens) after 7 days. Two adults had M.tb isolated after 30 and 60 days of 
treatment respectively: both o f these organisms were resistant to isoniazid and 
streptomycin. CSF cultures were sterile from 13 patients in which bacilli were seen. Nine 
were in specimens taken before the onset of treatment, and 4/13 taken after the start of 
treatment. All these specimens came from patients with clinical features o f probable 
TBM who responded appropriately to ATC, and were not considered false positive.
4.3.3 Variables associated with positive ZN stain and culture
The variables associated by univariate analysis with finding bacilli and isolatingM .^6 
from the CSF analysis are presented in Table 4.2. These data show infection with HIV 
and increased CSF neutrophil percentage is significantly associated (p<0.05) with a 
positive stain and a positive culture. In addition, low CSF lymphocyte percentage, high
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Table 4.2 Variables associated with positive CSF stain and culture before the start 
of ATC by univariate analysis (median and range).
Bacilli seen No bacilli P-
value
M.tb
cultured
Sterile CSF P-
value
Age(years) 30(15-68) 34(15-79) 0.302 30(15-69) 36(15-79) 0.129
Male Sex 42/73(57%) 36/70(51%) 0.464 51/93(55%) 27/50(54%) 0.923
Grade 1 19/73(26%) 24/70(34%) 28/93(30%) 15/50(30%)
Grade 2 36/73(49%) 32/70(46%) 0.504 45/93(48%) 23/50(46%) 0.937
Grade 3 18/73(25%) 14/70(21%) 20/93(22%) 12/50(24%)
ffiv + 11/14(79%) 3/14(21%) 0.030 13/14(93%) 1/14(7%) 0.022
ffiv- 62/129(48%) 67/129(52%) 80/129(62%) 49/129(38%)
Symptoms 15(6-60) 17(5-60) 0.302 15(5-60) 15(5-51) 0.274
(days)
CSF 23(5-41) 22(7-40) 0.805 23(5-40) 21(7-41) 0.481
Pressure
(cm H2O)
CSF WCC 317(1-1880) 360(5-1750) 0.678 312(1-1880) 378(5-1750) 0.453
% neut 37(0-95) 27(0-84) 0.048 37(0-95) 20(0-81) 0.004
% lymphs 63(5-100) 71(16-100) 0.083 63(5-100) 80(19-100) 0.009
CSF Protein 200(45-1800) 180(64-800) 0.270 200(45-1800) 161(64-700) 0.069
(mg/dl)
Lactate 6.8(2.1-15.1) 5.9(1.1-16.4) 0.181 6.8(1.5-16.4) 5.5(1.1-9.8) <0.001
(mmol/1)
Chloride 104(81-129) 107(76-129) 0.270 101(76-129) 107(90-129) 0.021
(mmol/1)
CSFiblood 0.23(0.04- 0.29(0.04- 0.157 0.25(0.05- 0.25(0.04- 0.923
glucose ratio 0.67) 0.67) 0.67) 0.55)
Volume(mls) 4.0(0.5-10) 3.0(0.2-12) 0.096 4.0(0.2-12.0) 3.0(0.4-8.0) 0.236
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CSF lactate concentration, and low CSF chloride concentration, are significantly 
associated with a positive CSF culture.
When the same variables were compared by multivariate analysis using forward logistic 
regression, only the CSFiblood glucose ratio (OR 0.03, 95% Cl 0.002-0.621, p=0.023) is 
independently predictive o f seeing AFB in the CSF. The factors independently associated 
with the bacteriological confirmation of TBM {M.tb cultured from the CSF and/or AFB 
seen in the CSF) are presented in Table 4.3.
Table 4.3 Factors associated with the bacteriological confirmation of TBM before 
the start of ATC by forward logistic regression
Factor Odds
ratio
95% confidence interval p-value
Duration of symptoms (days) 1.05 1.00-1.10 0.050
Volume o f CSF (mis) 1.36 1.06-1.75 0.017
CSF neutrophils (% of WCC) 1.03 1.01-1.05 0.008
CSF lactate (mmol/1) 1.42 1.16-1.73 0.001
CSFiblood glucose ratio 0.03 0.02-0.62 0.023
The median time to see bacilli in the CSF before the start o f treatment was 10 minutes 
(range 1-50). Figure 4.1 presents a histogram of the times taken to see bacilli, and the 
cumulative percentages of positive slides as the time to examine the slide increases.
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Figure 4.1 Time to see bacilli in the CSF before the start o f treatment
Cumulative percentage of positive slides
36% 56% 64% 75% 79% 85% 88% 95% 99% 180%
0 5  10 15 20 25 30 %  40 45
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Figure 4.2 Volume of CSF submitted for culture, and the likelihood o f culturing 
Mtb
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The median volume o f CSF examined was 4.0mls (range 0.2-12.Omis), and the median 
time to examine each slide was 20 minutes (range 1-50 minutes). The median volume of 
CSF submitted after starting ATC was 3.Omis (range 1.0-12.Omis). Figure 4.2 shows the 
affect o f increasing volume upon culture rates in  H IV  negative individuals b efore the 
start o f treatment. M.tb was isolated from smaller CSF volumes from HIV-infected 
individuals (medians l.Smls vs 4.Omis, p=0.001).
4.4 Discussion
The search for AFB in the CSF is widely believed to be too insensitive to assist in the 
management of many patients. The decision to start ATC cannot wait until M.tb has been 
cultured from the CSF; therefore many patients are treated for TBM on clinical suspicion 
alone. C hapter 3 explores the possibility of improving clinical diagnostic methods, 
particularly in settings with limited diagnostic microbiology. However, this study shows 
that the performance o f CSF stain and culture can be substantially improved and 
identifies both procedural and clinical variables that are associated with improved 
performance.
The isolation o f M.tb from the CSF is the gold standard diagnostic test for TBM, but 
limited sensitivity has resulted in many authors replacing this gold standard with a set of 
clinical diagnostic criteria. This introduces problems when assessing the performance of 
old or new diagnostic tests: there are no universally accepted diagnostic criteria, and none 
have been prospectively assessed against the true gold standard o f culture. This study
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presents performance data using culture and clinical diagnostic gold standards (Table 
4.1). Using the culture of M.tb from the CSF as gold standard, the sensitivity o f CSF ZN 
stain before the start o f ATC was 72%. This figure is similar to one reported by Kennedy 
(Kennedy DH et a l ,  1979), although less than that reported b y  Stewart (Stewart SM, 
1953). The excellent results reported by Stewart may be partly due to available ATC at 
the time o f their study (pre-1953). As this study demonstrates, 4-drug ATC containing 
these two drugs rapidly sterilises the CSF: after 2 days the sensitivity o f ZN stain and 
culture fell respectively to 18% and 36%, and to 7% and 15% after 7 days.
M.tb was only cultured from the CSF of 2 patients after 7 days o f treatment, and both 
isolates were resistant to isoniazid and streptomycin. Rifampicin and isoniazid were 
unavailable during Stewart’s study, which was performed in the 1940’s, and early 1950’s, 
and there was limited availability of streptomycin and PAS. Therefore, Stewart’s ability 
to find AFB in the CSF in more than 90% may be due to repeated CSF sampling from 
patients on weakly active ATC (PAS and streptomycin alone) or no treatment at all. 
C hapter 5 examines the impact o f drug resistance on the isolation o f M.tb from the CSF 
after the start o f ATC.
The duration o f treatment for TBM, and the potential toxicity of the drugs, mandates high 
diagnostic specificity. This study suggests both ZN stain and culture for M.tb in the CSF 
is highly specific. However, AFB were reported but not cultured in 8 specimens taken 
before the start o f ATC. These may represent false positives: debris from poorly filtered 
carbol fuscin can mimic AFB, as can small scratches on the surface o f the slide.
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However, the stringent requirement o f this study to see 2 or more bacilli before calling a 
slide positive makes this explanation unlikely. Also, the clinical features of all the 
patients were consistent with TBM and all responded appropriately to ATC. There may 
be two explanations for these sterile cultures. First, the concentration o f bacilli in some 
specimens will be on the limit of detection for stain and culture (considered to be around 
10"* bacilli/ml (Collins CH et a l,  1997)): the chance distribution o f bacilli between the 
divided deposit may result in a concentration insufficient for culture. The characteristic of 
M.tb in clinical specimens to stick together in clumps makes this explanation more 
tenable. Alternatively, the AFB seen in the CSF may not be viable.
Most patients with TBM present after many days of symptoms, and are often treated 
initially for suspected pyogenic infections. In particular, prior treatment in the community 
with fluroquinolone antibiotics is common in Vietnam. These drugs have bactericidal 
activity against M.tb, and could account for non-viable AFB in the CSF. The 
phenomenon of visible but non-cultivable AFB is well recognised in the sputum of 
partially treated pulmonary tuberculosis, and has also been reported in the CSF of 
patients with TBM (Bonington A et a l,  2000). In this study AFB were found but not 
cultured in the CSF from 4 patients after the start o f treatment -  all had M.tb isolated 
from the CSF before ATC. These organisms are presumed to represent dead bacilli.
Many authors have considered the low sensitivity of the bacteriological diagnosis of 
TBM to be due to low concentration of organisms in the CSF. As a consequence, the 
volume of CSF examined is believed to be critical to diagnostic performance; but there
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are few data to support this assertion. This study shows that CSF volume is independently 
associated with bacteriological diagnosis (Odds ratio 1.36, 95% Cl 1.06-1.75 p=0.017). 
Figure 4.2 shows that M.tb was isolated from 80% of specimens when more than 6 mis 
o f CSF were cultured, and from 40 % when less than 2 mis were cultured. Low 
concentrations o f bacilli in the CSF often requires prolonged microscopy to confirm their 
presence, and this study showed that 20% of positive slides required more than 25 
minutes microscopy to find AFB. However, the relationship between duration of 
microscopy and the number o f positive slides was not linear (Figure 4.1): 36% slides 
were found to be positive after less than 5 minutes microscopy, but a further 45 minutes 
microscopy to confirm the remaining 64%. The reason for this relationship is likely to be 
due to  microscopy technique and the characteristic o i M . t b h  acilli to  stick together in 
clinical specimens. It was observed early in the study that AFB were most commonly 
found in the areas o f the slide with the highest cellular density. Thereafter, these areas 
were identified first under low power and a careful search was made o f them under high 
power. If  this proved fhiitless the rest o f the slide was examined systematically. Directing 
the initial search for bacilli to areas most likely to contain them probably explains the 
high yield (56%) in the first 10 minutes of microscopy. However, these data also confirm 
theim portanceofpro longedm icroscopy( g rea te rth an 2 0 m in u tes)to  the diagnosis in 
25% of cases.
It may be difficult for laboratories with limited staff and resources to perform the level of 
microscopy required to achieve the best results. For this reason, clinical predictors of the
137
Bacteriological diagnosis
diagnosis o f TBM, and the likelihood of achieving bacteriological confirmation, might be 
helpful in directing resources to specimens most likely to be positive. C hapter 3 
investigates whether TBM might be distinguished clinically from other causes of 
bacterial meningitis, and the algorithms described could be used to distinguish patients in 
whom careful microscopy and culture for M.tb is warranted. The variables described in 
Table 4.3 could be applied to patients selected by these algorithms to further assess the 
likelihood of obtaining a bacteriological diagnosis: the search for AFB should be 
especially stringent when the patient has a long history, a CSF pleocytosis with a high 
percentage o f neutrophils, a high concentration o f CSF lactate, and a low CSF:blood 
glucose ratio.
The effect o f HIV infection upon the performance o f conventional bacteriology appears 
marked, although there were only 14 HIV-infected patients with TBM in this study. M.tb 
was isolated from significantly smaller CSF volumes from HIV infected individuals 
compared to those without the virus (medians l.Smls vs 4.Omis, p=0.001). These data 
suggest these adults may have greater CSF bacterial concentrations, and the bacterial 
diagnosis may be easier to confirm. Other clinical variables independently associated 
with bacteriological diagnosis (Table 4.3) may also reflect bacillary concentration. If  this 
is true these variables may also be associated with pathogenesis and outcome. These 
speculations are explored further in C hapter 8.
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CHAPTER 5
THE MOLECULAR DIAGNOSIS OF
TUBERCULOUS MENINGITIS
5.1 Introduction
Early reports suggested the amplification of nucleic acid specific to M.tb from the CSF of 
patients with TBM might improve upon conventional bacteriology (Kaneko K et a l, 
1990; Shankar P et a l ,  1991). A recent systematic review and meta-analysis o f the 
accuracy o f nucleic acid amplification (NAA) tests for the diagnosis of TBM concluded 
these tests were specific, but insensitive (sensitivity of commercial assays 56% [95% Cl 
46-66%]) (Pai M et a l ,  2003). There are a number of reasons why these methods have 
failed to meet initial expectations. First, a wide variety of methods are reported, many are 
in-house, and conclusions regarding their general applicability are difficult. Second, few 
studies have been able to compare performance against a bacteriological gold standard, 
instead choosing a variety of clinical diagnostic criteria that have never been 
prospectively assessed. Lastly, TBM is rare in most settings capable o f applying the 
required technology; consequently most published studies are small, reporting few 
patients with TBM, and lack the statistical power to demonstrate unequivocal 
improvements in performance.
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The FDA of the United States have licensed two assays for the direct detection o f M.tb 
nucleic acid in smear positive respiratory samples: the Gen-Probe Amplified 
Mycobacterium Tuberculosis Direct Test (MTD) (Gen-Probe, San Diego, California) and 
the AMPLICOR Mycobacterium tuberculosis test (Roche Diagnostics, Indianapolis, 
Indiana). Neither o f these kits is licensed for use on non-respiratory samples, and there 
are limited data regarding their performance using CSF. Studies using the Roche 
AMPLICOR assay suggest it does not improve upon microscopy for acid-fast bacilli in 
the CSF (Bonington A et a l ,  1998; Brienze VM et a l ,  2001).
The MTD is a target-amplified nucleic acid probe test for the in-vitro diagnostic detection 
of M.tb ribosomal ribonucleic acid (rRNA). The test uses Transcription-Mediated 
Amplification (TMA) and the Gen-Probe Hybridisation Protection Assay (HPA) to 
qualitatively detect rRNA from all organisms of the M.tb complex. It is a two-part test in 
which amplification and detection take place in a single tube. Initially, nucleic acids are 
released from mycobacterial cells by sonication. Heat is used to denature the nucleic 
acids and disrupt the secondary structure o f rRNA. The TMA amplifies a specific rRNA 
target by transcription at a constant 42®C, resulting in multiple copies o f M.tb rRNA 
amplicon. M.tb specific sequences are detected by probing with chemiluminescent- 
labeled complimentary DNA. A luminometer is used to detect stable RNA:DNA hybrids.
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Molecular diagnosis
There have been seven published studies that report the use o f MTD for the diagnosis of 
TBM (Table 5.1). These data suggest it may be more sensitive than conventional 
bacteriology and other NAA tests (pooled sensitivity of MTD 61%, 95% Cl 49-72%), but 
the effect o f anti-tuberculosis chemotherapy (ATC) upon the performance of 
conventional and molecular diagnostic methods is also uncertain. There is some evidence 
to suggest repeated sampling after the start o f ATC improves the diagnostic yield o f CSF 
ZN stain and culture (Kennedy DH et a l,  1979). There are also some data that suggest 
M.tb DNA can be detected in the CSF for at least 4 weeks after the start o f treatment 
(Donald PR et a l,  1993), in which case molecular diagnostic techniques may be 
especially useful once treatment has started. Organisms resistant to first-line drugs may 
be more readily detected by all methods after treatment, but this issue remains 
unexamined in patients with TBM.
The aim of this study was test the hypothesis that NAA (by MTD) is more sensitive than 
conventional bacteriology for the diagnosis of TBM, and to investigate the impact o f drug 
resistant M.tb upon the sensitivity of these methods after the start o f treatment.
5.2 Methods
5.2.1 Clinical methods
As described in C hapter 4, a special laboratory diagnostic service for TBM was set up at 
the CRU, and the attending physicians were encouraged to submit 5-1 Omis of 
cerebrospinal fluid from any adult admitted to with possible TBM. The volume o f each
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CSF sample submitted to the service was recorded, and processed according to the 
methods described in Chapter 2. The supernatant was removed to leave a volume 
equivalent o f 5 or 6 drops into which the deposit was vigorously re-suspended. The 
deposit was divided into three equal volumes for ZN staining, MTD (frozen at -70^C), 
and culture.
The clinical and laboratory features, and the final diagnosis o f each patient admitted to 
the CRU were recorded prospectively in individual study notes as described in Chapter 
2. All patients with TBM were tested for antibodies to HIV.
Lumbar punctures were performed on days 2, 7, 30, 60, and 270 o f treatment for TBM. 
The samples were treated by the same methods described above. CSF cell counts and 
biochemistry were performed by standard methods upon each sample, as were Gram’s 
and Indian ink stains with culture for fungi and pyogenic bacteria.
5.2.2 Adaptation of the MTD for CSF
Pfyffer et a l  have reported a low sensitivity when using the MTD on untreated spiked 
CSF, and demonstrated improved sensitivity following pre-treatment with SDS-NaOH (5 
X 10  ^cells/ml detected if  untreated vs. 2 x 1 0 ^  cells/ml detected if  treated) (Pfyffer GE et 
a l,  1996). These experiments were repeated prior to starting MTD testing. CSF from a 
patient with culture confirmed cryptococcal meningitis was divided into 450ul aliquots 
and spiked with 5Oui 1/10 dilution series o f a clinical M.tb isolate (in PBS) in triplicate. 
Each dilution series was then subjected to one o f three protocols: centrifugation and
143
Molecular diagnosis
re-suspension in 450ul phosphate buffer according to the package insert protocol for 
sputum; centrifugation and re-suspension in lOOul phosphate buffer (in order to increase 
rRNA concentration in lysed sample); and pre-treatment according to the method of 
Pfyffer et al.
Briefly, dIÎ20 was added to the sample to make 500ul, followed by 500ul 3.16% SDS-1% 
NaOH. This was vortexed, incubated for 40 minutes, then neutralised with 500ul 1.43% 
H3PO4, and washed with 500ul dH2 0 . The deposit was then re-suspended in 45Oui 
phosphate buffer and subjected to  M TD according to the manufacturers protocol. The 
effect of 1, 2, 3 and 4-hour amplification incubation times on sensitivity were also tested 
using spiked CSF. Positive and negative cell controls, and two additional phosphate 
buffer negative controls, were included with each run according to the manufacturers 
recommendations. Results were interpreted according to the manufacturers 
specifications: >500,000 RLU positive, < 30,000 RLU negative and 30,000- 499,999 
deemed equivocal and re-tested.
5.2.3 Statistical analysis
The paired proportions o f positive tests before and after treatment were compared by 
McNemar’s test. Unpaired proportions were compared by the Chi Squared test. The 
analysis was performed using Stata 6.0.
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5.3 Results
5.3.1 Adaptation of the MTD to CSF
The limit o f detection for untreated spiked CSF was 3 x 1 0 ^  cells/ml. Re-suspension of 
CSF in a lower volume of lysis buffer decreased the sensitivity to 3 x lO"^  cells/ml, and 
pre-treatment according to the method o f Pfyffer et al improved detection to 30 cells/ml. 
Experimentation with the enzyme incubation period suggested 3-hours gave the best 
sensitivity. Consequently, the protocol for testing all the clinical specimens was adapted 
to include pre-treatment, and 3-hour enzyme incubation.
5.3.2 Specimens, clinical data and controls
A ZN stain, a culture for M.tb, and the MTD were performed on 341 CSF samples from 
152 adults admitted to the ward. 262 specimens came from 73 adults treated for TBM, 
and serial samples taken before and after ATC were available from 59 patients.
CSF specimens from 14 adults who started ATC before the start o f the study were also 
included. A bacteriological diagnosis was confirmed in 57/73 (78%), 12/73 (15%) had 
probable TBM, and 4/73 (7%) had possible TBM. The admission clinical and laboratory 
findings are shown in Table 5.2.
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Table 5.2 Admission data from  59 adults with TBM included before the s ta rt of 
ATC
Variable Num ber (% )/median (range)
Male sex 30 (50.8%)
Age (years) 33 (15-69)
HIV infection 5 (8.5%)
Disease severity: Grade I 17 (28.8%)
Grade II 29 (49.2%)
Grade III 13 (22.0%)
Duration o f symptoms before ATC (days) 15 (5-35)
Volume o f CSF (mis) 4.0(1-12)
CSF opening pressure (cm H2O) 23 (6-40)
CSF total white cells (x lOVml) 461 (1-1750)
% neutrophils 27 (0-90)
% lymphocytes 73 (10-100)
CSF Protein (mg/dl) 169 (66-4700)
CSF Lactate (mmol/1) 5.8 (1.1-16.4)
CSF chloride 104 (84-129)
CSF:blood glucose 0.25 (0.05-0.67)
9-month survival 45 (76.3%)
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The diagnosis o f TBM was excluded in 79 adults (Table 5.3), and 79 admission CSF 
specimens from these patients served as negative controls.
Table 5.3 Diagnoses of control group
Diagnosis CSF samples
Bacterial meningitis:
i) Confirmed ^ 13
ii) Probable ^ 7
Pyogenic brain abscess 1
Viral meningo-encephalitis 22
Mumps meningitis 1
Eosinophilic meningitis 12
Cryptococcal meningitis 20
Subarachnoid hemorrhage 2
TOTAL 79
either CSF gram stain or culture positive
 ^short history, cloudy CSF, mostly neutrophils, recovered without ATC
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5.3.3 Diagnostic performance before ATC
The sensitivity o f CSF ZN stain (52%) and MTD (38%) were not significantly different 
before the start o f ATC (p=0.150). The sensitivity, specificity, and positive and negative 
predictive values for each of the tests are shown in Table 5.4. ZN stain was 52% 
sensitive (95% Cl 40 to 64%) and 100% specific against a clinical diagnostic gold 
standard, and 57% sensitive (95% Cl 41 to 72%), 90% specific against a culture gold 
standard. AFB were seen but not cultured from 8 specimens, all were from adults with 
evidence of extra-neural tuberculosis who responded appropriately to ATC. The MTD 
was 38% sensitive (95% Cl 26 to 51%), 99% specific against a clinical gold standard, 
and 50% sensitive (95% Cl 34 to 66%), 95% specific against culture gold standard.
Table 5.5 presents the numbers of discrepant and concordant positive results with ZN 
stain and MTD, and their combined sensitivity, before and after starting treatment. Before 
treatment, the MTD w as negative in  20/34 (59%) ZN  positive specimens, bu t the  ZN  
stain was negative in 11/25 (44%) specimens positive by MTD. The combined pre­
treatment sensitivity o f ZN stain and MTD (ZN+ and/or MTD+) was 45/66 (68%), but 
only 14/45 (31%) specimens were positive by both tests.
There was one false positive MTD from the CSF of an adult believed to have viral 
meningo-encephalitis. They made a complete recovery in hospital without ATC, and the 
patient was contacted and found to be well 18-months after admission, excluding a 
diagnosis o f TBM.
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Table 5.4 Sensitivity, specificity, and positive and negative predictive values of CSF
ZN stain, MTD, and culture before the s ta rt of ATC
CLINICAL DIAGNOSTIC GOLD STANDARD
Positive Negative
Sensitivity Specificity predictive predictive
(%) (%) value (%) value (%)
[95% Cl] [95% Cl] [95% Cl] [95% Cl]
Z N 34/66 (52%) 79/79 (100%) 34/34 (100%) 79/111 (71%)
[39-64%] [95-100%] [90-100%] [62-79%]
MTD 25/66 (38%) 78/79 (99%) 25/26 (96%) 79/120 (66%)
[26-51%] [95-100%] [80-100%] [57-74%]
C ulture 38/66 (58%) 79/79 (100%) 38/38 (100%) 79/107 (74%)
[45-70%] [95-100%] [91-100%] [64-81%]
CULTURE GOLD STANDARD^
Z N 24/42 (57%) 71/79 (90%) 24/34 (71%) 79/97 (81%)
[41-72%] [81-95%] [52-85%] [72-88%]
MTD 21/42 (50%) 75/79 (95%) 21/25 (84%) 79/97 (81%)
[34-66%] [88-98%] [64-95%] [72-88%]
Culture 38/42 (90%) 79/79 (100%) 38/38 (100%) 79/83 (95%)
[77-97%] [95-100%] [91-100%] [88-99%]
^M.tb isolated from  the CSF at any time before or after starting  ATC
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Table 5.5 Num ber of positive tests before and after starting ATC with concordant 
and discordant results of ZN stain and MTD over the first 40 days of treatm ent
Pre-ATC 2-5 days 6-15 days 16-40
days
41-80
days
260-
280
days
Patients/specimens
ZN positive 34/66(52%) 8/34(24%) 2/43(5%) 0/48 0/35 0/36
MTD positive 25/66(38%) 14/34(41%) 12/43(28%) 2/48(4%) 0/35 0/36
95% C l of
difference -4 to 31% -40 to 4% -41 to -5%
p value 0.150 0.146 0.013
C ulture positive 38/66(58%) 12/34(35%) 6/43(14%) 0/48 1/35(3%) 0/36
MTD + / Z N - 11/66(17%) 9/34(26%) 12/43(28%) 2/48(4%)
M T D - / ZN + 20/66(30%) 3/34(9%) 2/43(5%) 0/48
M T D + / ZN + 14/66(21%) 5/34(15%) 0/43 0/48
MTD+ and/or 45/66(68%) 17/34(50%) 14/43(33%) 2/48(4%)
ZN +
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5.3.4 Diagnostic performance after starting ATC
The sensitivity of ZN stains fell faster than MTD with treatment (Table 5.5 and Figure
5.1). The sensitivity o f MTD did not fall between days 2-5 o f therapy, but was nearly 6 
times more sensitive than ZN stain after 5-15 days o f treatment (28% vs 5%, 95% Cl of 
difference 5-41%, p=0.013). Agreement between ZN stains and MTD positive results 
worsened after the start o f treatment: both tests were positive in 5/17 (29%) specimens 
positive by either test taken 2-5 days after treatment, and in 0/16 positive after 5 days. 
Table 5.6 shows the number o f new positive tests on  repeated CSF samples from  5 9 
patients before and after starting ATC.
Table 5.6 New positive tests before and after starting ATC on 59 adults with serial 
samples
Pre- 2-5 5-15 15-40 40-80 260-280 TOTALS (%)
ATC days days days days days [95% Cl]
ZN+ 34 3 1 0 0 0 38/59 (64%) 
[51-76%]
MTD+ 24 10 1 0 0 0 35/59 (59%) 
[46-72%]
ZN+
and/or 45 4 0 0 0 0 49/59 (83%)
MTD+ [71-92%]
Culture 38 3 1 0 0 0 42/59 (71%) 
[58-82%]
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A repeat CSF day 2-5 improved the overall sensitivity o f ZN stain by 3/33 (10%), and o f 
MTD by 10/24 (42%). Repeated sampling resulted in a cumulative sensitivity o f 38/59 
(64%) for ZN stain, 35/59 (59%) for MTD, and 42/59 (71%) for culture g a in st a clinical 
gold standard. The cumulative sensitivity o f ZN stain and MTD combined was 49/59 
(83%).
Figure 5.1 The sensitivity o f ZN stain, MTD, culture, and combined ZN/MTD on 
262 specimens taken before and after treatment from 73 patients with a clinical 
diagnosis o f TBM
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5 3 .5  Impact o f drug resistance on diagnostic performance
Table 5.7 presents the effect o f  resistance upon the performance o f  ZN, MTD and culture 
before and after the start o f treatment. 10 isolates were resistant to streptomycin alone, 
one was resistant to isoniazid alone, 6 were resistant to both isoniazid and streptomycin, 
and one patient had multi-drug resistant M.tb (resistant to rifampicin, isoniazid, and 
streptomycin) and died before further samples could be taken. The 9-month survival for 
those with sensitive M.tb (22/28, 79%) was not significantly different from those with a 
drug resistant isolate (14/18, 78%).
Figure 5.2 Tbe effect o f drug resistance on tbe percentage o f culture positive CSF 
before and after treatment
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Table 5.7 The effect of drug resistance upon the perform ance of ZN, MTD, and 
culture before and after starting ATC
SENSITIVE M.tb^
Pre-ATC 2-5 days 5-15 days 15-40 days 40-80
days
260-
280
days
ZN
positive
14/27(51.8%) 2/11(18.2%) 1/14(7.1%) 0/16 0/10 0/15
MTD
positive
12/27(44.4%) 6/11(54.5%) 4/14(28.2%) 2/16(12.5%) 0/10 0/15
C ulture
positive
24/27(88.8%) 2/11(18.2%) 3/14(21.4%) 0/16 
DRUG RESISTANT M .tb’’
0/10 0/15
ZN
positive
10/15(66.6%) 4/10(40%) 0/12 0/11 0/10 0/10
MTD
positive
8/15(53.3%) 6/10(60%) 5/12(41.6%) 0/11 0/10 0/10
C ulture
positive
14/15(93.3%) 10/10(100%) 3/12(25%) 0/11 1/10(10%) 0/10
^Sensitive to all first-line ATC 
 ^Resistant to 1 or more first-line ATC
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Before the start o f ATC there were no significant differences between the sensitivity of 
ZN stain, MTD, and culture in patients with sensitive or resistant M.tb (Table 5.7). After 
2-5 days o f treatment 2/11(18%) with sensitive M tb  were positive by ZN, compared with 
4/10(40%) if  resistant (p=0.269). Drug resistant M.tb was cultured from all (10/10) 
specimens after 2-5 days o f ATC, compared with 18% (2/11) if  fully sensitive (p<0.001) 
(Figure 5.2). The MTD was positive in 5/12 (42%) specimens 5-15 days after treatment 
i f  M.tb was drug resistant, and 4/14 (28%) if  the isolate was sensitive (p=0.484).
5.4 Discussion
The detection o f M.tb nucleic acid in the CSF has been possible for more than 10 years, 
but its role in the rapid diagnosis of TBM remains poorly defined. The aim o f this study 
was to compare conventional bacteriology with the detection o f M.tb rRNA in the CSF 
using the Gen-Probe MTD. The strength o f the study is the large number o f serial CSF 
samples taken before and after treatment from patients with a confirmed bacteriological 
diagnosis of TBM. The MTD was chosen because it is a universally available commercial 
test, and is recognised by the FDA to perform with sufficient sensitivity and specificity to 
be granted a license for use on smear negative sputum. There are no commercial tests 
currently with an FDA license for use on extra-pulmonary samples.
These data shows that before the start o f treatment the sensitivity o f ZN stain is greater 
than MTD (52% vs 38%) against a clinical diagnostic gold standard, although the 
difference is not significant (p=0.150) (Table 5.4).
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It has long been recognised that the sensitivity o f CSF ZN stain can exceed 50%, 
although modem laboratories and many textbooks rarely report this level o f performance. 
C hapter 4 shows that the sensitivity of conventional bacteriology is dependent upon the 
volume o f CSF examined and the duration of microscopy. The factors that govern the 
performance of MTD are uncertain. The combined pre-treatment sensitivity o f ZN stain 
and MTD was 45/66 (68%), with only 14/45 (31%) specimens positive by both tests 
(Table 5.5). Analysis of the discordant results between the tests reveal MTD was 
negative in 20/34 (59%) o f ZN positive specimens, and the Z N  s tain w as n egative in  
11/25 (44%) o f MTD positive specimens (Table 5.5). It is difficult to understand why 
rRNA cannot be detected in CSF in which acid-fast bacilli have been seen. Pfyffer et al 
found that high concentrations of organisms were required in spiked CSF 
(>5xl0^cells/ml) to  obtain a positive MTD, and suggested interference from  unknown 
compounds in the CSF caused assay inhibition. These experiments have been repeated 
with similar results. Pfyffer also found that increasing the volume of sample used, pre­
treatment with a denaturing agent such as SDS-NaOH, and increasing the amplification 
time from 2 to 3 hours could improve MTD sensitivity on CSF. Experimentation with 
the assay procedures concur with these findings, and suggests that inadequate rRNA 
extraction from small numbers o f organisms in the CSF may be a factor in producing 
false negative MTD tests. The existence and impact o f factors inhibitory to nucleic acid 
amplification in CSF remains unclear, but if  present these factors are likely to be
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substantially reduced b y  the d etergent and washing actions o f the pre-treatment 
protocol, and may partly explain the improvement in sensitivity produced by these steps. 
Freezing the CSF for later testing may also reduce sensitivity, although the high numbers 
o f ZN stain negative, MTD positive specimens [11/25 (44%)] before treatment suggests 
an alternative explanation. There is a tendency fox M.tb bacilli to stick together in clinical 
samples. This characteristic suggests bacilli are not evenly distributed through the sample 
and increases the chance of the divided deposit (for staining, MTD, and culture) 
containing different concentrations o f bacilli. These sampling effects become particularly 
important when the CSF contains few bacilli and both tests are performing close to their 
limits o f detection. This may explain the greater combined sensitivity o f ZN stain and 
MTD: the larger the volume of sample tested by either test, the larger the chance of 
detecting
Following the start o f anti-tuberculosis treatment the sensitivity o f ZN stain and culture 
fell rapidly (Figure 5.1). The sustained sensitivity of MTD results presumably from dead, 
non-cultivable bacilli. The value of repeated lumbar punctures after the start o f treatment 
is still debated, but these data suggest they increase diagnostic sensitivity. The cumulative 
sensitivities o f ZN stain, MTD, and the two tests combined are 64%, 59%, and 83% 
respectively, if  they are repeated at least twice during the first 15 days o f therapy (Table 
5.6). The value of a repeat MTD during the first 5 days o f treatment was particularly 
evident, as a repeat test detected 10/35 (29%) more cases than a single sample before
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ATC. This should discourage dangerous delays in starting ATC, and may be useful to 
specialist centres admitting patients already started on ATC for unconfirmed TBM.
The impact o f drug resistance upon bacterial clearance from the CSF is unknown, and 
this study could only assess the effect of streptomycin and isoniazid resistance. Evidence 
from pulmonary tuberculosis suggests these two drugs, and in particular isoniazid, are 
responsible for the majority of bactericidal activity in the first few days o f treatment 
(Mitchison DA, 2000). This evidence, together with known excellent CSF penetration of 
isoniazid, suggests resistance may have a detrimental effect upon outcome in TBM, but 
this remains unsubstantiated. This study suggests that resistance to isoniazid and/or 
streptomycin does affect CSF bacterial clearance: M.tb was cultured from all specimens 
after 2-5 days o f ATC if  the organism was resistant, but from only 18% if  the organism 
was sensitive (p<0.001) (Figure 5.2). The only organism to be cultured after 40 days of 
treatment was resistant to both drugs. The performance of ZN stain and MTD were not 
significantly different in patients with sensitive or resistant M.tb. Although these data 
suggest isoniazid and/or streptomycin resistance reduces early bactericidal activity in the 
CSF, a larger study is required to define whether a positive ZN and/or MTD after the start 
o f ATC can predict resistance, and whether resistance to these agents worsens outcome. 
More useful still would be to predict multi-drug resistance by these methods, which 
carries a far worse prognosis and necessitates early intervention with second-line anti­
tuberculosis drugs.
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The time to get a result, and cost should also be considered when comparing CSF ZN 
stain with the MTD. These are especially important to busy laboratories in poorly 
resourced settings -  where the majority o f TBM occurs. A CSF ZN stain takes 
approximately one hour from lumbar puncture to result (15 minutes centrifugation, 15 
minutes preparing the slide, and 3 0 minutes microscopy), although more than 50% of 
positive slides are confirmed within the first 10 minutes o f microscopy (Chapter 4), and 
can be performed without addition to basic laboratory equipment. It takes a minimum of 
6 hours to perform the CSF-modified MTD, regardless of result, and the laboratory must 
have a luminometer ($12,500 -  Gen Probe, 2003), a sonicator ($495 -  Gen-Probe, 2003), 
and m ust purchase t est kits that cost o ver $20 per test ( 5 0 1ests/ k it; $1,100/kit: Gen- 
Probe, 2003).
In conclusion, this study shows that before the start o f ATC a careful search for AFB in 
the CSF is as good or better than the MTD detection of M.tb rRNA for the diagnosis of 
TBM. The ZN stain is also faster and much less expensive. However, adding MTD to a 
careful microscopic examination of the CSF improves performance further, and detects 
nearly 70% of cases before the start o f treatment. Once ATC has been started the MTD 
retains sensitivity longer than ZN stain or culture, and may be more useful in settings 
where pre-admission treatment with ATC is common. Resistance to one or more first-line 
anti-tuberculosis drugs slows bacterial clearance from the CSF, and significantly 
increases the likelihood of isolating M.tb from the CSF after 2-5 days o f treatment. 
Repeated sampling after the start o f treatment improves the sensitivity o f all methods.
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particularly MTD. These results suggest that MTD alone does not offer advantage over 
careful bacteriology before the start o f treatment. However, performing a combination of 
these tests on repeated samples can improve sensitivity to greater than 80%, whilst 
retaining high specificity. Nevertheless, the fatal consequences o f delayed treatment 
demand a more sensitive single diagnostic test.
Until such time as cheaper, more sensitive assays are developed, the rapid diagnosis of 
TBM in most laboratories should depend upon the meticulous and repeated search for 
acid-fast bacilli from a large volume (>6mls) of CSF. The clinical algorithms described 
in C hapter 3 may identify patients most likely to have TBM, on whom the most time 
should be spent.
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CHAPTER 6
THE PATHOPHYSIOLOGY OF
TUBERCULOUS MENINGITIS
6.1 Introduction
The following two chapters are concerned with the pathogenesis o f TBM and the factors 
that affect disease progression and outcome. TBM is the most dangerous form of 
infection w ithM .^h, bu t the pathogenesis remains unclear. An excessive intra-cerebral 
inflammatory response is considered responsible for the neurological damage, and 
adjunctive immunosuppression with corticosteroids has long been suggested, although 
the clinical benefit is uncertain (Prasad K et a l , 2000).
Studies in rabbits have suggested a central role for tumour necrosis factor-a (TNF-a) in 
the pathogenesis and progression of TBM (Tsenova L et a l ,  1999), and thalidomide, an 
inhibitor TNF-a production, reduced mortality in these models (Tsenova L et a l ,  1998). 
The mechanisms that underlie human disease are less well studied. There are differences 
between the cytokines expressed in the CSF o f patients with viral, bacterial, fungal and 
tuberculous meningitides (Akalin H et a l ,  1994; Glimaker M et a l ,  1993). High 
concentrations o f CSF TNF-a have been observed repeatedly in untreated bacterial 
meningitis (Akalin H et a l ,  1994; Glimaker M et a l ,  1993; Rydberg J et a l ,  1995).
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The CSF concentrations reported in TBM are lower, but probably persist for longer 
(Donald PR et a l ,  1995). The role of soluble TNF-a receptors is uncertain. Higher TNF- 
a: receptors ratios in TBM compared with bacterial meningitis may reflect lower 
concentrations of biologically active TNF-a, which may prolong the inflammatory 
process (Rydberg J et a l,  1995). TBM is also characterised by increased CSF expression 
of other pro inflammatory cytokines interferon-y (IFN-y), interleukin-Ip, interleukin-8 
(IL-8), and the anti inflammatory cytokine interleukin-10 (XL-10) (Mastroianni CM et a l,  
1997).
There is evidence o f significant BBB breakdown in patients with TBM (Brown HC et a l , 
2000). The mechanisms are probably multi-factorial, although the matrix 
metalloproteinases (MMPs) have recently been implicated (Matsuura E et a l ,  2000). 
These molecules, secreted by monocytes and macrophages, are zinc-containing proteases 
that degrade extra-cellular matrix (Goetzl EJ et a l ,  1996). They may cause cerebral 
injury by disrupting the BBB, facilitating leukocyte migration, and cleaving myelin 
proteins. Elevated CSFm atrixm etalloproteinase-9 (MMP-9) concentrations have been 
associated with focal neurological deficit and fatal outcome in Vietnamese adults with 
TBM (Price NM et a l,  2001). The activity o f the specific tissue inhibitors o f MMPs 
(TIMPs) may be equally important, in particular the balance between MMP-9 and TIMP- 
1 (its specific inhibitor).
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There are few studies describing the expression o f these molecules over the duration of 
treatment for TBM, and their relationship with BBB dysfunction, clinical progression, 
and outcome after 9 months of anti-tuberculosis chemotherapy (ATC).
The purpose o f this study was to describe the effect o f treatment upon the constituents of 
the CSF - in particular the CSF expression of a range o f pro and anti-inflammatory 
molecules, MMP-9 and TIMP-1, and the integrity o f the BBB - and to test the hypothesis 
that the cellular and molecular intra-cerebral immune response predicts death or survival 
from TBM. The relationship between CSF leucocytes and M.tb was explored using 
electron microscopy.
6.2 Methods
The adults in this study were all admitted to the CRU as described in C hapter 2.
6.2.1 L aboratory  investigations
Commercial capture ELISA kits were used to measure CSF and blood concentrations of 
IFN-y, TNF-a, IL-8, and IL-10 (OPTEIA ELISA, Becton Dickinson, San Jose, 
California, USA), and the CSF concentrations o f MMP-9, TIMP-1, and the soluble TNF- 
a  receptors 1 and 2 (R and D systems, Abingdon, UK). Details o f the methods are 
provided in C hapter 2. The lower limits of detection were 10 pg/ml o f IFN-y, TNF-a, 
TNF-a R l, TNF-a R2, and IL-8; 15 pg/ml of IL-10; 200 pg/ml o f TIMP-1, and 350 
pg/ml o f MMP-9. Albumin and IgG concentrations were measured in blood and CSF and 
their respective indices calculated as described in C hapter 2.
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6.2.2 Electron microscopy of the CSF
A centrifuged CSF deposit containing numerous AFB by ZN stain was selected, fixed in 
4% glutaraldehyde in O.IM phosphate buffer, and transported to Oxford University, UK, 
for electron microscopy. On arrival the samples were post-fixed in 2% osmium tetroxide 
in p hosphate b uffer, d ehydrated i n e thanol, t hen t reated w ith p ropylene o xide prior to 
embedding in Spurr’s epoxy resin. 1pm sections stained with Azure A were examined by 
light microscopy to identify areas o f interest. Thin sections of suitable areas were cut and 
stain with uranyl acetate and lead citrate prior to examination in a Jeol 1200EX electron 
microscope.
6.2.2 Statistical methods
Normally distributed variables were compared by the Student’s t-test; all other 
continuous variables were compared by the Mann-Whitney U test. Analysis o f correlation 
between Variables w as p erformed b y  Spearman’s test. Variables associated with death 
(p<0.1) by univariate analysis were incorporated into multivariate logistic regression.
I
Forward stepwise variable selection procedure was used with p-to-enter <0.05 and p-to- 
remove >0.1 to identify independent predictors of death. The analysis was performed 
using ‘Statistical Product and Service Solutions’ (SPSS) software version 10.0 
(Microsoft, USA).
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6.3 Results
21 adults consented to enter the study between October 2000 and April 2001. At the start 
o f treatment 8 were grade I, 6 grade II, and 7 grade III. None o f the adults had antibodies 
to HIV. A diagnosis o f TBM was confirmed (AFB seen in the CSF, or M.tb cultured from 
the CSF) in 15/21 (71%). One isolate was resistant to isoniazid, the rest were sensitive to 
all first-line agents. The CSF was sterile in 12/15 confirmed cases by day 3 o f ATC, 
and in all by day 7. A diagnosis of TBM was highly probable in the unconfirmed cases: 
brain computerised tomography showed hydrocephalus and basal meningeal 
enhancement in 4/6, 3 of these had chest X-ray appearances consistent with active 
pulmonary tuberculosis. The remaining 2 adults were diagnosed with TBM on the basis 
o f typical clinical and laboratory findings, and response to treatment. The median length 
o f symptoms before admission was 18 days (range 6-45). 5/21 (24%) died before 
completing treatment: 2 after 2 days, the others after 13, 88 and 138 days o f treatment. 
2/16 (13%) survivors had severe neurological sequelae after 9 months o f ATC. The rest 
made a complete recovery by the end of treatment. There was no relationship between 
length o f symptoms before admission and disease severity or outcome.
6.3.1 Changes in CSF cellular and biochemical parameters over time
The effect o f ATC upon CSF white cell counts (WCC), protein, glucose, and lactate 
concentration is shown in Figure 6.1. The mean WCC before treatment was 445 x 10  ^
cells/ml (Standard Deviation [SD] 308); 533 x 10  ^cells/ml (SD 549) at day 7;
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Figure 6.1 Mean values (with 95% confidence intervals) of CSF total WCC, protein, 
and CSF:blood glucose over treatment. Continuous horizontal line represents the 
upper limit o f  the normal range.
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173 X 10  ^cells/ml (SD 213) by day 30; and 48 x 10  ^cells/ml (SD 62) by day 60. CSF 
WCC was elevated (>5 x 10  ^cells/ml) in 8/13 samples taken after 270 days o f ATC. CSF 
protein was elevated (>45 mg/dl) in many patients throughout treatment (Figure 6.1b). 
The mean concentration at the start o f treatment was 266 mg/dl (SD 350) and was 
elevated in 5/13 (38%) patients at day 270.
The ratio of CSFiblood glucose concentration was low (<0.5) in 23/24 measurements 
taken before the start o f ATC (Figure 6.1c). After 270 days treatment the ratio was 
normal in 15/16 (94%) patients. The mean CSF lactate concentration was 6.9 mmol/1 (SD
3.2) before treatment, 4.7 mmoFl (SD 1.6) on day 2, 4.8 mmol/1 (SD 1.8) on day 7, and
2.3 mmoFl (SD 0.59) on day 30. CSF opening pressure was greater than 20 cm H2O in 
12/24 (50%) measurements taken from 21 patients before the start o f ATC, 6/16 (38%) 
patients by day 7, 2/14 (14%) by day 30, 1/16 (6%) by day 60, and 0/13 by the end of 
treatment. Two patients had CSF pressures greater than 40 cm H2O at the start o f 
treatment both of whom died.
6.3.2 CSF and blood cytokines
The CSF before treatment contained elevated concentrations o f IL-8 (mean 8297 pg/ml, 
SD 9640), and IFN-y (mean 708 pg/ml, SD 887) compared with values a t the end o f  
treatment (Figure 6.2). CSF concentrations of TNF-a were lower than those o f IL-8 and 
IFN-y (mean 66 pg/ml, SD 108) and undetectable in 15/17 (88%) adults at day 7 o f 
treatment.
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Figure 6.2 Mean concentrations (with 95% confidence intervals) of CSF and blood 
pro-inflammatory cytokines over treatment. The horizontal line represents the limit o f  
detection o f  the assay. The concentration o f  IFN-y and TNF-a in sera was below the limit 
o f detection fo r  the assays, and is not included in the figure.
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Figure 6.3 The mean concentrations (with 95% confidence intervals) of IL-10 and 
TNF-alpha receptors 1 and 2 over treatment. The horizontal line represents the limit 
o f detection o f  the assay.
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In contrast, concentrations o f TNF-a receptors R l and R2 were easily detectable after 60 
days of treatment, falling to respective mean concentrations o f 20 ng/ml and 25 ng/ml at 
the end o f treatment (Figure 6.3c and 6.3d). Before treatment the mean concentration 
ratios o f R l: TNF-a, and R2: TNF-a were 2.8 (0.24-11.5) and 7.7 (1.2-19.2) respectively 
(molar ratios 8.2 [SD 10.9] and 22.9 [SD 18.6]). These values rose to 9.9 (SD 12.6) and
18.1 (SD 20.1) by day 2, although only 3 patients had detectable concentrations o f TNF- 
a  at this time (molar ratios 29.2 [SD 37.1] and 53.6 [SD 59.5]). CSF concentrations of 
IL-10 fell with treatment to undetectable concentrations at 9 months (mean 2 pg/ml, 
range 0-14) (Figure 6.3 a).
6.3.3 CSF matrix metalloproteinases
Figure 6.4 shows the mean CSF concentration o f MMP-9 and TIMP-1 over treatment. 
Before treatment the mean CSF concentrations o f MMP-9 and TIMP-1 were 146 ng/ml 
(SD 186) and 463 ng/ml (SD 192) respectively, which fell with treatment to 70 ng/ml 
(SD 139) and 269 ng/ml (SD 213) by day 60.
6.3.4 Albumin and IgG indices
The albumin and IgG indices provide a useful measure o f the extent o f BBB 
permeability, and the serial values are presented in Figure 6.4. There is evidence of 
breakdown in the BBB throughout the first 60 days of treatment. Only at 9 months are the 
means o f both indices within the normal range.
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Figure 6 .4 M can CSF concentrations ( with 9 5% confidence intervals) of MMP-9 
and TIMP-1 {the horizontal line represents the limit of detection of the assay), and 
Log^ ® of the Albumin and IgG indices over treatment {normal ranges indicated by 
horizontal lines).
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6.3.5 Prognosis
Variables from those who died before the end of treatment were compared with those 
who survived (Table 6.1). Before treatment only CSF lactate concentration was 
significantly higher in  those who died (p=0.029, 9 5% C l fo r the  difference 0.4 to 6.8 
mmol/1). When all values from day 0-7 were included the following were significantly 
associated with death: lower CSF WCC (95% Cl -68 to -584, p=0.014), higher CSF % 
lymphocytes (95% Cl 4 to 33, p=0.013), higher total CSF lymphocyte counts (95% Cl 3 
to 369, p=0.047), higher CSF lactate (95% Cl 1.4 to 5.3, p=0.001), and lower CSF 
glucose:blood ratio (95% Cl -0.04 to -0.19, p=0.003). Lower total CSF neutrophil counts 
were also associated with death (p=0.025).
Multivariate analysis was performed to predict variables independently associated with 
death. CSF lactate concentration was associated with death (Odds ratio 1.6, 95% Cl 0.97- 
2.64, p=0.065) before treatment, and CSF WCC (Odds ratio 0.98, 95% Cl 0.97-0.99, 
p=0.027) was associated with death over the first 7 days o f treatment.
The same analysis was performed for those presenting with and without coma, and with 
or without focal neurological signs. None of the variables were significantly associated 
with these parameters (data not presented).
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Table 6.1 CSF variables associated with death (p<0.10). Mean, standard deviation (in 
parentheses), and 95%  C l o f  difference shown fo r normally distributed variables. The 
median, and range (in parentheses) is given for all others.
Variable Survived Died 95% Cl of P
N=16 N=5 difference value
CSF before treatm ent
Total WCC (xloVml) 509(289) 213 (284) -7 to + 599 0.055
% lymphocytes 66 (21) 87 (13) -42 to + 1 0.058
% neutrophils 31 (23) 13 (13) -4 to + 42 0.098
Lactate (mmol/1) 5.9 (2.6) 9.5 (3.3) -6.8 to -0 .4 0.029
CSF:blood glucose 0.30 (0.11) 0.20 (0.11) -0.007 to 0.067
+0.2
TIMP (ng/ml) 433 (187) 674 (23) -532 to +51 0.098
Total neutrophils (xlO^/ml)^ 108 (2-972) 3 (0-126) 0.062
All CSF day 0-7
Total WCC (xloVml) 534 (388) 207 (262) 68 to 584 0.014
% neutrophils 29 (22) 15(15) -0.1 to 29 0.052
% lymphocytes 67 (22) 86 (15) -33 to -4 0.013
Total lymphocytes (xlO^/ml) 336 (276) 150 (180) 3 to 369 0.047
Lactate (mmol/1) 5.0 (2.1) 8.4 (3.1) -5.3 to -1 .4 0.001
CSF: blood glucose 0.36(0.12) 0.24(0.09) 0.04 to 0.19 0.003
Total neutrophils (xlO^/ml)^ 85 (0-1206) 6 (0-297) 0.025
MMP-9 (ng/ml)^ 198 (0-395) 392(0-784) 0.058
 ^Not normally distributed: Mann-Whitney test used.
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6.3.6 Correlation between variables
This analysis focused upon variables associated with death, only using data from the first 
7 days o f treatment. Figure 6.5 presents the relationships between CSF lactate, CSF IL-8, 
and CSF IFN-y. CSF lactate was correlated with CSF IL-8 (r=0.727, p<0.001), CSF TNF- 
a  (r=0.584, p<0.001), CSF IFN-y (r=0.758, p<0.001), and CSF TIMP-1 (r=0.521, 
p=0.002). CSF IL-10 concentration was correlated with CSF WCC (r=0.497, p=0.001), 
and IgGI (r=0.527, p=0.001). CSFiblood glucose ratio was weakly correlated with CSF 
IL-8 (r=0.387, p=0.004), CSF WCC (r=0.284, p=0.031), IgGI (r=0.327, p=0.026) and 
CSF lactate (r=-0.351, p=0.039). MMP-9 levels were correlated with CSF IL-8 (r=0.476, 
p=0.001), IFN-y (r=0.513, p=0.001), with weak association between TIMP-1 (r=0.320, 
p=0.041), CSF protein (r=0.298, p=0.034) and CSF lactate (r=0.362, p=0.042). CSF 
concentrations o f TIMP-1 were correlated with CSF lactate (r=0.502, p=0.009), CSF IL-8 
(r=0.5, p=0.001), and IFN-y (r=0.574, p=0.001). No significant relationship was found 
between MMP-9, TIMP-1 and the AI and IgGI, or between CSF neutrophil count, CSF 
IL-8 concentration, and the length of symptoms before treatment.
6.3.7 Electron micrographs of the CSF
Figure 6.6 presents the electron micrographs taken, and demonstrates extra (6.6 a) and 
intra-cellular bacilli (6.6 b, c, d). Bacilli are seen within the phagasomes o f neutrophils.
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Figure 6.5 The relationship between CSF lactate, IL-8, and IFN-y during the first 7 
days of treatm ent, giving correlation coefficient (r) and p value by Spearm an’s test 
of correlation.
6.5 a The relationship between CSF 
lactate and CSF IL-8.
6.5 b The relationship between CSF 
lactate and IFN-y.
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Figure 6.6 Electron m icrographs of CSF deposit containing AFB from  an adult with 
culture-confirm ed TBM showing bacilli in the phagosomes of neutrophils
6.6 a Extra cellular bacillus (arrow) 
(x 40,000)
6.6b Bacilli within the phagasomes of 
neutrophils (arrows) (x 30,000)
'
6.6c Bacillus within neutrophil (arrow)
(x 30,000)
6.6d Bacillus within neutrophil (arrow)
(x 12,000)
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6.4 Discussion
This study followed 21 HIV negative adult patients throughout their treatment for TBM 
(none of the patients received corticosteroids). The concentrations o f various pro and 
anti-inflammatory indices were recorded on serial CSF samples, the timing o f which 
reflects the clinically important periods o f the disease. The CSF specimen taken at the 
end o f ATC (9 months) serves as an important indicator o f successful treatment, and as a 
control for those samples taken earlier in the infection.
Ninety per cent of deaths from TBM occur in the first month o f treatment (Girgis NI et 
a l,  1998). Deaths after this period are usually caused by complications arising from 
neurological sequelae, such as sepsis originating from the respiratory or urinary tract. 
Prognosis is dependent upon starting ATC before the onset of coma (Kennedy DH et a l, 
1979). These facts suggest the inflammatory response immediately before and after 
starting ATC is critical to the outcome o f the patient. Previous studies have shown CSF 
parameters respond slowly to treatment (Lepper MH et a l,  1963; Schoeman JF et a l,  
2001), and the requirement for 6 to 12 months chemotherapy suggests a prolonged 
inflammatory response.
In this study blood and CSF samples taken before starting ATC reveal a highly 
compartmentalised immune response. Concentrations o f CSF IL-8 were approximately 
40 times that of blood, and neither IFN-y nor TNF-a were detectable in blood despite 
easily detectable concentrations in the CSF (Figure 6.2). IL-8 is an inflammatory 
chemokine that is produced by many cell types and functions as a chemo-attractant for
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neutrophils and a subset of T lymphocytes. When macrophages phagocytose M.tb in 
vitro, they express IL-8 in a TNF-a and IL -ip dependent manner (Zhang M et a l ,  1995). 
IL-8 has been detected in plasma (Juffermans NP et a l,  1999) and bronchoalveolar 
lavage fluid (Kurashima K et a l ,  1997) from patients with pulmonary tuberculosis and, 
as observed in this study, remained detectable for many months. The mechanisms driving 
prolonged expression o f IL-8 in a disease not characterised by a strong neutrophilic 
response is unknown.
IFN-y and TNF-a are recognised to be key cytokines in  the control o f M .76 infection 
(Flynn JL et a l ,  2001). T cells and natural killer (NK) cells produce IFN-y in response to 
M.tb infection, but absolute levels may be an unreliable correlate o f protection (Zhang M 
et a l, 1995). This study found high concentrations of CSF IFN-y before treatment but 
there was no association with outcome. Animal studies suggest TNF-a is central to TBM 
pathogenesis as TNF-a inhibition improves outcome (Tsenova L et a l ,  1998). This 
study, as in previous reports, found low pre-treatment concentrations o f CSF TNF-a, and 
there was no association between CSF TNF-a concentration and death. However, the 
biological activity o f TNF-a may depend upon the relative concentrations of its 
soluble receptors, which may antagonise the biological effects o f TNF-a at high 
concentrations, and promote them at low concentrations (Aderka et al, 1992). In this 
study the mean pre-treatment concentration ratios of soluble TNF-a receptors R l:TN F-a, 
and R2:TNF-a, were 2.8 and 7.7 respectively, compared to 27.2 and 28 reported by 
Rydberg et al (Rydberg J et a l ,  1995). This suggests larger biologically active fractions
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of TNF-a in our group of patients, although it is unclear whether the CSF in Rydberg’s 
study was taken before or after treatment. This study suggests treatment reduces the CSF 
concentrations o f TNF-a rapidly, whilst slowly reducing the receptor concentrations. By 
day 2 o f treatment the ratios o f receptors to TNF-a increased to 9.9 and 18.1. This may 
have the paradoxical effect of prolonging the biological activity o f TNF-a despite falling 
CSF concentrations. Further investigation is required to address this hypothesis.
In bacterial meningitis it is hypothesised that bacterial lysis, induced by treatment with 
antibiotics, may contribute to the inflammation in the subarachnoid space and lead to a 
worse outcome (Tauber MG et a l, 1985). The same may be true for TBM, and has been a 
rationale behind adjuvant corticosteroids for many years. This study provides little 
support for this hypothesis. Only mean CSF WCC rose in the first 7 days o f treatment 
(Figure 6.1a), and in all patients, regardless of outcome, ATC produced a rapid reduction 
in the CSF concentrations of IL-8, TNF-a, and IFN-y (Figure 6.2). This response is in 
contrast to the kinetics o f the CSF WCC, CSF protein, CSFiblood glucose ratio, CSF IL- 
10, CSF TNF-a receptors (Figure 6.3) and CSF MMP-9 and TIMP-1 (Figure 6.4), all o f 
which were either detectable, or above the normal range, after 60 days o f chemotherapy. 
Evidence for the longevity of the immune response is supported by the extent and 
duration o f the BBB breakdown (Figure 6.5). These data suggests there may be two 
phases to the inflammatory response in TBM. The first is characterised by high CSF 
concentrations of IL-8 and IFN-y, and lower concentrations o f TNF-a, and is rapidly 
attenuated by ATC. The severity of this phase can be assessed by the concentration of
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CSF lactate. The second phase is characterised by a persistent inflammatory response and 
breakdown in the BBB despite treatment, and may be maintained by the continued 
activity of CSF TNF-a soluble receptors, and the relative concentrations o f MMP-9 and 
TIMP-1.
This study has limited power to associate the concentrations o f any o f these variables 
with death. However, CSF lactate concentration appears to be a good guide to prognosis: 
concentrations before and during the first 7 days o f treatment were significantly higher in 
those who died (95%CI 1.4-5.3, p=0.001). Lactate is produced in all tissues in response 
to hypoxia. TBM causes an obliterative vasculitis with ischaemia, and often infarction 
(Dastur DK et a l,  1995), and CSF lactate concentration may reflect the severity o f this 
process. CSF IL-8, IFN-y, TNF-a, MMP-9, and TIMP-1 were all significantly correlated 
with CSF lactate suggesting these molecules might be associated with the pathogenesis. 
The CSF cellular response also appears significant to outcome: death was associated with 
a lower CSF WCC by univariate (95% Cl -68  to -584, p=0.014) and multivariate 
analysis (Odds ratio 0.98, 95% Cl 0.97-0.99, p=0.027). This is a surprising finding: 
previous reports have associated low CSF white cell counts with older age and HIV 
infection (Karstaedt AS et a l, 1998), suggesting an attenuated CSF cellular response as 
part of a systemic immune paresis. The phenotype of the cellular response may also carry 
prognostic significance. Survival was associated with a lower percentage o f lymphocytes, 
and a higher percentage of neutrophils (Table 6.1). The electron micrographs o f the CSF 
show bacilli phagocytosed by neutrophils (Figure 6.6) and although it is impossible to
180
Pathophysiology
infer functional activity from these pictures, together with associations between 
neutrophils in the CSF and survival and the likelihood o f isolating bacilli, these findings 
suggest neutrophils may have a more important role in the early response to M.tb cerebral 
infection than previously thought. Murine studies have suggested neutrophils may have a 
protective role against M.tb infection (Pedrosa J et a l ,  2000), but further study is needed 
to clarify their function.
The correlation between total CSF WCC and CSF IL-10 concentration may also be 
significant. It is tempting to speculate that IL-10 derived from infiltrating white cells 
might mediate immunosuppressive activity in the subarachnoid space. Before these 
hypotheses can be addressed, the functional phenotype o f the CSF white cells needs to be 
characterised. There is evidence gamma delta T-cells may be important in the CSF 
response to M.tb (Dieli F et a l ,  1999), but serial flow cytometric analysis o f CSF is 
required to further define the cellular immune response. Larger studies are needed to 
further characterise the molecules and cells important to pathogenesis and outcome. 
These may suggest alternative therapeutic approaches that might supersede the blind use 
o f corticosteroids.
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CHAPTER 7
OTHER PROGNOSTIC FACTORS IN
TUBERCULOUS MENINGITIS
7.1 Introduction
The mortality from TBM remains high, even in those with uncomplicated disease who 
are treated early. This may be partly explained by host immunity to M.tb and the intra­
cerebral inflammatory response, as discussed in Chapter 6. However, survival may also 
depend upon the variable penetration o f individual drugs to the site o f disease and their 
differing ability to alter the disease pathogenesis. This chapter focuses upon other factors 
that may have a significant impact upon disease progression and outcome, in particular 
HIV infection, drug resistance, and bacterial genotype.
Isoniazid and rifampicin form the core o f successful short course chemotherapy for 
pulmonary tuberculosis. Isoniazid has potent early bactericidal activity and kills about 
95% of pulmonary organisms within 2 days o f treatment. Rifampicin then assumes the 
major bactericidal role, and is believed responsible for the eradication o f persisting 
organisms in the continuation phase of treatment (Mitchison DA, 2000). However, the 
addition o f rifampicin to isoniazid in the treatment of TBM has not appeared to improve 
outcome or reduce the length of treatment required (Humphries MJ et a l ,  1990; 
Ramachandran P et a l ,  1986; Ramachandran P et a l ,  1989).
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The limited passage o f rifampicin across the blood-brain barrier may partly explain this 
observation (Ellard GA et a l ,  1993). I n c  ontrast, i soniazid p enetrates freely into C SF 
(Ellard GA et a l ,  1993) (see Table 1.4). This property, in combination with potent early 
bactericidal activity, suggests isoniazid is critical for successful TBM treatment. These 
features have prompted some to suggest higher doses (10-20mg/kg) o f isoniazid may be 
indicated for the treatment o f TBM to compensate for the uncertain penetration and 
efficacy o f the other drugs in the regimen (Donald PR et a l ,  1998; Humphries M, 1992). 
Resistance to first-line anti-tuberculosis agents is increasingly common. Isoniazid 
resistance, alone and in combination with other drugs, is the commonest pattern of 
resistance worldwide (Espinal MA et a l ,  2001). The effect of lone isoniazid resistance on 
the treatment o f pulmonary tuberculosis is minimal provided the drug regimen contains 
rifampicin (Mitchison DA et a l,  1986). Nevertheless, there have been recent reports of 
treatment failure in isoniazid resistant pulmonary tuberculosis (Coninx R  et a l ,  1999). 
The impact o f isoniazid resistance on the outcome o f those with TBM is unknown, but 
may be more substantial given the uncertain efficacy of rifampicin in the treatment o f this 
disease.
The ‘Beijing’ genotype o f M.tb, associated with isoniazid and streptomycin resistance, 
may have emerged recently in Vietnam (Anh DD et a l ,  2000). This genotype was 
discovered in 54% of 563 Vietnamese pulmonary isolates collected in 1998/99, and the 
association with young age suggested it was responsible for recent transmission and 
primary infection.
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The relationship between age, admission clinical features, HIV infection, drug resistance, 
genotype, and outcome in those with TBM is uncertain. Furthermore, a comparison o f the 
genotype and drug resistance profiles from CSF and lung M.tb isolates collected over the 
same period has not been performed. The aim o f this study was to examine the hypothesis 
that outcome is dependent upon HIV infection, drug resistance, and bacterial genotype.
7.2 Methods
The adults described in this study were admitted to the HTD Clinical Research Unit as 
described in C hapter 2.
7.2.1 Investigations
Fifty-six cultures containing AFB isolated from the CSF were sent to the Mycobacterial 
Reference Unit, Dulwich, United Kingdom for identification, drug susceptibility testing, 
and genotyping. The isolates were identified as M.tb by the Accu-probe method (Gen- 
probe, San Diego, USA), and drug susceptibility testing was performed by the resistance 
ratio method for isoniazid, rifampicin, pyrazinamide, streptomycin, and ethambutol 
(Collins CH et a l ,  1997). In this method the growth of sensitive M.tb control strains are 
compared with a test isolate on a series o f media containing different drug concentrations. 
The ‘resistance ratio’ of the test isolate is calculated by dividing the minimum inhibitory 
concentration (MIC) of the test by the modal MIC o f the control strains. As doubling 
dilutions o f drug in the media are used the resistance ratio is 1, 2, 4, or 8. Test isolates 
giving a resistance ratio o f 1 or 2 are
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reported as susceptible. Those isolates with a resistance ratio o f 4 or 8 are reported as 
resistant and highly resistant respectively.
Genotyping of all M.tb isolates was carried out in accordance with a standardised 
protocol for spoligotyping (Kamerbeek J et a l,  1997). Briefly, DNA was prepared from 
each isolate and subject to PCR analysis using the primers, Dra: 5’ -C C G  AGA GGG 
GAG GGA AAC-3’, and Drb: 5’ -GGT TTT GGG TCT GAG GAC-3’. Chromosomal 
DNA of M.tb H37Rv and Mycobacterium bovis BCG were used as positive controls and 
were included in each PCR and subsequent hybridisation. Sterile double distilled water 
was the negative control. The PCR products were heat-denatured, and hybridised to the 
spoligotype membrane (Isogen Biosciences, Asmaarssen, Netherlands). Hybridisation 
was detected by chemiluminescence (ECL, Amersham, UK) and the patterns analysed for 
clusters using Microsoft Word software. Patterns were compared against the Beijing and 
‘Vietnam’ spoligotypes described by Anh et al (Anh DD et a l ,  2000).
7.2.2 Statistical Analysis
Thirty clinical and laboratory variables (Table 7.1) from each patient TBM confirmed by 
culture were recorded in a database. Three questions were addressed using these data:
1. Are there any significant differences between the admission clinical features, drug 
resistance profiles, genotypes, and outcomes of HIV positive and negative 
patients?
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2. Is resistance to isoniazid and streptomycin, alone or in combination, associated 
with a worse outcome or any other clinical variable?
3. Are any admission clinical or laboratory features, resistance patterns, or outcome 
associated with M.tb genotype?
Table 7.1
Clinical and laboratory variables included in the analysis
Variables
Sex CSF opening pressure
Age CSF total white cell count
Days of illness before admission CSF neutrophil %
History of coma CSF lymphocyte %
Body temperature CSF/blood glucose ratio
Glasgow coma score on admission CSF lactate
Cranial nerve palsies CSF chloride
Hemiplegia on admission CSF protein
Admission disease stage CSF ZN stain
Disease stage at start of treatment Sensitivity to isoniazid
HIV status Sensitivity to streptomycin
Blood white cell count M.tb spoligotype
Blood neutrophil % Days of illness to ATC
Blood sodium Days of in-hospital ATC
Days of admission to ATC In-hospital survival
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Kruskal-Wallis test was used to compare continuous parameters between two or more 
groups o f patients; the chi square test with Yates’ correction (or Fisher’s exact test) was 
used for comparison of categorical variables. Variables identified in univariate analysis as 
associated with the outcome variable (clinical outcome, HIV infection, resistance ovM.tb 
genotype) (p<0.05) were then incorporated in multivariate logistic regression. Forward 
stepwise variable selection procedure was used to identify independent predictors. The 
analysis was performed using ‘Statistical Product and Service Solutions’ (SPSS) software 
version 10.0 (Microsoft, USA).
7.3 Results
M.tb was identified in the CSF of 56 adult patients. The mean age was 36 years (15-69 
years); 36 (64%) were male. Fifteen adults (27%) presented with Grade I TBM, 19 (34%) 
with Grade II, and 22 (39%) with Grade III TBM. HIV infection was confirmed 
according to WHO criteria in 11 (20%) adults: all were male. One patient refused testing 
but had no risk factors for infection. Twenty-four (43%) died in-hospital: 2 (13%) in 
Grade I, 7 (37%) in Grade II, and 15 (68%) in Grade III. The mean length o f stay in 
hospital for those who survived was 65 days. Table 7.2 summarises the clinical data. 
Univariate analysis revealed 4 variables that were associated with death: history o f pre­
admission coma, low admission Glasgow Coma score, admission disease stage, and 
disease stage at the start o f ATC (Table 7.3). By multivariate logistic regression analysis.
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only admission GCS proved to be independently predictive o f in­
ratio 0.73, 95% Cl 0.61-0.87, p=0.001).
Table 7.2 Sum m ary of clinical details and drug resistance
-hospital death ( odds
Variable All patients Isoniazid
resistance
Streptomycin
resistance
INK + SM 
Resistance
Num ber (%) 56 9 (16%) 10(18%) 6(11% )
Age (years) 33 30 39 37
Median
range
16-64 15-64 18-64 18-64
Male sex 
n(% )
M RC grade 
n(%)
36 (64%) 7 (78%) 7 (70%) 5 (83%)
I 15 (27%) 4 (44%) 1 (10%) 1 (17%)
II 19 (34%) 3 (33%) 4 (40%) 3 (50%)
III 22 (39%) 2 (22%) 5 (50%) 2 (33%)
HIV positive 
n (% )
11 (20%) 5 (56%) 6 (60%) 4 (67%)
M ortality 
In  hospital 
n(% )
24 (43%) 2 (22%) 6 (60%) 2 (33%)
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By univariate analysis five variables were associated with HIV infection: male sex, low 
peripheral blood white cell count, low CSF total white cell count, isoniazid resistance, 
and streptomycin resistance (Table 7.4). There was no significant difference between the 
percentage o f lymphocytes and neutrophils in the CSF of HIV infected and uninfected 
adults. Two variables entered the logistic model as independently predictive o f HIV 
infection: a lower CSF total white cell count was weakly associated (odds ratio 0.99, 95% 
Cl 0.98-0.999, p=0.025), whereas streptomycin resistance was strongly associated (odds 
ratio 43.4, 95% Cl 3.67-513, p=0.003).
All isolates were sensitive to rifampicin, pyrazinamide, and ethambutol. Only isoniazid 
and streptomycin resistance were detected. Nine patients were found to have M.tb highly 
resistant to isoniazid (resistance ratio of 8); 6 o f these isolates were also highly resistant 
to streptomycin. Four adults had M.tb highly resistant to streptomycin alone. 
Streptomycin and isoniazid resistance, either alone or in combination, was not associated 
with death in  hospital. However, those adults w ith isoniazid resistant M.tb were more 
likely to have HIV infection and streptomycin resistant organisms. Streptomycin 
resistance was independently associated with HIV infection (odds ratio 7.04, 95% 1.15- 
45.5, p=0.035) and isoniazid resistance (odds ratio 13.3, 95% Cl 2.05-86.5, p=0.007). 
Sixteen (28%) M.tb isolates were o f the ‘Beijing’ spoligotype, 6 (11%) were o f the 
recently designated ‘Vietnam’ spoligotype (Anh DD et a l ,  2000), and the rest belonged 
to a heterogeneous group of 24 unique spoligotypes. There was no significant association
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Table 7.3 Admission variables associated with in-hospital mortality by univariate 
analysis
Variable Survivors Died in hospital P value
Number 32 24
History of pre-admission coma
n(%)
10 (31%) 18 (75%) 0.001
Admission GCS 14 9 0.0002
Median
range
Admission MRC grade n (%)
7-15 4-15
I 13 (14%) 2(8%)
II 12 (37%) 7 (29%) 0.003
HI
MRC grade at start of ATC 
n(%)
7 (22%) 15 (63%)
I 7 (22%) 1 (4%)
II 18 (56%) 6 (25%) 0.001
HI 7 (22%) 17(71%)
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Table 7.4 Admission variables associated with HIV infection by univariate analysis
Variable HIV positive HIV negative P value
Number 11 44
Male sex n (%) 11 (100%) 24 (55%) 0.004
Total White cells in blood 7200 9800 0.023
(10^/ml) Median range 2660-13800 5199-16500
Total white blood cell count in 152 356 0.007
CSF (10^/ml) Median range 34-430 100-1435
Resistance to isoniazid n (%) 5 (45%) 4(9%) 0.011
Resistance to streptomycin n (%) 6 (55%) 4(9%) 0.002
Table 7.5 Clinical variables and Af.76 spoligotype
Variable Beijing Vietnam Other P value
spoligotype spoligotype spoligotype
Number 16(28%) 6(11%) 34 (61%)
Age (years) median range 33 16-50 51 26-67 31 15-64 0.060
Male Sex n (%) 12 (75%) 3 (50%) 21 (62%) 0.490
HIV infection n (%) 3 (20%) 1 (17%) 7 (21%) 1.000
Isoniazid resistant 3 (19%) 0 (0%) 6(18%) 0.749
n(%)
Streptomycin resistant 5(31%) 1(17%) 4 (12%) 0.176
n(%)
Combined INH and SM 3(19%) 0(0%) 3(9%) 0.422
resistance n (%)
Mortality in hospital 7 (44%) 3 (50%) 14 (41%) 1.000
n(%)
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between the ‘Beijing’ genotype and HIV infection, younger age, drug resistance, or death 
(Table 7.5).
Nor does isoniazid resistance appear to slow clinical recovery: adults with resistant 
organisms were discharged from hospital after a median o f 47 days (range 11-105 days), 
whereas those with sensitive organisms left hospital after a median of 71 days (range 25- 
153 days).
7.4 Discussion
This study explores the relationship between HIV infection, drug resistance, M.tb 
genotype, and the outcome o f adults with TBM. The insensitivity of CSF culture for the 
diagnosis of TBM has limited study of these areas, as an organism is not isolated in many 
treated cases. Univariate and multivariate analyses o f the variables predicting death in 
this series showed that the level consciousness, assessed by Glasgow coma score, 
predicted death most reliably. This is consistent with previous studies (Hosoglu S et a l,  
2002; Humphries MJ et a l ,  1990; Kalita J et a l,  1999), and emphasises the importance of 
early diagnosis and treatment. However, the relationship between the  duration o f  p re ­
admission symptoms and prognosis may not be linear. Nine adults in this series died 
despite presenting with less than 10 days of symptoms, compared with 15/42 presenting 
with more than 10 days o f symptoms (p=0.06). The rate o f disease progression is 
unpredictable. There may be adults with rapidly progressive TBM  w ho would benefit 
particularly from early treatment and this merits further research.
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Previous reports suggest that HIV infection does not alter the clinical features and in- 
hospital mortality o f TBM (Berenguer J et a l,  1992; Dube MP et a l ,  1992). In this study, 
peripheral blood and CSF white cell counts were significantly lower in HIV infected 
adults. This finding has been reported previously in CSF (Dube MP et a l ,  1992), but not 
blood and may create clinical diagnostic difficulties. TBM with few white cells in the 
CSF can occur in the HIV infected and the elderly (Karstaedt AS et a l ,  1998), and the 
diagnosis should always be suspected in these groups despite atypical laboratory findings. 
All o f the HIV infected patients in this study were male: the majority (8/11) admitted 
intra-venous drug use, a male dominated habit in Ho Chi Minh City. The in-hospital 
mortality of the HIV infected and uninfected adults with TBM were not significantly 
different. A larger cohort, with more prolonged follow-up is required to confirm this 
preliminary finding.
HIV infected adults w ith TBM  were m ore 1 ikely to  b e  infected w ith M .tb  resistant to 
isoniazid (p=0.011) and streptomycin (p=0.002). Streptomycin resistance was 
independently predictive of HIV infection, supporting the local policy for treating HIV 
infected adults with ethambutol rather than streptomycin. Why those with HIV should be 
infected with more resistant organisms is unclear. Common behavioural patterns may 
result in the spread o f resistant organisms amongst the intra-venous drug users in the city, 
although the heterogeneous spoligotype patterns of the M.tb isolates from these patients 
do not support this suggestion. Alternatively, as HIV infection probably shortens the time 
between primary M  76 infection and the onset of TBM, the CSF M.tb isolates from these
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adults may show similar resistance profiles to contemporary pulmonary isolates. The 
similar incidence o f isoniazid resistant [119/499 (24%)] and streptomycin resistant 
[ 156/499 (31 %)] p ulmonary i solates from H o C hi M inh C ity i n 1 998/99 s upports this 
suggestion (Anh DD et a l,  2000).
Resistance to isoniazid or streptomycin, or both, was not associated with increased in- 
hospital mortality. O f adults with M.tb sensitive to all 4 drugs 42% (18/43) died, 
compared to 22% (2/9) with an isolate highly resistant to isoniazid. Death from TBM 
usually occurs within the first month o f treatment (Girgis NI et a l ,  1998). In this study 
only 2/24 (4%) deaths occurred after 28 days o f ATC; both these patients were infected 
with fully sensitive organisms.
Although this study has limited power, and there are no data available on long-term 
outcome measures, these results suggest isolated isoniazid resistance has little prognostic 
impact in adults with TBM. This is a surprising finding given the important role in the 
treatment o f TBM attributed to isoniazid and there are a number o f possible explanations. 
First, the CSF levels o f isoniazid may be sufficiently high to have some bactericidal 
effect despite in vitro resistance. Ellard et al showed that 4 hours after an oral dose of 
about 9mg/kg isoniazid the mean CSF concentration was 3.2mg/l; over 30 times the MIC 
of isoniazid against sensitive M.tb (Ellard GA et a l ,  1993). Assuming dose-linearity, the 
CSF levels achieved using 5mg/kg isoniazid, as in this study, would be expected to be 
approximately 16 times higher than the MIC of sensitive isolates and twice that o f ‘highly 
resistant’ isolates. Second, the action of the other anti-tuberculosis drugs may be
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sufficient to negate the effect o f isoniazid resistance. This would place fi*esh emphasis on 
the role of rifampicin in the treatment of TBM, and suggests it may be o f equal 
importance to isoniazid. Third, isoniazid resistant organisms may be less virulent. There 
are data that suggest isoniazid resistant strains o f M.tb are less virulent than drug- 
susceptible isolates in guinea pigs; although more recent studies suggest there is no 
significant loss o f bacterial fitness resulting from mutations in the KatG  gene responsible 
for conferring resistance to isoniazid in more than half o f M.tb clinical isolates (Pym AS 
et a l ,  2002) (see also Table 1.1).
Definite conclusions cannot be drawn without more detailed modelling o f the 
pharmocokinetic and pharmacodynamic properties of the anti-tuberculosis drugs in TBM. 
However, these results suggest that isoniazid resistance, with or without streptomycin 
resistance, does not affect the outcome of TBM as long as four drugs are used. These 
findings also suggest that doses of isoniazid greater than 5 mg/kg may not improve 
outcome in the treatment of TBM, provided rifampicin is part o f the regimen.
Of the 56 M.tb isolates 28% (16/56) were of the ‘Beijing’ genotype. This was not 
associated significantly with age, admission clinical features, HIV status, drug resistance, 
or outcome. Over the same period A nh e t a l reported that 53% o f pulmonary isolates 
from Ho Chi Minh City were the ‘Beijing’ genotype (Anh DD et a l ,  2000), significantly 
more than recovered from CSF (p<0.001). Resistance profiles from lung and CSF isolates 
were not significantly different. A number o f hypotheses may explain the smaller 
proportion of ‘Beijing’ genotype found in the CSF. Firstly, M.tb responsible for
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meningitis in adults may have been acquired at a time when the ‘Beijing’ genotype was 
less prevalent in Vietnam. However, the ‘Beijing’ genotype in CSF was not associated 
with younger age, or with HIV infection. Secondly, the ‘Beijing’ genotype may be less 
neurovirulent than other strains. Genotype-dependent neurovirulence may occur 
(Arvanitakis Z et a l,  1998), although a predominant genotype causing TBM was not 
found in this study. Thirdly, the Vietnamese immune response to ‘Beijing’ M.tb may 
reduce the likelihood o f dissemination to the central nervous s ystem. F urther s tudy i s 
required to address these hypotheses.
In conclusion, this study confirms the importance of diagnosing and treating TBM before 
the onset of coma. In Vietnam, HIV infection is associated with isoniazid and 
streptomycin resistant organisms, but isoniazid resistant M.tb is not associated with 
increased in-hospital mortality. This finding suggests three possible explanations: the 
CSF levels o f isoniazid may still have significant activity against ‘highly resistant’ 
organisms; rifampicin and the other 2 drugs are more active than previously thought; or 
M.tb resistant to isoniazid causes less severe disease. This study supports the use of 
ethambutol over streptomycin in HIV infected adults in Vietnam, but does not support the 
use o f higher dose isoniazid in combination with rifampicin for the routine management 
o f adults with TBM.
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CHAPTER 8
DISCUSSION
The aim o f this thesis was to address three important questions:
1. What is the best method for distinguishing TBM from other central nervous 
system disorders?
2. How does disease pathophysiology relate to treatment and clinical outcome?
3. What other variables influence outcome?
The extent to which these questions have been answered will now be discussed.
8.1 The diagnosis of tuberculous meningitis
The diagnosis o f TBM has exercised physicians ever since it became a treatable disease 
in 1948; and the significant association between early diagnosis, treatment and survival 
accentuates its importance. There are three m ajor impediments to diagnosis. First, the 
presenting clinical features of the disease are non-specific. Second, low concentrations of 
bacilli in the CSF reduce the sensitivity of conventional bacteriology. Third, alternative 
diagnostic methods have n o t b  een properly assessed. These problems are increased in  
settings with limited resources, where most cases o f TBM are seen. Therefore, the answer 
to the first question posed b y  this thesis may be different depending upon where it is 
asked.
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C hapter 3 examines whether TBM can be distinguished from bacterial meningitis 
without the help o f a microbiology laboratory. The results suggest it can: p respective 
assessment of a diagnostic rule based upon the values o f 5 clinical features demonstrated 
86% sensitivity, and 79% specificity.However, the development and use o f these 
algorithms are greatly affected by tuberculosis and HIV prevalence. Co-infection with 
HIV may alter the presenting features of TBM as reported in C hapter 7, and changes the 
spectrum of disorders presenting with similar clinical syndromes. In particular, the 
algorithms were not developed to distinguish TBM from cryptococcal meningitis, a 
common cause of meningitis in HIV-infected individuals. Alternative algorithms need to 
be developed and tested in areas with high prevalence o f HIV infection.
The value o f conventional bacteriology for the diagnosis of TBM is often debated. Old 
reports suggested AFB could be found in nearly every case if  the microscopist was 
prepared to look hard (Stewart SM, 1953), but this has rarely been the experience of 
contemporary laboratories (Garg RK, 1999). Only Kennedy, in more recent times, was 
able to demonstrate that repeated CSF sampling improved the sensitivity o f ZN stain to 
over 80% (Kennedy DH et a l ,  1979). The factors that determine the sensitivity o f 
bacteriology have not been previously examined systematically: C hapter 4 confirms that 
it is possible to make a bacteriological diagnosis of TBM in more than 80% of patients, 
and demonstrates the volume of CSF examined is independently predictive o f either 
seeing or culturing M.tb from the CSF. These are critical data when trying to assess the
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best diagnostic test for TBM and suggest simple methods can dramatically improve the 
performance o f conventional bacteriology.
The value of commercial molecular diagnostic tests for TBM is unclear. Previous 
attempts to clarify the diagnostic role o f NAA have failed because o f low numbers of 
cases and inadequate bacteriological diagnostic comparison. In theory, molecular 
methods should improve upon bacteriology, but the data presented in C hapter 5 and the 
results of a recent meta-analysis suggest otherwise (Pai M et a l ,  2003). These authors 
calculate that the sensitivity from 14 studies (110 CSF specimens from patients with 
TBM) with commercial NAA was 56% (95% Cl 46-66%), and conclude that their overall 
low sensitivity precludes the use of these tests to rule out TBM with certainty. The results 
in this thesis from 79 adults with TBM strengthen this conclusion: the sensitivity o f MTD 
before the start o f treatment was 38% (95% Cl 26-51%). If the results o f previous studies 
using MTD are combined with this result (see Table 5.1), the overall sensitivity and 
specificity of the test is 50% (69/138) (95% Cl 41-58%) and 99% (569/575) (95% Cl 98- 
100%). These data strongly suggest that careful bacteriology is as good, or better, than 
the MTD. However, a combination of ZN stain and MTD on serial samples detected 83% 
of cases (95% Cl 71-92%); and after treatment has started the MTD test retained 
sensitivity for longer than ZN stain or culture, presumably reflecting continued detection 
o f rRNA from non-viable organisms.
In conclusion, in settings without microbiological facilities a diagnostic algorithm based 
on simple clinical features will help distinguish TBM from other severe central nervous
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infections. In all other settings the meticulous microscopy of large volumes o f CSF 
remains the best single diagnostic test. A combination o f careful bacteriology and MTD 
may help in the rapid detection o f over 80% of cases. However, the fatal consequences of 
delayed treatment demand a more sensitive single diagnostic test. Alternative solutions 
will be discussed later.
8.2 The pathophysiology of tuberculous meningitis
The second part of this thesis examined the pathophysiology o f TBM before and after 
starting treatment and defined the variables that influence outcome. The purpose o f this 
section is to bring together the findings and suggest a coherent scheme o f events that lead 
to death or survival.
The pathogenesis o f TBM begins with a bacteraemia secondary to a pulmonary infection. 
Primary progressive pulmonary tuberculosis and HIV infection increase both the duration 
of bacteraemia (Bouza E e t ah, 1993) and the likelihood of disseminated tuberculosis 
(Iseman MD, 2000). Differences in host genetic susceptibility and mycobacterial 
virulence may also govern the probability of dissemination, although these factors have 
not been addressed in this thesis. The clinical onset of the TBM begins with the release of 
M.th into the subarachnoid space from a Rich focus (Rich AR et a l ,  1933). Evidence 
presented in Chapters 4 and 6 suggest that outcome after this event is dependent upon 
the relationship between bacillary load and the host immune response and is best 
predicted by CSF lactate concentration.
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Chapter 4 d emonstrates t hat t he 1 ikelihood o f  s eeing o r  c ulturing M . tb f  rom the CSF 
before treatment w as independently associated w ith larger volumes o f CSF examined, 
longer duration o f preceding symptoms, higher CSF neutrophil counts, lower CSFiblood 
glucose ratios and higher CSF lactate concentrations. Chapter 6 reveals that death was 
associated with three of these five variables in a sub-section o f the same population: CSF 
neutrophil count, glucose ratio, and lactate. The concentrations o f CSF lactate and 
glucose are inversely related to one another and their concentrations reflect the 
degree of tissue hypoxia and anaerobic glycolysis (Fishman R, 1992). As such, they are 
the consequence not the cause of the cerebral pathology. The role o f neutrophils in the 
CSF appears more complex: although higher numbers were indirectly associated with 
more bacilli in the CSF, they were also associated with increased survival. These data 
suggest they may have an important role in a successful inflammatory response to 
cerebral M.th, which is supported by the electron micrographs showing bacilli within the 
phagasomes o f neutrophils. Greater proportions o f CSF neutrophils have been described 
in early disease (Garg RK, 1999), which could account for the association with better 
outcome, but there was no relationship between duration o f symptoms and CSF 
neutrophil counts in these studies.
The cellular CSF response to M.th infection is coordinated by cytokines and chemokines 
(Flynn JL et a l ,  2001). The host response to increasing numbers o f cerebral bacilli 
appears highly compartmentalised, characterised by increased CSF concentrations o f IL- 
8, TNF-a, and IFN-y, with little or none of these molecules detectable in paired plasma.
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Although IL-8, TNF-a, and IFN-y did not correlate directly with outcome, they are all 
significantly correlated with CSF lactate concentration, which suggests they may have a 
concentration dependent effect upon immune activation and cerebral inflammation. 
However, there was no correlation between CSF concentration o f IL-8 (a potent 
neutrophil chemo-attractant) and CSF neutrophil numbers. Only CSF XL-10 
concentrations were significantly correlated with CSF cellular response.
The conclusions drawn from Chapter 6 are limited. CSF may not accurately reflect 
disease at the site o f infection, or the concentrations of cytokines their biological activity. 
These types o f studies would b e  improved b y  attempting to  correlate changes in  CSF 
inflammatory molecules with serial MRI documenting macroscopic brain parenchymal 
changes such as infarction, tuberculoma formation, and hydrocephalus. Figure 8.1 
presents an overview o f the pathogenesis of TBM and highlights variables o f proven and 
speculative prognostic importance addressed in this thesis. Unfortunately, these and 
previous studies do not suggest novel rational interventions aimed at modifying critical 
aspects of disease pathogenesis.
8.3 Other variables that influence prognosis
Early treatment with standard anti-tuberculosis drugs remains the largest contribution a 
physician can make to improve outcome. The severity o f coma on admission proved to be 
independently predictive of death (OR 0.73, 95% Cl 0.61-0.87, p=0.001), although the 
duration o f illness before admission did not correlate with coma score or outcome.
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Discussion
This may be because the relatives of comatose patients (on whom the physicians must 
rely for the history) underestimate the length of symptoms. Alternatively, there may be 
more virulent strains o f M.tb that cause more rapidly progressive disease; or some people 
may be more susceptible to rapid disease progression than others. Chapter 7 suggests the 
first explanation is less likely as no relationship was observed between spoligotype and 
duration of symptoms and outcome. However, the numbers o f isolates in this study was 
small, and evidence is accumulating that suggest different strains o f M.tb are capable o f 
producing different clinical phenotypes (Manabe YC  et a l ,  2003). Future studies aimed 
at investigating this possibility will be discussed later.
The influence o f host susceptibility on TBM progression and outcome is poorly defined, 
even with respect to co-infection with HIV. Chapter 7 reports that adults with HIV and 
TBM presented with lower numbers of white cells in their blood and CSF and were more 
likely to be infected with M.tb resistant to streptomycin and/or isoniazid. These findings 
have implications for diagnosis and treatment: low or even absent white cells in the CSF 
may mask the diagnosis of TBM in HIV infected individuals, and the likelihood of 
resistant organisms suggest alternative drugs should be considered in this population. 
However, HIV infection and/or isoniazid/streptomycin resistance did not alter in-hospital 
mortality. This is surprising, particularly when data in Chapter 4 suggests adults with 
HIV have greater numbers of CSF bacilli, and Chapter 5 shows resistance to 
isoniazid/streptomycin slows bacterial clearance from the CSF. These findings must be
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confirmed by larger studies with longer follow-up (at least 9 months from start of 
treatment).
8.4 Future directions
8.4.1 Diagnosis: alternative strategies
This thesis shows novel approaches to the diagnosis of TBM are still required, although 
their development cannot be divorced from the settings in which they are most needed i.e. 
the developing world. Suitable tests must be cheap, easy to perform and must have 
reagents with long shelf lives that do not require refrigeration. However, these 
specifications should not hinder research and development o f new assays: commercial 
kits can simplify techniques, costs may reduce and laboratories may improve. The most 
potent reason for few new diagnostic tests for TBM is their lack o f commercial 
possibility: the populations that need them most can afford them least.
But this may change. Increased global concern regarding pulmonary tuberculosis has lead 
to the development of several new diagnostic assays, which could be adapted for use on 
CSF. The identification o f immunodominant antigens such as ESAT-6 and antigen 85A/B 
have suggested novel diagnostic assays for the detection o f  tuberculosis infection. A n 
enzyme-linked immunospot (ELISPOT) assay for IFN-y identified ESAT-6-specific T 
cells in the blood as an accurate marker o f M.tb infection (Lalvani A et a l ,  2001). A 
commercial whole-blood assay has been developed to detect IFN-y production to this and 
other antigens that may be more appropriate for use in resource-limited settings
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(Johnson PD et a l ,  1999). It is not known whether either o f these methods could be 
successfully adapted for use on CSF. The low numbers o f lymphocytes in the CSF would 
necessitate taking large (>5mls) volumes of CSF to obtain sufficient cells, which would 
be impossible in some cases (particularly children) and reduce the likelihood of 
bacteriological diagnostic confirmation in most others. It is also unclear whether these 
assays can distinguish between past infection and current disease, which could be a 
problem in areas o f high tuberculosis prevalence.
The detection o f various M.tb antigens in the CSF by ELISA has a short history that 
deserves revisiting (Mathai A et a l,  1994; Radhakrishnan VV et a l ,  1990; Sada E et a l,  
1983; Watt G et a l ,  1988). New possibilities stem from the complete sequencing o f the 
M.tb genome (Cole ST et a l ,  1998), which offers a unique opportunity to identify novel 
diagnostic targets. The availability of this sequence enables screening of complete protein 
families that contain immunodominant molecules, such as ESAT-6 (Louise R et a l,  
2001). Subcellular protein fractions o f M.tb can be resolved by two-dimensional liquid 
phase electrophoresis, and particular fractions isolated that stimulate dominant T cell 
responses. Individual proteins can be identified within these fractions and their DNA 
sequence predicted (Covert BA et a l,  2001). This ‘post-genomic’ approach has not yet 
been employed upon the CSF from patients with TBM, and may identify novel detectable 
antigens. In addition, the growing availability of monoclonal antibodies to a range of 
M.tb antigens and peptides will improve the specificity o f these assays.
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Immunodominant antigens, identified by the methods described above, may not be 
secreted in the CSF in sufficient concentrations to enable consistent detection by ELISA, 
and other molecules and methods o f detection should be considered. There are 
inconclusive reports suggesting that tuberculosteric acid, a component o f M.tb cell wall, 
can be detected by gas-liquid chromatography o f CSF from patients with TBM (Brooks 
IB et a l ,  1990). Advances in analytic techniques, for example liquid chromatography -  
mass spectroscopy, suggest these methods may now be capable o f identifying and 
consistently detecting molecules unique to the CSF of those with TBM a t pico-molar 
concentrations. Although these methods are a long way from incorporation into the 
conventional diagnostic laboratory, they deserve further investigation.
Recently, bacteriophages have been used to identify M.tb in sputum, and to assess drug 
susceptibility (Banaiee N et a l,  2001; Banaiee N et a l ,  2003; Park DJ et a l ,  2003; 
Wilson SM et a l,  1997). Two methods are described. The first uses a phage carrying the 
firefly luciferase gene that infects viable M.tb labelling it with the ability to produce light 
(Banaiee N et a l, 2001). The second uses a phage that infects viable M.tb, and can be 
transferred to infect a plate of fast-growing mycobacteria causing visible areas o f lysis 
(Wilson SM et a l ,  1997). The considerable advantage of the later method is that it does 
not require special laboratory equipment and may be better suited to resource-poor 
settings. Field trials have suggested that this assay performs well in specimens other than 
sputum (Marei AM et a l ,  2003), although there are no reports o f its use on CSF.
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It remains to be seen whether this assay has sufficient sensitivity to detect the small 
numbers o f bacilli found in the CSF.
8.4.2 Pathophysiology and outcome: what can we improve?
Improving outcome from TBM remains a major priority and one that has yet to be 
properly addressed. Prevailing dogma suggests that poor prognosis results from an 
inappropriate immune response within the confined space o f the brain. As discussed 
earlier, the evidence to support this view is poor. Animal models have suggested an 
important role for TNF-a (Tsenova L et a l,  1999), and demonstrated improved outcome 
following TNF-a inhibition by thalidomide (Tsenova L et a l ,  1998). However, like 
previous reports, this thesis was unable to confirm a relationship between CSF TNF-a 
concentration and outcome in humans, although concentration in the CSF may have little 
relation to biological activity at the site o f disease. U se o f  adjunctive thalidomide (in  
addition to corticosteroids) in humans has been reported with inconclusive results 
(Schoeman JF et a l ,  2000; Roberts MT et a l,  2003) and has yet to be subject to a 
controlled trial.
Despite poor understanding o f the pathogenesis of TBM, physicians continue to advocate 
adjuvant corticosteroids in the face of meagre data from clinical trials. Putative 
mechanisms o f action o f corticosteroids in this setting include down regulation o f T-cell 
functioning; regulation of a range of cytokines; and impairing the blood-brain barrier 
dysfunction via interference with cell adhesion, migration, and matrix metalloproteinase
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activity. A large, randomised controlled trial is urgently required, in parallel with studies 
assessing the effect o f corticosteroid upon CSF cellular phenotypes (by flow cytometry), 
cytokine expression and blood-brain barrier integrity. If  an adequately powered clinical 
trial demonstrates an impact upon outcome, CSF studies might clarify how 
corticosteroids alter pathogenesis and identify new molecules o f prognostic importance. 
These studies are currently being performed at HTD, but further investigations could 
consider techniques employed by those investigating the pathogenesis o f multiple 
sclerosis, a common inflammatory disease o f the developed world. In particular, cDNA 
micro arrays have been employed for gene-expression analysis o f peripheral blood 
mononuclear cells from patients treated with different immunomodulatory drugs. Using 
these methods, several genes involved in innate and specific immune responses have 
been identified that are potential effector targets for the drugs on trial for this disease 
(predominantly interferon beta) (Wandinger KP et a l ,  2001; Wandinger KP et a l ,  2003). 
A similar approach could be adopted with TBM, exploring potentially important genes in 
pathogenesis by using host cDNA micro arrays of mononuclear cells from blood and CSF 
taken over the course of treatment with corticosteroids, or other candidate drugs such as 
thalidomide.
Imaging techniques promise complementary insights into disease pathogenesis, in 
particular on the development and response to treatment of infarctions, tuberculomas, and 
hydrocephalus. MRI is increasingly available, and serial scans on consecutive patients 
would offer much valuable data regarding the timing, typical anatomical locations, and
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resolution o f these complications. Doppler ultra-sound studies have been used to assess 
the nature and extent of TBM-related cerebral vasculopathy (Kilic T et a l , 2002), but 
magnetic resonance angiography (MRA) would provide greater resolution and allow 
arterial changes to be studied in anatomically defined areas. The techniques o f functional 
MRI and single photon emission computorised tomography (SPECT) may provide further 
data regarding regional cerebral blood flow, perfusion and parenchymal metabolic 
activity (Kalita J et a l ,  2002). These techniques could provide a powerful way of 
investigating TBM pathogenesis and assessing response to novel interventions, 
particularly if  used in conjunction with the molecular and cellular investigations 
described above.
Future research should also be directed at investigating why some patients infected with 
M.tb develop meningitis, and others do not. There may be  genetic and  environmental 
reasons why some patients are more susceptible to this form of the disease (Bloom BR et 
a l,  1998). Alternatively, there may be strains o f M.tb that are more likely to cause 
cerebral infection, and this possibility is explored in C hapter 7. There is however, very 
little information on the molecular characteristics of M.tb strains associated with different 
clinical phenotypes or outcomes. Although large numbers of isolates would be required, 
it may be possible to compare strains o f M.tb from the CSF and lung by RFLP, 
spoligotyping o r  mycobacterial interspersed repeat units (MIRU) typing (Barnes PF et 
a l,  2003), and identify certain strains more commonly isolated from the CSF or the lung. 
The biological characteristics o f these organisms could be further characterised by
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comparing disease phenotype in animal models, infection characteristics in 
macrophage/monocyte cell lines, and M.tb gene expression in different environments by 
micro array.
The outcome o f future patients with TBM is threatened by increasing M.tb resistance to 
the first-line anti-tuberculosis drugs. Although the impact o f isoniazid and/or 
streptomycin on outcome is uncertain, the treatment of multi-drug resistant TBM is 
severely impaired by the high likelihood o f death before the results o f susceptibility tests 
are known (Daikos GL et a l ,  2003). Two areas require urgent further investigation: the 
rapid prediction or detection of resistant M.tb in the CSF, and the CSF pharmacokinetcs 
and pharmacodynamics of second line drugs.
Conventional drug susceptibility testing takes too long to be clinically relevant for TBM, 
therefore alternative methods need to be considered. It may be possible to develop 
clinical algorithms to predict the likelihood o f drug resistant M.tb based upon admission 
data, CSF parameters, and clinical response over the first 3-5 days o f ATC. These 
algorithms may be good at assessing the chance o f resistance in a given community, but 
are unlikely to have sufficient sensitivity and specificity to be used alone and in different 
populations. NAA assays have been developed that detect mutations in the M.tb rpoB 
gene that predict phenotypic rifampicin resistance (Mokrousov I et a l ,  2003). Lone 
rifampcin is rare in most settings and is usually found in combination with isoniazid 
resistance. Therefore, this assay has been shown to be useful in the early prediction of 
multi-drug resistant pulmonary disease (Johansen IS et a l ,  2003). The sensitivity and
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specificity of the assay for the diagnosis o f rifampicin resistant TBM is unknown, and 
requires investigation. Phage based systems for rapid drug susceptibility testing, as 
described above, are unlikely to be useful as they currently require mycobacterial 
populations that may take 1-2 weeks to cultivate from CSF.
Finally, the treatment o f drug resistant tuberculosis presents an enormous challenge to 
future researchers. It is not clear which drugs constitute the best second line drug regimen 
and there are no published controlled trials addressing this issue for any form of 
tuberculosis (Frieden TR et a l,  2003). The treatment o f drug resistant TBM is made 
especially difficult, as any potential drug must also penetrate the BBB. Fluoroquinolones 
are bactericidal for M.tb (Beming SE, 2001) and WHO recommends them for the 
treatment of multi-drug resistant pulmonary tuberculosis (Crofton J et a l ,  1997), but their 
use in TBM is restricted to case reports (Beming SE et a l ,  2001). Data regarding CSF 
penetration and pharmacokinetics are scant (Fish DN et a l ,  1997; Nan R et a l ,  1990) and 
it is uncertain which fluoroquinolone represents the best dmg for treating TBM. The CSF 
pharmacokinetics and pharmacodynamics of ciprofloxacin, levofloxacin, gatifloxacin and 
moxifioxacin requires investigation before randomised controlled trials can be proposed. 
Limitations on the firequency of lumbar punctures suggest these studies should employ 
population pharmacokinetic designs and analysis. These techniques allow the variability 
in dmg concentration or pharmacological effect to be studied between individuals when 
standard dosage regimens are administered, and are especially suited to the type o f sparse 
data TBM CSF studies may produce (Sun H et a l,  1999).
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8.5 Concluding comments
The outcome from TBM has not improved since the introduction of isoniazid in 1952, 
and neither have diagnostic methods. This thesis suggests simple clinical methods are 
useful, but on its 120* anniversary, the Ziehl-Neelsen stain remains the best available 
single diagnostic test for TBM. Laboratories with the most money and time should 
consider the combined p erformance o f  meticulous b acteriology and M TD on  repeated 
samples, as this approach detected the most cases. Laboratories with fewer resources 
could identify patients who most warrant this approach by clinical diagnostic algorithms. 
This thesis has shown that treatment early in the disease before the onset o f coma is the 
best way to prevent death, but the pathogenesis o f TBM remains elusive. CSF lactate is 
an important CSF marker of disease severity and bacterial load, and neutrophils may have 
an important and hitherto unreported protective role, but the cellular and molecular 
response to infection requires greater characterisation.
Further research is urgently required to evaluate the diagnostic role o f new antigen and 
phage-based assays; to confirm or refute the value o f adjunctive corticosteroids; to 
identify new drugs for the treatment of resistant M.tb\ and to identify the mechanisms o f 
disease that may be amenable to novel interventions. I f  these problems are not addressed 
the outcome o f patients admitted to the Hospital for Tropical Diseases in Ho Chi Minh 
City and elsewhere will not improve for another 50 years.
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